16. Literaturverzeichnis – Prostatakarzinom

1. Robert, Koch-Institut, Gesellschaft epidemiologischer Krebsregister in, Deutschland, Krebs in Deutschland für 2015/2016, 2019., https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_node.html

2. Zeegers, M.P., Jellema, A., Ostrer, H., Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis, Cancer, 2003. 97(8): p. 1894-1903., https://www.ncbi.nlm.nih.gov/pubmed/12673715

3. Johns, L.E., Houlston, R.S., A systematic review and meta-analysis of familial prostate cancer risk, BJU Int, 2003. 91(9): p. 789-794., http://www.ncbi.nlm.nih.gov/pubmed/12780833

4. Taylor, M.L., Mainous, A.G., III, Wells, B.J., Prostate cancer and sexually transmitted diseases: a meta-analysis, Fam Med, 2005. 37(7): p. 506-512., http://www.ncbi.nlm.nih.gov/pubmed/15988645

5. Ries, L.A.G., Melbert, D., Krapcho, M., Mariotto, A., Miller, B.A., Feuer, E.J., et.al. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute. Section 23: Prostate Cancer, 2007., http://www.seer.cancer.gov/csr/1975_2004/results_merged/sect_23_prostate.pdf

6. Graham, S., Haughey, B., Marshall, J., Priore, R., Byers, T., Rzepka, T., et.al. Diet in the epidemiology of carcinoma of the prostate gland, J Natl. Cancer Inst, 1983. 70(4): p. 687-692., http://www.ncbi.nlm.nih.gov/pubmed/6572757

7. Hebert, J.R., Hurley, T.G., Olendzki, B.C., Teas, J., Ma, Y., Hampl, J.S., Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study, J Natl. Cancer Inst, 1998. 90(21): p. 1637-1647., http://www.ncbi.nlm.nih.gov/pubmed/9811313

8. Morton, R.A., Jr., Racial differences in adenocarcinoma of the prostate in North American men, Urology, 1994. 44(5): p. 637-645., http://www.ncbi.nlm.nih.gov/pubmed/7526522

9. Ozasa, K., Nakao, M., Watanabe, Y., Hayashi, K., Miki, T., Mikami, K., et.al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men, Cancer Sci, 2004. 95(1): p. 65-71., http://www.ncbi.nlm.nih.gov/pubmed/14720329

10. Etminan, M., Takkouche, B., Caamano-Isorna, F., The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies, Cancer Epidemiol Biomarkers Prev, 2004. 13(3): p. 340-345., http://www.ncbi.nlm.nih.gov/pubmed/15006906

11. Wertz, K., Siler, U., Goralczyk, R., Lycopene: modes of action to promote prostate health, Arch Biochem. Biophys, 2004. 430(1): p. 127-134., http://www.ncbi.nlm.nih.gov/pubmed/15325920

12. Nelson, W.G., Prostate cancer prevention, Curr. Opin. Urol, 2007. 17(3): p. 157-167., http://www.ncbi.nlm.nih.gov/pubmed/17414513

13. Dennis, L.K., Dawson, D.V., Meta-analysis of measures of sexual activity and prostate cancer, Epidemiology, 2002. 13(1): p. 72-79., http://www.ncbi.nlm.nih.gov/pubmed/11805589

14. Dennis, L.K., Lynch, C.F., Torner, J.C., Epidemiologic association between prostatitis and prostate cancer, Urology, 2002. 60(1): p. 78-83., http://www.ncbi.nlm.nih.gov/pubmed/12100928

15. Dennis, L.K., Dawson, D.V., Resnick, M.I., Vasectomy and the risk of prostate cancer: a meta-analysis examining vasectomy status, age at vasectomy, and time since vasectomy, Prostate Cancer Prostatic. Dis, 2002. 5(3): p. 193-203., http://www.ncbi.nlm.nih.gov/pubmed/12496981

16. Strickler, H.D., Wylie-Rosett, J., Rohan, T., Hoover, D.R., Smoller, S., Burk, R.D., et.al. The relation of type 2 diabetes and cancer, Diabetes Technol. Ther, 2001. 3(2): p. 263-274., http://www.ncbi.nlm.nih.gov/pubmed/11478333

17. Kasper, J.S., Giovannucci, E., A meta-analysis of diabetes mellitus and the risk of prostate cancer, Cancer Epidemiol Biomarkers Prev, 2006. 15(11): p. 2056-2062., http://www.ncbi.nlm.nih.gov/pubmed/17119028

18. Bonovas, S., Filioussi, K., Tsantes, A., Diabetes mellitus and risk of prostate cancer: a meta-analysis, Diabetologia, 2004. 47(6): p. 1071-1078., http://www.ncbi.nlm.nih.gov/pubmed/15164171

19. MacInnis, R.J., English, D.R., Body size and composition and prostate cancer risk: systematic review and meta-regression analysis, Cancer Causes Control, 2006. 17(8): p. 989-1003., http://www.ncbi.nlm.nih.gov/pubmed/16933050

20. Giovannucci, E., Rimm, E.B., Stampfer, M.J., Colditz, G.A., Willett, W.C., Height, body weight, and risk of prostate cancer, Cancer Epidemiol Biomarkers Prev, 1997. 6(8): p. 557-563., http://www.ncbi.nlm.nih.gov/pubmed/9264267

21. Calof, O.M., Singh, A.B., Lee, M.L., Kenny, A.M., Urban, R.J., Tenover, J.L., et.al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials, J Gerontol. A Biol Sci Med Sci, 2005. 60(11): p. 1451-1457., https://www.ncbi.nlm.nih.gov/pubmed/16339333

22. Gerstenbluth, R.E., Maniam, P.N., Corty, E.W., Seftel, A.D., Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement, J Androl, 2002. 23(6): p. 922-926., http://www.ncbi.nlm.nih.gov/pubmed/12399540

23. Hajjar, R.R., Kaiser, F.E., Morley, J.E., Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis, J Clin Endocrinol. Metab, 1997. 82(11): p. 3793-3796., http://www.ncbi.nlm.nih.gov/pubmed/9360543

24. Marks, L.S., Mazer, N.A., Mostaghel, E., Hess, D.L., Dorey, F.J., Epstein, J.I., et.al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial, JAMA, 2006. 296(19): p. 2351-2361., http://www.ncbi.nlm.nih.gov/pubmed/17105798

25. Rhoden, E.L., Morgentaler, A., Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia, J Urol, 2003. 170(6 Pt 1): p. 2348-2351., http://www.ncbi.nlm.nih.gov/pubmed/14634413

26. Wang, C., Cunningham, G., Dobs, A., Iranmanesh, A., Matsumoto, A.M., Snyder, P.J., et.al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men, J Clin Endocrinol. Metab, 2004. 89(5): p. 2085-2098., http://www.ncbi.nlm.nih.gov/pubmed/15126525

27. Boyle, P., Koechlin, A., Bota, M., d'Onofrio, A., Zaridze, D.G., Perrin, P., et.al. Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate specific antigen (PSA): a meta-analysis, BJU Int, 2016., http://www.ncbi.nlm.nih.gov/pubmed/26779889

28. Kang, D.Y., Li, H.J., The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis, Medicine (Baltimore), 2015. 94(3): p. e410., http://www.ncbi.nlm.nih.gov/pubmed/25621688

29. Cui, Y., Zong, H., Yan, H., Zhang, Y., The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis, Prostate Cancer Prostatic. Dis, 2014. 17(2): p. 132-143., http://www.ncbi.nlm.nih.gov/pubmed/24445948

30. Thompson, I.M., Goodman, P.J., Tangen, C.M., Lucia, M.S., Miller, G.J., Ford, L.G., et.al. The influence of finasteride on the development of prostate cancer, N Engl J Med, 2003. 349(3): p. 215-224., http://www.ncbi.nlm.nih.gov/pubmed/12824459

31. Thompson, I.M., Lucia, M.S., Redman, M.W., Darke, A., La Rosa, F.G., Parnes, H.L., et.al. Finasteride decreases the risk of prostatic intraepithelial neoplasia, J Urol, 2007. 178(1): p. 107-109., http://www.ncbi.nlm.nih.gov/pubmed/17499284

32. Wilt, T.J., MacDonald, R., Hagerty, K., Schellhammer, P., Kramer, B.S., Five-alpha-reductase Inhibitors for prostate cancer prevention, Cochrane Database Syst Rev, 2008. p. CD007091., http://www.ncbi.nlm.nih.gov/pubmed/18425978

33. Kramer, B.S., Hagerty, K.L., Justman, S., Somerfield, M.R., Albertsen, P.C., Blot, W.J., et.al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline, J Clin Oncol, 2009. 27(9): p. 1502-1516., http://www.ncbi.nlm.nih.gov/pubmed/19252137

34. Kushi, L.H., Byers, T., Doyle, C., Bandera, E.V., McCullough, M., McTiernan, A., et.al. American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity, CA Cancer J Clin, 2006. 56(5): p. 254-281., http://www.ncbi.nlm.nih.gov/pubmed/17005596

35. Lippman, S.M., Klein, E.A., Goodman, P.J., Lucia, M.S., Thompson, I.M., Ford, L.G., et.al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT), JAMA, 2009. 301(1): p. 39-51., http://www.ncbi.nlm.nih.gov/pubmed/19066370

36. Lucia, M.S., Epstein, J.I., Goodman, P.J., Darke, A.K., Reuter, V.E., Civantos, F., et.al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial, J Natl Cancer Inst, 2007. 99(18): p. 1375-1383., http://www.ncbi.nlm.nih.gov/pubmed/17848673

37. Teillac, P., Abrahamsson, P.A., The prostate cancer prevention trial and its implications for clinical practice: a European consensus, Eur Urol Suppl, 2006. 5(9): p. 640-646.

38. Andriole, G.L., Headline Results of the REDUCE Trial: The Effect of Dutasteride on Prostate Cancer Risk Reduction. 107th Annual Meeting, American Urological Association (AUA)AUA, 2009.

39. Feng, X, Zahed, H, Onwuka, J, Callister, MEJ, Johansson, M, Etzioni, R, et.al. Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening: A Systematic Review and Meta-Analysis., JAMA, 2024. 331 (22)(22): p. 1910-1917., https://pubmed.ncbi.nlm.nih.gov/38583868/

40. Dubben, HH, Trials of prostate-cancer screening are not worthwhile., Lancet Oncol, 2009. 10 (3)(3): p. 294-8., https://pubmed.ncbi.nlm.nih.gov/19261258/

41. de Vos, II, Meertens, A, Hogenhout, R, Remmers, S, Roobol, MJ, A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer., Eur Urol, 2023. 84 (4)(4): p. 426-434., https://pubmed.ncbi.nlm.nih.gov/37029074/

42. Arnsrud Godtman, R, Holmberg, E, Lilja, H, Stranne, J, Hugosson, J, Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial., Eur Urol, 2015. 68 (3)(3): p. 354-60., https://pubmed.ncbi.nlm.nih.gov/25556937/

43. Vickers, A, O'Brien, F, Montorsi, F, Galvin, D, Bratt, O, Carlsson, S, et.al. Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit., BMJ, 2023. 381 (): p. e071082., https://pubmed.ncbi.nlm.nih.gov/37197772/

44. Vynckier, P, Annemans, L, Raes, S, Amrouch, C, Lindgren, P, Májek, O, et.al. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe., Eur Urol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/38789306/

45. Muchandifunga T. Muchadeyi, Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study (in submission), 2024 (vor.).

46. Nordström, T, Discacciati, A, Bergman, M, Clements, M, Aly, M, Annerstedt, M, et.al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial., Lancet Oncol, 2021. 22 (9)(9): p. 1240-1249., https://pubmed.ncbi.nlm.nih.gov/34391509/

47. Krilaviciute, A, Kaaks, R, Seibold, P, de Vrieze, M, Lakes, J, Radtke, JP, et.al. Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial., Eur Urol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/38749854/

48. Krilaviciute, A, Becker, N, Lakes, J, Radtke, JP, Kuczyk, M, Peters, I, et.al. Digital Rectal Examination Is Not a Useful Screening Test for Prostate Cancer., Eur Urol Oncol, 2023. 6 (6)(6): p. 566-573., https://pubmed.ncbi.nlm.nih.gov/37806841/

49. Matsukawa, A, Yanagisawa, T, Bekku, K, Kardoust Parizi, M, Laukhtina, E, Klemm, J, et.al. Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysis., Eur Urol Oncol, 2024. 7 (4)(4): p. 697-704., https://pubmed.ncbi.nlm.nih.gov/38182488/

50. Hugosson, J., Roobol, M. J., Månsson, M., Tammela, T. L. J., Zappa, M., Nelen, V., et.al. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer, European urology, 2019. 76(1): p. 43-51., https://pubmed.ncbi.nlm.nih.gov/30824296/

51. Jin, Y, Jung, JH, Han, WK, Hwang, EC, Nho, Y, Lee, N, et.al. Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis., Investig Clin Urol, 2022. 63 (3)(3): p. 251-261., https://pubmed.ncbi.nlm.nih.gov/35534215/

52. Paschen, U, Sturtz, S, Fleer, D, Lampert, U, Skoetz, N, Dahm, P, Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care., BJU Int, 2022. 129 (3)(3): p. 280-289., https://pubmed.ncbi.nlm.nih.gov/33961337/

53. Matti, B, Xia, W, van der Werf, B, Zargar-Shoshtari, K, Age-Adjusted Reference Values for Prostate Specific Antigen - A Systematic Review and Meta-Analysis., Clin Genitourin Cancer, 2022. 20 (2)(2): p. e114-e125., https://pubmed.ncbi.nlm.nih.gov/34969631/

54. Arsov, C, Albers, P, Herkommer, K, Gschwend, J, Imkamp, F, Peters, I, et.al. A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial., Int J Cancer, 2022. 150 (11)(11): p. 1861-1869., https://pubmed.ncbi.nlm.nih.gov/35076933/

55. Hugosson, J, Månsson, M, Wallström, J, Axcrona, U, Carlsson, SV, Egevad, L, et.al. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only., N Engl J Med, 2022. 387 (23)(23): p. 2126-2137., https://pubmed.ncbi.nlm.nih.gov/36477032/

56. Eklund, M, Jäderling, F, Discacciati, A, Bergman, M, Annerstedt, M, Aly, M, et.al. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening., N Engl J Med, 2021. 385 (10)(10): p. 908-920., https://pubmed.ncbi.nlm.nih.gov/34237810/

57. Fazekas, T, Shim, SR, Basile, G, Baboudjian, M, Kói, T, Przydacz, M, et.al. Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis., JAMA Oncol, 2024. 10 (6)(6): p. 745-754., https://pubmed.ncbi.nlm.nih.gov/38576242/

58. Page, EC, Bancroft, EK, Brook, MN, Assel, M, Hassan Al Battat, M, Thomas, S, et.al. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers., Eur Urol, 2019. 76 (6)(6): p. 831-842., https://pubmed.ncbi.nlm.nih.gov/31537406/

59. Bancroft, EK, Page, EC, Brook, MN, Thomas, S, Taylor, N, Pope, J, et.al. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study., Lancet Oncol, 2021. 22 (11)(11): p. 1618-1631., https://pubmed.ncbi.nlm.nih.gov/34678156/

60. Xu, X, Kharazmi, E, Tian, Y, Mukama, T, Sundquist, K, Sundquist, J, et.al. Risk of prostate cancer in relatives of prostate cancer patients in Sweden: A nationwide cohort study., PLoS Med, 2021. 18 (6)(6): p. e1003616., https://pubmed.ncbi.nlm.nih.gov/34061847/

61. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.1, 2019, AWMF Registernummer: 043/022OL., www.leitlinienprogramm-onkolo-gie.de/leitlinien/prostatakarzinom/

62. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF), Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Evidenztabellen, Version 5.0, 2018, AWMF Registernummer: 043/022OL., www.leitlinienprogramm-onkologie.de/Prostatakarzinom.58.0.html

63. Ilic, D, Djulbegovic, M, Jung, JH, Hwang, EC, Zhou, Q, Cleves, A, et.al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis., BMJ, 2018. 362 (): p. k3519., https://pubmed.ncbi.nlm.nih.gov/30185521/

64. Martin, RM, Turner, EL, Young, GJ, Metcalfe, C, Walsh, EI, Lane, JA, et.al. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial., JAMA, 2024. 331 (17)(17): p. 1460-1470., https://pubmed.ncbi.nlm.nih.gov/38581198/

65. Hugosson, J, Godtman, RA, Carlsson, SV, Aus, G, Grenabo Bergdahl, A, Lodding, P, et.al. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality., Scand J Urol, 2018. 52 (1)(1): p. 27-37., https://pubmed.ncbi.nlm.nih.gov/29254399/

66. Van Poppel, H, Hogenhout, R, Albers, P, van den Bergh, RCN, Barentsz, JO, Roobol, MJ, A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer., Eur Urol Oncol, 2021. 4 (5)(5): p. 731-739., https://pubmed.ncbi.nlm.nih.gov/34364829/

67. Merriel, SWD, Pocock, L, Gilbert, E, Creavin, S, Walter, FM, Spencer, A, et.al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients., BMC Med, 2022. 20 (1)(1): p. 54., https://pubmed.ncbi.nlm.nih.gov/35125113/

68. Eldred-Evans, D, Burak, P, Connor, MJ, Day, E, Evans, M, Fiorentino, F, et.al. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study., JAMA Oncol, 2021. 7 (3)(3): p. 395-402., https://pubmed.ncbi.nlm.nih.gov/33570542/

69. Nam, R, Patel, C, Milot, L, Hird, A, Wallis, C, Macinnis, P, et.al. Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial., BMJ Open, 2022. 12 (11)(11): p. e059482., https://pubmed.ncbi.nlm.nih.gov/36351725/

70. TRANSFORM-Studie UK, 2024 (vor.)., https://prostatecanceruk.org/research/transform-trial

71. Arsov, C, Becker, N, Hadaschik, BA, Hohenfellner, M, Herkommer, K, Gschwend, JE, et.al. Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial., Eur Urol, 2013. 64 (6)(6): p. 873-5., https://pubmed.ncbi.nlm.nih.gov/23707067/

72. Vickers, A.J., Ulmert, D., Sjoberg, D.D., Bennette, C.J., Björk, T., Gerdtsson, A., et.al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis, BMJ (Clinical research ed.), 2013. 346: p. f2023., www.ncbi.nlm.nih.gov/pubmed/23596126

73. Vickers, AJ, Sjoberg, DD, Ulmert, D, Vertosick, E, Roobol, MJ, Thompson, I, et.al. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen., BMC Med, 2014. 12 (): p. 26., https://pubmed.ncbi.nlm.nih.gov/24512643/

74. Draisma, G., Boer, R., Otto, S.J., van der Cruijsen, I.W., Damhuis, R.A., Schroder, F.H., et.al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer, J Natl Cancer Inst, 2003. 95(12): p. 868-878., http://www.ncbi.nlm.nih.gov/pubmed/12813170

75. Walter, SD, Hu, J, Talala, K, Tammela, T, Taari, K, Auvinen, A, Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer., Cancer Causes Control, 2021. 32 (11)(11): p. 1299-1313., https://pubmed.ncbi.nlm.nih.gov/34313874/

76. Hogenhout, R, Remmers, S, van Slooten-Midderigh, ME, de Vos, II, Roobol, MJ, From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life., Eur Urol Oncol, 2024. 7 (4)(4): p. 713-720., https://pubmed.ncbi.nlm.nih.gov/37690917/

77. Carlsson, S, Assel, M, Ulmert, D, Gerdtsson, A, Hugosson, J, Vickers, A, et.al. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study., Eur Urol, 2017. 71 (1)(1): p. 46-52., https://pubmed.ncbi.nlm.nih.gov/27084245/

78. Nielsen ,Sigrid Brisson, , Spalletta ,Olivia, , Toft Kristensen ,Mads Aage, and Brodersen ,John, Psychosocial consequences of potential overdiagnosis in prostate cancer a qualitative interview studyTaylor & Francis, Scandinavian Journal of Primary Health Care, 2020. 38(4): p. 439 - 446., https://doi.org/10.1080/02813432.2020.1843826

79. DeFrank, Jessica T., Barclay, Colleen, Sheridan, Stacey, Brewer, Noel T., Gilliam, Meredith, Moon, Andrew M., et.al. The Psychological Harms of Screening: the Evidence We Have Versus the Evidence We Need, 2015. 30(2): p. 242 - 248., https://doi.org/10.1007/s11606-014-2996-5

80. Mian, BM, Feustel, PJ, Aziz, A, Kaufman, RP, Bernstein, A, Fisher, HAG, Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial., J Urol, 2024. 212 (1)(1): p. 21-31., https://pubmed.ncbi.nlm.nih.gov/38700844/

81. Hu, JC, Assel, M, Allaf, ME, Vickers, AJ, Ehdaie, B, Cohen, AJ, et.al. Transperineal vs Transrectal Prostate Biopsy-The PREVENT Randomized Clinical Trial., JAMA Oncol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/39298143/

82. Sathianathen, NJ, Omer, A, Harriss, E, Davies, L, Kasivisvanathan, V, Punwani, S, et.al. Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis., Eur Urol, 2020. 78 (3)(3): p. 402-414., https://pubmed.ncbi.nlm.nih.gov/32444265/

83. Russo, J, Giri, VN, Germline testing and genetic counselling in prostate cancer., Nat Rev Urol, 2022. 19 (6)(6): p. 331-343., https://pubmed.ncbi.nlm.nih.gov/35449224/

84. Denijs, FB, van Harten, MJ, Meenderink, JJL, Leenen, RCA, Remmers, S, Venderbos, LDF, et.al. Risk calculators for the detection of prostate cancer: a systematic review., Prostate Cancer Prostatic Dis, 2024. 27 (3)(3): p. 544-557., https://pubmed.ncbi.nlm.nih.gov/38830997/

85. ERSPC-Riskcalculator oder arribia „PSA-Screening“, 2024 (z. g.)., www.prostatecancer-riskcalculator.com/, , oder, https://arriba-hausarzt.de/uploads/files/arriba-Brosch%C3%BCre-PSA.pdf

86. Auvinen, A, Tammela, TLJ, Mirtti, T, Lilja, H, Tolonen, T, Kenttämies, A, et.al. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial., JAMA, 2024. 331 (17)(17): p. 1452-1459., https://pubmed.ncbi.nlm.nih.gov/38581254/

87. Kawada, T, Shim, SR, Quhal, F, Rajwa, P, Pradere, B, Yanagisawa, T, et.al. Diagnostic Accuracy of Liquid Biomarkers for Clinically Significant Prostate Cancer Detection: A Systematic Review and Diagnostic Meta-analysis of Multiple Thresholds., Eur Urol Oncol, 2024. 7 (4)(4): p. 649-662., https://pubmed.ncbi.nlm.nih.gov/37981495/

88. Kobayashi, M, Kijima, T, Yashi, M, Kamai, T, Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels., Prostate Int, 2023. 11 (1)(1): p. 27-33., https://pubmed.ncbi.nlm.nih.gov/36910897/

89. Roddam, AW, Duffy, MJ, Hamdy, FC, Ward, AM, Patnick, J, Price, CP, et.al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis., Eur Urol, 2005. 48 (3)(3): p. 386-99; discussion 398-9., https://pubmed.ncbi.nlm.nih.gov/15982797/

90. BEKANNTGABEN DER HERAUSGEBER: Bundesärztekammer Aktualisierung der Richtlinie der Bundesärztekammer zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen – Rili-BÄK Dtsch Arztebl 2023; 120(21-22): A-994 / B-858, 2023., DOI:, 10.3238/arztebl.2023.rili_baek_QS_Labor

91. Hugosson, J, Godtman, RA, Wallstrom, J, Axcrona, U, Bergh, A, Egevad, L, et.al. Results after Four Years of Screening for Prostate Cancer with PSA and MRI., N Engl J Med, 2024. 391 (12)(12): p. 1083-1095., https://pubmed.ncbi.nlm.nih.gov/39321360/

92. Beebe-Dimmer, JL, Kapron, AL, Fraser, AM, Smith, KR, Cooney, KA, Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes., J Clin Oncol, 2020. 38 (16)(16): p. 1807-1813., https://pubmed.ncbi.nlm.nih.gov/32208047/

93. Kiciński, M, Vangronsveld, J, Nawrot, TS, An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis., PLoS One, 2011. 6 (10)(10): p. e27130., https://pubmed.ncbi.nlm.nih.gov/22073129/

94. Stanford, JL, Ostrander, EA, Familial prostate cancer., Epidemiol Rev, 2001. 23 (1)(1): p. 19-23., https://pubmed.ncbi.nlm.nih.gov/11588848/

95. Eeles, RA, Olama, AA, Benlloch, S, Saunders, EJ, Leongamornlert, DA, Tymrakiewicz, M, et.al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array., Nat Genet, 2013. 45 (4)(4): p. 385-91, 391e1-2., https://pubmed.ncbi.nlm.nih.gov/23535732/

96. Hemminki, K, Li, X, Försti, A, Eng, C, Are population level familial risks and germline genetics meeting each other?, Hered Cancer Clin Pract, 2023. 21 (1)(1): p. 3., https://pubmed.ncbi.nlm.nih.gov/36882784/

97. Heidegger, I, Tsaur, I, Borgmann, H, Surcel, C, Kretschmer, A, Mathieu, R, et.al. Hereditary prostate cancer - Primetime for genetic testing?, Cancer Treat Rev, 2019. 81 (): p. 101927., https://pubmed.ncbi.nlm.nih.gov/31783313/

98. Schumacher, FR, Al Olama, AA, Berndt, SI, Benlloch, S, Ahmed, M, Saunders, EJ, et.al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci., Nat Genet, 2018. 50 (7)(7): p. 928-936., https://pubmed.ncbi.nlm.nih.gov/29892016/

99. Conti, DV, Darst, BF, Moss, LC, Saunders, EJ, Sheng, X, Chou, A, et.al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction., Nat Genet, 2021. 53 (1)(1): p. 65-75., https://pubmed.ncbi.nlm.nih.gov/33398198/

100. Wang, A, Shen, J, Rodriguez, AA, Saunders, EJ, Chen, F, Janivara, R, et.al. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants., Nat Genet, 2023. 55 (12)(12): p. 2065-2074., https://pubmed.ncbi.nlm.nih.gov/37945903/

101. Tanigawa, Y, Qian, J, Venkataraman, G, Justesen, JM, Li, R, Tibshirani, R, et.al. Significant sparse polygenic risk scores across 813 traits in UK Biobank., PLoS Genet, 2022. 18 (3)(3): p. e1010105., https://pubmed.ncbi.nlm.nih.gov/35324888/

102. Seibert, TM, Garraway, IP, Plym, A, Mahal, BA, Giri, V, Jacobs, MF, et.al. Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention., Eur Urol, 2023. 83 (3)(3): p. 241-248., https://pubmed.ncbi.nlm.nih.gov/36609003/

103. Amini, AE, Hunter, AE, Almashad, A, Feng, AJ, Patel, ND, O'Dea, MR, et.al. Magnetic Resonance Imaging-based Prostate Cancer Screening in Carriers of Pathogenic Germline Mutations: Interim Results from the Initial Screening Round of the Prostate Cancer Genetic Risk Evaluation and Screening Study., Eur Urol Oncol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/38453598/

104. Kim, A, Chung, KC, Keir, C, Patrick, DL, Patient-reported outcomes associated with cancer screening: a systematic review., BMC Cancer, 2022. 22 (1)(1): p. 223., https://pubmed.ncbi.nlm.nih.gov/35232405/

105. Krilaviciute, A, Albers, P, Lakes, J, Radtke, JP, Herkommer, K, Gschwend, J, et.al. Adherence to a risk-adapted screening strategy for prostate cancer: First results of the PROBASE trial., Int J Cancer, 2023. 152 (5)(5): p. 854-864., https://pubmed.ncbi.nlm.nih.gov/36121664/

106. Bratt, O, Godtman, RA, Jiborn, T, Wallström, J, Akre, O, Carlsson, S, et.al. Population-based Organised Prostate Cancer Testing: Results from the First Invitation of 50-year-old Men., Eur Urol, 2024. 85 (3)(3): p. 207-214., https://pubmed.ncbi.nlm.nih.gov/38042646/

107. Drost, F. J. H., Osses, D. F., Nieboer, D., Steyerberg, E. W., Bangma, C. H., Roobol, M. J., et.al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer, Cochrane Database Syst Rev, 2019. 4(4): p. CD012663., https://pubmed.ncbi.nlm.nih.gov/31022301/

108. Kasivisvanathan, V, Rannikko, AS, Borghi, M, Panebianco, V, Mynderse, LA, Vaarala, MH, et.al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis., N Engl J Med, 2018. 378 (19)(19): p. 1767-1777., https://pubmed.ncbi.nlm.nih.gov/29552975/

109. Rouvière, O., Puech, P., Renard-Penna, R., Claudon, M., Roy, C., Mège-Lechevallier, F., et.al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST), The Lancet. Oncology, 2019. 20(1): p. 100-109., https://pubmed.ncbi.nlm.nih.gov/30470502/

110. van der Leest, M, Cornel, E, Israël, B, Hendriks, R, Padhani, AR, Hoogenboom, M, et.al. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study., Eur Urol, 2019. 75 (4)(4): p. 570-578., https://pubmed.ncbi.nlm.nih.gov/30477981/

111. Haider, MA, Brown, J, Yao, X, Chin, J, Perlis, N, Schieda, N, et.al. Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer: an Updated Systematic Review., Clin Oncol (R Coll Radiol), 2021. 33 (12)(12): p. e599-e612., https://pubmed.ncbi.nlm.nih.gov/34400038/

112. Tu, X, Liu, Z, Zhang, C, Chang, T, Xu, H, Bao, Y, et.al. Diagnostic Role of Magnetic Resonance Imaging-Targeted Biopsy for Prostate Cancer in Biopsy-Naïve Men: A Meta-Analysis., Urol Int, 2020. 104 (3-4)(3-4): p. 187-198., https://pubmed.ncbi.nlm.nih.gov/31825927/

113. Albertsen, PC, Moore, DF, Shih, W, Lin, Y, Li, H, Lu-Yao, GL, Impact of comorbidity on survival among men with localized prostate cancer., J Clin Oncol, 2011. 29 (10)(10): p. 1335-41., https://pubmed.ncbi.nlm.nih.gov/21357791/

114. Wang, L, He, W, Shi, G, Zhao, G, Cen, Z, Xu, F, et.al. Accuracy of novel urinary biomarker tests in the diagnosis of prostate cancer: A systematic review and network meta-analysis., Front Oncol, 2022. 12 (): p. 1048876., https://pubmed.ncbi.nlm.nih.gov/36457516/

115. Josefsson, A, Månsson, M, Kohestani, K, Spyratou, V, Wallström, J, Hellström, M, et.al. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial., Eur Urol, 2024. 86 (3)(3): p. 223-229., https://pubmed.ncbi.nlm.nih.gov/38772787/

116. Stabile, A, Giganti, F, Kasivisvanathan, V, Giannarini, G, Moore, CM, Padhani, AR, et.al. Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review., Eur Urol Oncol, 2020. 3 (2)(2): p. 145-167., https://pubmed.ncbi.nlm.nih.gov/32192942/

117. de Rooij, M, Israël, B, Tummers, M, Ahmed, HU, Barrett, T, Giganti, F, et.al. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training., Eur Radiol, 2020. 30 (10)(10): p. 5404-5416., https://pubmed.ncbi.nlm.nih.gov/32424596/

118. Giganti, F, Allen, C, Emberton, M, Moore, CM, Kasivisvanathan, V, Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial., Eur Urol Oncol, 2020. 3 (5)(5): p. 615-619., https://pubmed.ncbi.nlm.nih.gov/32646850/

119. Franiel, T., Asbach, P. , Beyersdorff, D. , Blondin, D., Kaufmann, S. , Mueller-Lisse, U.G. , et.al. mpMRI of the Prostate (MR-Prostatography): Updated Recommendations of the DRG and BDR on Patient Preparation and Scanning ProtocolRofo, 2021. Online ahead of print:, https://pubmed.ncbi.nlm.nih.gov/33735931/

120. Cuocolo, R, Verde, F, Ponsiglione, A, Romeo, V, Petretta, M, Imbriaco, M, et.al. Clinically Significant Prostate Cancer Detection With Biparametric MRI: A Systematic Review and Meta-Analysis., AJR Am J Roentgenol, 2021. 216 (3)(3): p. 608-621., https://pubmed.ncbi.nlm.nih.gov/33502226/

121. Boschheidgen, M, Albers, P, Schlemmer, HP, Hellms, S, Bonekamp, D, Sauter, A, et.al. Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial., Eur Urol, 2024. 85 (2)(2): p. 105-111., https://pubmed.ncbi.nlm.nih.gov/37863727/

122. Elwenspoek, MMC, Sheppard, AL, McInnes, MDF, Merriel, SWD, Rowe, EWJ, Bryant, RJ, et.al. Comparison of Multiparametric Magnetic Resonance Imaging and Targeted Biopsy With Systematic Biopsy Alone for the Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis., JAMA Netw Open, 2019. 2 (8)(8): p. e198427., https://pubmed.ncbi.nlm.nih.gov/31390032/

123. Wang, X, Xie, Y, Zheng, X, Liu, B, Chen, H, Li, J, et.al. A prospective multi-center randomized comparative trial evaluating outcomes of transrectal ultrasound (TRUS)-guided 12-core systematic biopsy, mpMRI-targeted 12-core biopsy, and artificial intelligence ultrasound of prostate (AIUSP) 6-core targeted biopsy for prostate cancer diagnosis., World J Urol, 2023. 41 (3)(3): p. 653-662., https://pubmed.ncbi.nlm.nih.gov/35852595/

124. Lombardo, R, Tema, G, Nacchia, A, Mancini, E, Franco, S, Zammitti, F, et.al. Role of Perilesional Sampling of Patients Undergoing Fusion Prostate Biopsies., Life (Basel), 2023. 13 (8)(8):, https://pubmed.ncbi.nlm.nih.gov/37629576/

125. Novara, G, Zattoni, F, Zecchini, G, Aceti, A, Pellizzari, A, Ferraioli, G, et.al. Role of targeted biopsy, perilesional biopsy, and random biopsy in prostate cancer diagnosis by mpMRI/transrectal ultrasonography fusion biopsy., World J Urol, 2023. 41 (11)(11): p. 3239-3247., https://pubmed.ncbi.nlm.nih.gov/37079076/

126. Duwe, G, Boehm, K, Haack, M, Sparwasser, P, Brandt, MP, Mager, R, et.al. Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: good functional results but oncologically not as safe as expected., World J Urol, 2023. 41 (5)(5): p. 1293-1299., https://pubmed.ncbi.nlm.nih.gov/36920492/

127. Noujeim, JP, Belahsen, Y, Lefebvre, Y, Lemort, M, Deforche, M, Sirtaine, N, et.al. Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling., Prostate Cancer Prostatic Dis, 2023. 26 (3)(3): p. 575-580., https://pubmed.ncbi.nlm.nih.gov/36509930/

128. Alberts, A.R., Roobol, M.J., Verbeek, J.F.M., Schoots, I.G., Chiu, P.K., Osses, D.F., et.al. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging, European urology, 2019. 75(2): p. 310-318., https://pubmed.ncbi.nlm.nih.gov/30082150/

129. Pagniez, MA, Kasivisvanathan, V, Puech, P, Drumez, E, Villers, A, Olivier, J, Predictive Factors of Missed Clinically Significant Prostate Cancers in Men with Negative Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis., J Urol, 2020. 204 (1)(1): p. 24-32., https://pubmed.ncbi.nlm.nih.gov/31967522/

130. Avolio, PP, Lughezzani, G, Fasulo, V, Maffei, D, Sanchez-Salas, R, Paciotti, M, et.al. Assessing the Role of High-resolution Microultrasound Among Naïve Patients with Negative Multiparametric Magnetic Resonance Imaging and a Persistently High Suspicion of Prostate Cancer., Eur Urol Open Sci, 2023. 47 (): p. 73-79., https://pubmed.ncbi.nlm.nih.gov/36601049/

131. Klotz, L, Chin, J, Black, PC, Finelli, A, Anidjar, M, Bladou, F, et.al. Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial., JAMA Oncol, 2021. 7 (4)(4): p. 534-542., https://pubmed.ncbi.nlm.nih.gov/33538782/

132. You, C, Li, X, Du, Y, Peng, L, Wang, H, Zhang, X, et.al. The Microultrasound-Guided Prostate Biopsy in Detection of Prostate Cancer: A Systematic Review and Meta-Analysis., J Endourol, 2022. 36 (3)(3): p. 394-402., https://pubmed.ncbi.nlm.nih.gov/34569293/

133. Sountoulides, P, Pyrgidis, N, Polyzos, SA, Mykoniatis, I, Asouhidou, E, Papatsoris, A, et.al. Micro-Ultrasound-Guided vs Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis., J Urol, 2021. 205 (5)(5): p. 1254-1262., https://pubmed.ncbi.nlm.nih.gov/33577367/

134. Xie, Y, Tokas, T, Grabski, B, Loch, T, Internal Fusion: exact correlation of transrectal ultrasound images of the prostate by detailed landmarks over time for targeted biopsies or follow-up., World J Urol, 2018. 36 (5)(5): p. 693-698., https://pubmed.ncbi.nlm.nih.gov/29282497/

135. Tokas, T, Grabski, B, Paul, U, Bäurle, L, Loch, T, A 12-year follow-up of ANNA/C-TRUS image-targeted biopsies in patients suspicious for prostate cancer., World J Urol, 2018. 36 (5)(5): p. 699-704., https://pubmed.ncbi.nlm.nih.gov/29275507/

136. Mitterberger, M., Horninger, W., Pelzer, A., Strasser, H., Bartsch, G., Moser, P., et.al. A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detection, Prostate, 2007. 67(14): p. 1537-1542., http://www.ncbi.nlm.nih.gov/pubmed/17705242

137. Braeckman, J., Autier, P., Garbar, C., Marichal, M.P., Soviany, C., Nir, R., et.al. Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer, BJU. Int, 2008. 101(3): p. 293-298., http://www.ncbi.nlm.nih.gov/pubmed/17922870

138. Eggert, T., Khaled, W., Wenske, S., Ermert, H., Noldus, J., Stellenwert der Elastographie in der klinischen Diagnostik des lokalisierten Prostatakarzinoms. Vergleich von Detektionsraten der B-Modus-Sonographie und der elastographieunterstutzten systematischen 10fach-Biopsie, Urologe A, 2008. 47(9): p. 1212-1217., http://www.ncbi.nlm.nih.gov/pubmed/18704361

139. Konig, K., Scheipers, U., Pesavento, A., Lorenz, A., Ermert, H., Senge, T., Initial experiences with real-time elastography guided biopsies of the prostate, J Urol, 2005. 174(1): p. 115-117., http://www.ncbi.nlm.nih.gov/pubmed/15947593

140. Miyagawa, T., Tsutsumi, M., Matsumura, T., Kawazoe, N., Ishikawa, S., Shimokama, T., et.al. Real-time elastography for the diagnosis of prostate cancer: evaluation of elastographic moving images, Jpn J Clin Oncol, 2009. 39(6): p. 394-398., http://www.ncbi.nlm.nih.gov/pubmed/19359330

141. Nelson, E.D., Slotoroff, C.B., Gomella, L.G., Halpern, E.J., Targeted biopsy of the prostate: the impact of color Doppler imaging and elastography on prostate cancer detection and Gleason score, Urology, 2007. 70(6): p. 1136-1140., http://www.ncbi.nlm.nih.gov/pubmed/18158034

142. Salomon, G., Köllerman, J., Thederan, I., Chun, F.K., Budäus, L., Schlomm, T., et.al. Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy, Eur Urol, 2008. 54(6): p. 1354-1362., http://www.ncbi.nlm.nih.gov/pubmed/18374470

143. Tsutsumi, M., Miyagawa, T., Matsumura, T., Kawazoe, N., Ishikawa, S., Shimokama, T., et.al. The impact of real-time tissue elasticity imaging (elastography) on the detection of prostate cancer: clinicopathological analysis, Int J Clin Oncol, 2007. 12(4): p. 250-255., http://www.ncbi.nlm.nih.gov/pubmed/17701002

144. Panebianco, V, Barchetti, G, Simone, G, Del Monte, M, Ciardi, A, Grompone, MD, et.al. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?, Eur Urol, 2018. 74 (1)(1): p. 48-54., https://pubmed.ncbi.nlm.nih.gov/29566957/

145. Grivas, N, Lardas, M, Espinós, EL, Lam, TB, Rouviere, O, Mottet, N, et.al. Prostate Cancer Detection Percentages of Repeat Biopsy in Patients with Positive Multiparametric Magnetic Resonance Imaging (Prostate Imaging Reporting and Data System/Likert 3-5) and Negative Initial Biopsy. A Mini Systematic Review., Eur Urol, 2022. 82 (5)(5): p. 452-457., https://pubmed.ncbi.nlm.nih.gov/35985901/

146. Venderink, W, Jenniskens, SF, Michiel Sedelaar, JP, Tamada, T, Fütterer, JJ, Yield of Repeat Targeted Direct in-Bore Magnetic Resonance-Guided Prostate Biopsy (MRGB) of the Same Lesions in Men Having a Prior Negative Targeted MRGB., Korean J Radiol, 2018. 19 (4)(4): p. 733-741., https://pubmed.ncbi.nlm.nih.gov/29962879/

147. Lee, KS, Koo, KC, Cho, KS, Lee, SH, Han, WK, Choi, YD, et.al. Indications for a second prostate biopsy in patients suspected with prostate cancer after an initial negative prostate biopsy., Prostate Int, 2017. 5 (1)(1): p. 24-28., https://pubmed.ncbi.nlm.nih.gov/28352620/

148. Ploussard, G, Nicolaiew, N, Marchand, C, Terry, S, Allory, Y, Vacherot, F, et.al. Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial., BJU Int, 2013. 111 (6)(6): p. 988-96., https://pubmed.ncbi.nlm.nih.gov/23452046/

149. Quentin, M, Boschheidgen, M, Radtke, JP, Spohn, F, Ullrich, T, Drewes, L, et.al. MRI in-bore biopsy following MRI/US fusion-guided biopsy in patients with persistent suspicion of clinically significant prostate cancer., Eur J Radiol, 2024. 175 (): p. 111436., https://pubmed.ncbi.nlm.nih.gov/38522396/

150. Perrin, A., Venderink, W., Patak, M. A., Möckel, Cl., Fehr, J.L., Jichlinski, P., et.al. The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy, Urologic oncology, 2020., https://pubmed.ncbi.nlm.nih.gov/33341358/

151. Beetz, NL, Dräger, F, Hamm, CA, Shnayien, S, Rudolph, MM, Froböse, K, et.al. MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed., Prostate Cancer Prostatic Dis, 2023. 26 (3)(3): p. 543-551., https://pubmed.ncbi.nlm.nih.gov/36209237/

152. Ploussard, G, Barret, E, Fiard, G, Lenfant, L, Malavaud, B, Giannarini, G, et.al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1)., Eur Urol Oncol, 2024. 7 (5)(5): p. 1080-1087., https://pubmed.ncbi.nlm.nih.gov/38403523/

153. Eichler, K., Hempel, S., Wilby, J., Myers, L., Bachmann, L.M., Kleijnen, J., Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review, J Urol, 2006. 175(5): p. 1605-1612., http://www.ncbi.nlm.nih.gov/pubmed/16600713

154. Bootsma, A.M., Laguna Pes, M.P., Geerlings, S.E., Goossens, A., Antibiotic prophylaxis in urologic procedures: a systematic review, Eur Urol, 2008. 54(6): p. 1270-1286., http://www.ncbi.nlm.nih.gov/pubmed/18423974

155. Pilatz, A, Dimitropoulos, K, Veeratterapillay, R, Yuan, Y, Omar, MI, MacLennan, S, et.al. Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis., J Urol, 2020. 204 (2)(2): p. 224-230., https://pubmed.ncbi.nlm.nih.gov/32105195/

156. Pradere, B, Veeratterapillay, R, Dimitropoulos, K, Yuan, Y, Omar, MI, MacLennan, S, et.al. Nonantibiotic Strategies for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-Analysis., J Urol, 2021. 205 (3)(3): p. 653-663., https://pubmed.ncbi.nlm.nih.gov/33026903/

157. Jacewicz, M, Günzel, K, Rud, E, Sandbæk, G, Magheli, A, Busch, J, et.al. Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial., Lancet Infect Dis, 2022. 22 (10)(10): p. 1465-1471., https://pubmed.ncbi.nlm.nih.gov/35839791/

158. Basourakos, SP, Alshak, MN, Lewicki, PJ, Cheng, E, Tzeng, M, DeRosa, AP, et.al. Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis., Eur Urol Open Sci, 2022. 37 (): p. 53-63., https://pubmed.ncbi.nlm.nih.gov/35243391/

159. Richman, J.M., Carter, H.B., Hanna, M.N., Murphy, J.D., Rowlingson, A.J., Andrews, R.A., et.al. Efficacy of periprostatic local anesthetic for prostate biopsy analgesia: a meta-analysis, Urology, 2006. 67(6): p. 1224-1228., http://www.ncbi.nlm.nih.gov/pubmed/16765183

160. Tiong, H.Y., Liew, L.C., Samuel, M., Consigliere, D., Esuvaranathan, K., A meta-analysis of local anesthesia for transrectal ultrasound-guided biopsy of the prostate, Prostate Cancer Prostatic Dis, 2007. 10(2): p. 127-136., http://www.ncbi.nlm.nih.gov/pubmed/17211441

161. von Knobloch, R, Weber, J, Varga, Z, Feiber, H, Heidenreich, A, Hofmann, R, Bilateral fine-needle administered local anaesthetic nerve block for pain control during TRUS-guided multi-core prostate biopsy: a prospective randomised trial., Eur Urol, 2002. 41 (5)(5): p. 508-14; discussion 514., https://pubmed.ncbi.nlm.nih.gov/12074792/

162. Bass, EJ, Donaldson, IA, Freeman, A, Jameson, C, Punwani, S, Moore, C, et.al. Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach., Prostate Cancer Prostatic Dis, 2017. 20 (3)(3): p. 311-317., https://pubmed.ncbi.nlm.nih.gov/28485391/

163. Immerzeel, J, Israël, B, Bomers, J, Schoots, IG, van Basten, JP, Kurth, KH, et.al. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 4: Transperineal Magnetic Resonance-Ultrasound Fusion Guided Biopsy Using Local Anesthesia., Eur Urol, 2022. 81 (1)(1): p. 110-117., https://pubmed.ncbi.nlm.nih.gov/34799197/

164. Xiang, J, Yan, H, Li, J, Wang, X, Chen, H, Zheng, X, Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis., World J Surg Oncol, 2019. 17 (1)(1): p. 31., https://pubmed.ncbi.nlm.nih.gov/30760274/

165. Pritchard, C.C., Mateo, J., Walsh, M.F., Sarkar, N., Abida, W., Beltran, H., et.al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer, The New England journal of medicine, 2016. 375(5): p. 443-453., https://pubmed.ncbi.nlm.nih.gov/27433846/

166. Breen, KE, Symecko, H, Spielman, K, Gebert, R, Shah, IH, Pundock, S, et.al. Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients., J Urol, 2023. 209 (5)(5): p. 918-927., https://pubmed.ncbi.nlm.nih.gov/36974724/

167. Haider, M.A., Yao, X., Loblaw, A., Finelli, A., Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer: A Systematic Review, Clin Oncol (R Coll Radiol), 2016. 28(9): p. 550-567., https://www.ncbi.nlm.nih.gov/pubmed/27256655

168. Roobol, MJ, Verbeek, JFM, van der Kwast, T, Kümmerlin, IP, Kweldam, CF, van Leenders, GJLH, Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth., Eur Urol, 2017. 72 (1)(1): p. 45-51., https://pubmed.ncbi.nlm.nih.gov/28162815/

169. Mannaerts, CK, Gayet, M, Verbeek, JF, Engelbrecht, MRW, Savci-Heijink, CD, Jager, GJ, et.al. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy., Eur Urol Oncol, 2018. 1 (2)(2): p. 109-117., https://pubmed.ncbi.nlm.nih.gov/31100233/

170. Hagens, MJ, Stelwagen, PJ, Veerman, H, Rynja, SP, Smeenge, M, van der Noort, V, et.al. External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort., World J Urol, 2023. 41 (1)(1): p. 13-18., https://pubmed.ncbi.nlm.nih.gov/36245015/

171. Bandala-Jacques, A, Castellanos Esquivel, KD, Pérez-Hurtado, F, Hernández-Silva, C, Reynoso-Noverón, N, Prostate Cancer Risk Calculators for Healthy Populations: Systematic Review., JMIR Cancer, 2021. 7 (3)(3): p. e30430., https://pubmed.ncbi.nlm.nih.gov/34477564/

172. SWOP – The Prostate Cancer Research Foundation, Reeuwijk, Rotterdam prostate cancer risk calculator (RPCRC) / ERSPC-Kohorte, 2024., www.prostatecancer-riskcalculator.com/seven-prostate-cancer-risk-calculators

173. PCPTRC 2.0 Risikokalkulator / Prostate Cancer Prevention Trial Kohorte, UT Health San Antonio, 2018., https://riskcalc.org/PCPTRC/

174. Remmers, S, Nieboer, D, Rijstenberg, LL, Hansum, T, van Leenders, GJLH, Roobol, MJ, Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy., Eur Urol Open Sci, 2022. 36 (): p. 19-22., https://pubmed.ncbi.nlm.nih.gov/34977692/

175. Palsdottir, T, Grönberg, H, Hilmisson, A, Eklund, M, Nordström, T, Vigneswaran, HT, External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort., Eur Urol Focus, 2023. 9 (3)(3): p. 455-462., https://pubmed.ncbi.nlm.nih.gov/36522257/

176. Davik, P, Remmers, S, Elschot, M, Roobol, MJ, Bathen, TF, Bertilsson, H, Performance of magnetic resonance imaging-based prostate cancer risk calculators and decision strategies in two large European medical centres., BJU Int, 2024. 133 (3)(3): p. 278-288., https://pubmed.ncbi.nlm.nih.gov/37607322/

177. Remmers, S, Kasivisvanathan, V, Verbeek, JFM, Moore, CM, Roobol, MJ, Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data., Eur Urol Open Sci, 2022. 36 (): p. 1-8., https://pubmed.ncbi.nlm.nih.gov/35098168/

178. Studenski, S, Perera, S, Patel, K, Rosano, C, Faulkner, K, Inzitari, M, et.al. Gait speed and survival in older adults., JAMA, 2011. 305 (1)(1): p. 50-8., https://pubmed.ncbi.nlm.nih.gov/21205966/

179. Randazzo, M, Müller, A, Carlsson, S, Eberli, D, Huber, A, Grobholz, R, et.al. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau)., BJU Int, 2016. 117 (4)(4): p. 576-83., https://pubmed.ncbi.nlm.nih.gov/26332304/

180. Becerra, MF, Bhat, A, Mouzannar, A, Atluri, VS, Punnen, S, Serum and urinary biomarkers for detection and active surveillance of prostate cancer., Curr Opin Urol, 2019. 29 (6)(6): p. 593-597., https://pubmed.ncbi.nlm.nih.gov/31436568/

181. Campistol, M, Morote, J, Regis, L, Celma, A, Planas, J, Trilla, E, Proclarix, A New Biomarker for the Diagnosis of Clinically Significant Prostate Cancer: A Systematic Review., Mol Diagn Ther, 2022. 26 (3)(3): p. 273-281., https://pubmed.ncbi.nlm.nih.gov/35471698/

182. Möller, A, Olsson, H, Grönberg, H, Eklund, M, Aly, M, Nordström, T, The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort., Prostate Cancer Prostatic Dis, 2019. 22 (1)(1): p. 137-142., https://pubmed.ncbi.nlm.nih.gov/30171228/

183. Morote, J, Campistol, M, Regis, L, Celma, A, de Torres, I, Semidey, ME, et.al. Who with suspected prostate cancer can benefit from Proclarix after multiparametric magnetic resonance imaging?, Int J Biol Markers, 2022. 37 (2)(2): p. 218-223., https://pubmed.ncbi.nlm.nih.gov/35200058/

184. Vigneswaran, HT, Eklund, M, Discacciati, A, Nordström, T, Hubbard, RA, Perlis, N, et.al. Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial., J Clin Oncol, 2024. (): p. JCO2400152., https://pubmed.ncbi.nlm.nih.gov/39038251/

185. Triquell, M, Campistol, M, Celma, A, Regis, L, Cuadras, M, Planas, J, et.al. Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review., Cancers (Basel), 2022. 14 (19)(19):, https://pubmed.ncbi.nlm.nih.gov/36230670/

186. Exterkate, L, Wegelin, O, Barentsz, JO, van der Leest, MG, Kummer, JA, Vreuls, W, et.al. Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial., BJU Int, 2023. 131 (3)(3): p. 313-320., https://pubmed.ncbi.nlm.nih.gov/35993590/

187. Hansen, NL, Barrett, T, Kesch, C, Pepdjonovic, L, Bonekamp, D, O'Sullivan, R, et.al. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer., BJU Int, 2018. 122 (1)(1): p. 40-49., https://pubmed.ncbi.nlm.nih.gov/29024425/

188. Omri, N, Kamil, M, Alexander, K, Alexander, K, Edmond, S, Ariel, Z, et.al. Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume., Prostate, 2020. 80 (16)(16): p. 1444-1449., https://pubmed.ncbi.nlm.nih.gov/32970856/

189. Schoots, IG, Padhani, AR, Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation., BJU Int, 2021. 127 (2)(2): p. 175-178., https://pubmed.ncbi.nlm.nih.gov/33089586/

190. Wang, S, Kozarek, J, Russell, R, Drescher, M, Khan, A, Kundra, V, et.al. Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis., Eur Urol Oncol, 2024. 7 (2)(2): p. 189-203., https://pubmed.ncbi.nlm.nih.gov/37640584/

191. Franiel, T., Quentin, M., Mueller-Lisse, U.G., Schimmoeller, L., Asbach, P., Rodel, S., et.al. MRT der Prostata: Empfehlungen zur Vorbereitung und Durchführung, Rofo, 2017. 189(1): p. 21-28., http://www.ncbi.nlm.nih.gov/pubmed/28002857

192. Lu, AJ, Syed, JS, Ghabili, K, Hsiang, WR, Nguyen, KA, Leapman, MS, et.al. Role of Core Number and Location in Targeted Magnetic Resonance Imaging-Ultrasound Fusion Prostate Biopsy., Eur Urol, 2019. 76 (1)(1): p. 14-17., https://pubmed.ncbi.nlm.nih.gov/31047733/

193. Sonmez, G, Demirtas, T, Tombul, ST, Ozturk, F, Demirtas, A, What is the ideal number of biopsy cores per lesion in targeted prostate biopsy?, Prostate Int, 2020. 8 (3)(3): p. 112-115., https://pubmed.ncbi.nlm.nih.gov/33102391/

194. Wegelin, O, Exterkate, L, van der Leest, M, Kummer, JA, Vreuls, W, de Bruin, PC, et.al. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies., Eur Urol, 2019. 75 (4)(4): p. 582-590., https://pubmed.ncbi.nlm.nih.gov/30522912/

195. Exterkate, L, Wegelin, O, Barentsz, JO, van der Leest, MG, Kummer, JA, Vreuls, W, et.al. Is There Still a Need for Repeated Systematic Biopsies in Patients with Previous Negative Biopsies in the Era of Magnetic Resonance Imaging-targeted Biopsies of the Prostate?, Eur Urol Oncol, 2020. 3 (2)(2): p. 216-223., https://pubmed.ncbi.nlm.nih.gov/31239236/

196. Oerther, B, Engel, H, Bamberg, F, Sigle, A, Gratzke, C, Benndorf, M, Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level., Prostate Cancer Prostatic Dis, 2022. 25 (2)(2): p. 256-263., https://pubmed.ncbi.nlm.nih.gov/34230616/

197. Hamm, CA, Asbach, P, Pöhlmann, A, Schoots, IG, Kasivisvanathan, V, Henkel, TO, et.al. Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer., JAMA Oncol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/39666360/

198. Lee, H.Y., Lee, H.J., Byun, S.S., Lee, S.E., Hong, S.K., Kim, S.H., Classification of focal prostatic lesions on transrectal ultrasound (TRUS) and the accuracy of TRUS to diagnose prostate cancer, Korean J Radiol, 2009. 10(3): p. 244-251., http://www.ncbi.nlm.nih.gov/pubmed/19412512

199. Tamsel, S., Killi, R., Hekimgil, M., Altay, B., Soydan, S., Demirpolat, G., Transrectal ultrasound in detecting prostate cancer compared with serum total prostate-specific antigen levels, J Med Imaging Radiat Oncol, 2008. 52(1): p. 24-28., http://www.ncbi.nlm.nih.gov/pubmed/18373822

200. Pavlovich, CP, Hyndman, ME, Eure, G, Ghai, S, Caumartin, Y, Herget, E, et.al. A multi-institutional randomized controlled trial comparing first-generation transrectal high-resolution micro-ultrasound with conventional frequency transrectal ultrasound for prostate biopsy., BJUI Compass, 2021. 2 (2)(2): p. 126-133., https://pubmed.ncbi.nlm.nih.gov/35474889/

201. Wiemer, L, Hollenbach, M, Heckmann, R, Kittner, B, Plage, H, Reimann, M, et.al. Evolution of Targeted Prostate Biopsy by Adding Micro-Ultrasound to the Magnetic Resonance Imaging Pathway., Eur Urol Focus, 2021. 7 (6)(6): p. 1292-1299., https://pubmed.ncbi.nlm.nih.gov/32654967/

202. Klotz, L, Lughezzani, G, Maffei, D, Sánchez, A, Pereira, JG, Staerman, F, et.al. Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer: A multicenter, prospective analysis., Can Urol Assoc J, 2021. 15 (1)(1): p. E11-E16., https://pubmed.ncbi.nlm.nih.gov/32701437/

203. Ukimura, O, Marien, A, Palmer, S, Villers, A, Aron, M, de Castro Abreu, AL, et.al. Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies., World J Urol, 2015. 33 (11)(11): p. 1669-76., https://pubmed.ncbi.nlm.nih.gov/25656687/

204. Lorusso, V, Kabre, B, Pignot, G, Branger, N, Pacchetti, A, Thomassin-Piana, J, et.al. External validation of the computerized analysis of TRUS of the prostate with the ANNA/C-TRUS system: a potential role of artificial intelligence for improving prostate cancer detection., World J Urol, 2023. 41 (3)(3): p. 619-625., https://pubmed.ncbi.nlm.nih.gov/35249120/

205. Penzkofer, T, Padhani, AR, Turkbey, B, Ahmed, HU, Assessing the clinical performance of artificial intelligence software for prostate cancer detection on MRI., Eur Radiol, 2022. 32 (4)(4): p. 2221-2223., https://pubmed.ncbi.nlm.nih.gov/35195746/

206. Lee, MS, Kim, YJ, Moon, MH, Kim, KG, Park, JH, Sung, CK, et.al. Transitional zone prostate cancer: Performance of texture-based machine learning and image-based deep learning., Medicine (Baltimore), 2023. 102 (39)(39): p. e35039., https://pubmed.ncbi.nlm.nih.gov/37773806/

207. Hamm, CA, Baumgärtner, GL, Biessmann, F, Beetz, NL, Hartenstein, A, Savic, LJ, et.al. Interactive Explainable Deep Learning Model Informs Prostate Cancer Diagnosis at MRI., Radiology, 2023. 307 (4)(4): p. e222276., https://pubmed.ncbi.nlm.nih.gov/37039688/

208. Saha, A, Bosma, JS, Twilt, JJ, van Ginneken, B, Bjartell, A, Padhani, AR, et.al. Artificial intelligence and radiologists in prostate cancer detection on MRI (PI-CAI): an international, paired, non-inferiority, confirmatory study., Lancet Oncol, 2024. 25 (7)(7): p. 879-887., https://pubmed.ncbi.nlm.nih.gov/38876123/

209. Schelb, P, Kohl, S, Radtke, JP, Wiesenfarth, M, Kickingereder, P, Bickelhaupt, S, et.al. Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment., Radiology, 2019. 293 (3)(3): p. 607-617., https://pubmed.ncbi.nlm.nih.gov/31592731/

210. Hosseinzadeh, M, Saha, A, Brand, P, Slootweg, I, de Rooij, M, Huisman, H, Deep learning-assisted prostate cancer detection on bi-parametric MRI: minimum training data size requirements and effect of prior knowledge., Eur Radiol, 2022. 32 (4)(4): p. 2224-2234., https://pubmed.ncbi.nlm.nih.gov/34786615/

211. Labus, S, Altmann, MM, Huisman, H, Tong, A, Penzkofer, T, Choi, MH, et.al. A concurrent, deep learning-based computer-aided detection system for prostate multiparametric MRI: a performance study involving experienced and less-experienced radiologists., Eur Radiol, 2023. 33 (1)(1): p. 64-76., https://pubmed.ncbi.nlm.nih.gov/35900376/

212. Dratsch, T, Chen, X, Rezazade Mehrizi, M, Kloeckner, R, Mähringer-Kunz, A, Püsken, M, et.al. Automation Bias in Mammography: The Impact of Artificial Intelligence BI-RADS Suggestions on Reader Performance., Radiology, 2023. 307 (4)(4): p. e222176., https://pubmed.ncbi.nlm.nih.gov/37129490/

213. Kaneko, M, Lenon, MSL, Storino Ramacciotti, L, Medina, LG, Sayegh, AS, La Riva, A, et.al. Multiparametric ultrasound of prostate: role in prostate cancer diagnosis., Ther Adv Urol, 2022. 14 (): p. 17562872221145625., https://pubmed.ncbi.nlm.nih.gov/36601020/

214. Cochlin, D.L., Ganatra, R.H., Griffiths, D.F., Elastography in the detection of prostatic cancer, Clin Radiol, 2002. 57(11): p. 1014-1020., https://www.ncbi.nlm.nih.gov/pubmed/12409113

215. Kamoi, K., Okihara, K., Ochiai, A., Ukimura, O., Mizutani, Y., Kawauchi, A., et.al. The utility of transrectal real-time elastography in the diagnosis of prostate cancer, Ultrasound Med Biol, 2008. 34(7): p. 1025-1032., http://www.ncbi.nlm.nih.gov/pubmed/18255215

216. Ren, X, Nur Salihin Yusoff, M, Hartini Mohd Taib, N, Zhang, L, Wang, K, None, Eur J Radiol, 2024. 170 (): p. 111274., https://pubmed.ncbi.nlm.nih.gov/38147764/

217. Zhao, Y, Simpson, BS, Morka, N, Freeman, A, Kirkham, A, Kelly, D, et.al. Comparison of Multiparametric Magnetic Resonance Imaging with Prostate-Specific Membrane Antigen Positron-Emission Tomography Imaging in Primary Prostate Cancer Diagnosis: A Systematic Review and Meta-Analysis., Cancers (Basel), 2022. 14 (14)(14):, https://pubmed.ncbi.nlm.nih.gov/35884558/

218. Mookerji, N, Pfanner, T, Hui, A, Huang, G, Albers, P, Mittal, R, et.al. Fluorine-18 Prostate-Specific Membrane Antigen-1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer., JAMA Oncol, 2024. 10 (8)(8): p. 1097-1103., https://pubmed.ncbi.nlm.nih.gov/38949926/

219. Ma, J, Yang, Q, Ye, X, Xu, W, Chang, Y, Chen, R, et.al. Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis., Eur Radiol, 2024. 34 (6)(6): p. 4017-4037., https://pubmed.ncbi.nlm.nih.gov/37981590/

220. Kornienko, K, Reuter, M, Maxeiner, A, Günzel, K, Kittner, B, Reimann, M, et.al. Follow-up of men with a PI-RADS 4/5 lesion after negative MRI/Ultrasound fusion biopsy., Sci Rep, 2022. 12 (1)(1): p. 13603., https://pubmed.ncbi.nlm.nih.gov/35948575/

221. Vickers, A.J., Cronin, A.M., Bjork, T., Manjer, J., Nilsson, P.M., Dahlin, A., et.al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study, BMJ, 2010. 341: p. c4521., http://www.ncbi.nlm.nih.gov/pubmed/20843935

222. Borboroglu, P.G., Sur, R.L., Roberts, J.L., Amling, C.L., Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy, J Urol, 2001. 166(3): p. 866-870., http://www.ncbi.nlm.nih.gov/pubmed/11490235

223. Iczkowski, K.A., Bassler, T.J., Schwob, V.S., Bassler, I.C., Kunnel, B.S., Orozco, R.E., et.al. Diagnosis of "suspicious for malignancy" in prostate biopsies: predictive value for cancer, Urology, 1998. 51(5): p. 749-757., http://www.ncbi.nlm.nih.gov/pubmed/9610588

224. Davidson, D., Bostwick, D.G., Qian, J., Wollan, P.C., Oesterling, J.E., Rudders, R.A., et.al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies, J Urol, 1995. 154(4): p. 1295-1299., http://www.ncbi.nlm.nih.gov/pubmed/7544835

225. Epstein, J.I., Herawi, M., Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care, J Urol, 2006. 175(3 Pt 1): p. 820-834., http://www.ncbi.nlm.nih.gov/pubmed/16469560

226. Netto, G.J., Epstein, J.I., Widespread high-grade prostatic intraepithelial neoplasia on prostatic needle biopsy: a significant likelihood of subsequently diagnosed adenocarcinoma, Am J Surg Pathol, 2006. 30(9): p. 1184-1188., http://www.ncbi.nlm.nih.gov/pubmed/16931964

227. Wiener, S, Haddock, P, Cusano, J, Staff, I, McLaughlin, T, Wagner, J, Incidence of Clinically Significant Prostate Cancer After a Diagnosis of Atypical Small Acinar Proliferation, High-grade Prostatic Intraepithelial Neoplasia, or Benign Tissue., Urology, 2017. 110 (): p. 161-165., https://pubmed.ncbi.nlm.nih.gov/28888752/

228. Örtegren, J, Kohestani, K, Elvstam, O, Janson, H, Åberg, D, Kjölhede, H, et.al. Risk Factors for Infection After Transrectal Prostate Biopsy: A Population-based Register Study., Eur Urol Open Sci, 2024. 67 (): p. 1-6., https://pubmed.ncbi.nlm.nih.gov/39104794/

229. Somoto, T, Utsumi, T, Ishitsuka, N, Noro, T, Suzuki, Y, Iijima, S, et.al. Clinical Predictors of Fluoroquinolone-Resistant Escherichia coli in Transrectal Ultrasound-Guided Prostate Biopsy: Insights for Tailored Prophylaxis., Int J Urol, 2025. ():, https://pubmed.ncbi.nlm.nih.gov/40275644/

230. Bouzouita, A, Rehaiem, A, Saadi, A, Zaghbib, S, Chakroun, M, Ayed, H, et.al. Antimicrobial prophylaxis protocol based on rectal swab culture before prostate biopsy to prevent infectious complications: a prospective randomized comparative study., Int Urol Nephrol, 2024. 56 (8)(8): p. 2495-2502., https://pubmed.ncbi.nlm.nih.gov/38448785/

231. Taylor, AK, Murphy, AB, Preprostate Biopsy Rectal Culture and Postbiopsy Sepsis., Urol Clin North Am, 2015. 42 (4)(4): p. 449-58., https://pubmed.ncbi.nlm.nih.gov/26475942/

232. Cook, I, Angel, JB, Vera, PL, Demos, J, Preston, D, Rectal swab testing before prostate biopsy: experience in a VA Medical Center urology practice., Prostate Cancer Prostatic Dis, 2015. 18 (4)(4): p. 365-9., https://pubmed.ncbi.nlm.nih.gov/26260997/

233. Singh, P, Kumar, A, Yadav, S, Prakash, L, Nayak, B, Kumar, R, et.al. "Targeted" prophylaxis: Impact of rectal swab culture-directed prophylaxis on infectious complications after transrectal ultrasound-guided prostate biopsy., Investig Clin Urol, 2017. 58 (5)(5): p. 365-370., https://pubmed.ncbi.nlm.nih.gov/28868509/

234. Summers, SJ, Patel, DP, Hamilton, BD, Presson, AP, Fisher, MA, Lowrance, WT, et.al. An antimicrobial prophylaxis protocol using rectal swab cultures for transrectal prostate biopsy., World J Urol, 2015. 33 (12)(12): p. 2001-7., https://pubmed.ncbi.nlm.nih.gov/25935330/

235. Benli, E, Yuce, A, Cirakoglu, A, Yazici, I, Kadim, N, Nalbant, I, Effect of targeted prophylaxis with rectal swab on complications after prostate biopsy: prospective randomized study., Ir J Med Sci, 2022. 191 (3)(3): p. 1147-1152., https://pubmed.ncbi.nlm.nih.gov/34304346/

236. Gatsos, S, Kalogeras, N, Dimakopoulos, G, Samarinas, M, Papakonstantinou, A, Petinaki, E, et.al. Infectious complications of transrectal prostate biopsy in patients receiving targeted antibiotic prophylaxis after urethral and rectal swab versus standard prophylaxis: A prospective comparative study., Prostate Int, 2024. 12 (1)(1): p. 35-39., https://pubmed.ncbi.nlm.nih.gov/38523904/

237. Hergan, L., Kashefi, C., Parsons, J.K., Local anesthetic reduces pain associated with transrectal ultrasound-guided prostate biopsy: a meta-analysis, Urology, 2007. 69(3): p. 520-525., https://www.ncbi.nlm.nih.gov/pubmed/17382157

238. Lichtenstein, P, Holm, NV, Verkasalo, PK, Iliadou, A, Kaprio, J, Koskenvuo, M, et.al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland., N Engl J Med, 2000. 343 (2)(2): p. 78-85., https://pubmed.ncbi.nlm.nih.gov/10891514/

239. Carter, BS, Bova, GS, Beaty, TH, Steinberg, GD, Childs, B, Isaacs, WB, et.al. Hereditary prostate cancer: epidemiologic and clinical features., J Urol, 1993. 150 (3)(3): p. 797-802., https://pubmed.ncbi.nlm.nih.gov/8345587/

240. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Analkarzinom (Diagnostik, Therapie und Nachsorge von Analkanal- und Analrandkarzinomen), Langversion 1.2, 2020, AWMF Registernummer: 081/004OL, 2020., https://www.leitlinienprogramm-onkologie.de/leitlinien/analkarzinom/

241. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.4, 2021, AWMF Registernummer: 032-045OL, 2021., http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/

242. Giri, VN, Knudsen, KE, Kelly, WK, Abida, W, Andriole, GL, Bangma, CH, et.al. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017., J Clin Oncol, 2018. 36 (4)(4): p. 414-424., https://pubmed.ncbi.nlm.nih.gov/29236593/

243. Giri, VN, Knudsen, KE, Kelly, WK, Cheng, HH, Cooney, KA, Cookson, MS, et.al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019., J Clin Oncol, 2020. 38 (24)(24): p. 2798-2811., https://pubmed.ncbi.nlm.nih.gov/32516092/

244. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer version 4.2024, 2024., www.nccn.org/guidelines/guidelines-detail?category=1&id=1459

245. Nicolosi, P, Ledet, E, Yang, S, Michalski, S, Freschi, B, O'Leary, E, et.al. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines., JAMA Oncol, 2019. 5 (4)(4): p. 523-528., https://pubmed.ncbi.nlm.nih.gov/30730552/

246. Greenberg, SE, Hunt, TC, Ambrose, JP, Lowrance, WT, Dechet, CB, O'Neil, BB, et.al. Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion., JCO Precis Oncol, 2021. 5 ():, https://pubmed.ncbi.nlm.nih.gov/34250421/

247. Truong, H, Breen, K, Nandakumar, S, Sjoberg, DD, Kemel, Y, Mehta, N, et.al. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer., Eur Urol, 2023. 83 (1)(1): p. 29-38., https://pubmed.ncbi.nlm.nih.gov/36115772/

248. Stadler, ZK, Maio, A, Chakravarty, D, Kemel, Y, Sheehan, M, Salo-Mullen, E, et.al. Therapeutic Implications of Germline Testing in Patients With Advanced Cancers., J Clin Oncol, 2021. 39 (24)(24): p. 2698-2709., https://pubmed.ncbi.nlm.nih.gov/34133209/

249. Darst, BF, Dadaev, T, Saunders, E, Sheng, X, Wan, P, Pooler, L, et.al. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer., J Natl Cancer Inst, 2021. 113 (5)(5): p. 616-625., https://pubmed.ncbi.nlm.nih.gov/32853339/

250. Lee, DJ, Hausler, R, Le, AN, Kelly, G, Powers, J, Ding, J, et.al. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer., Eur Urol, 2022. 81 (6)(6): p. 559-567., https://pubmed.ncbi.nlm.nih.gov/34711450/

251. Shore, N, Gazi, M, Pieczonka, C, Heron, S, Modh, R, Cahn, D, et.al. Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial., Eur Urol Oncol, 2023. 6 (5)(5): p. 477-483., https://pubmed.ncbi.nlm.nih.gov/37574391/

252. Choudry, MM, Durant, AM, Edmonds, VS, Warren, CJ, Kunze, KL, Golafshar, MA, et.al. Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study., J Urol, 2024. 212 (4)(4): p. 590-599., https://pubmed.ncbi.nlm.nih.gov/38860938/

253. Mohler, JL, Armstrong, AJ, Bahnson, RR, D'Amico, AV, Davis, BJ, Eastham, JA, et.al. Prostate Cancer, Version 1.2016., J Natl Compr Canc Netw, 2016. 14 (1)(1): p. 19-30., https://pubmed.ncbi.nlm.nih.gov/26733552/

254. Wittekind, C., Klimpfinger, M., Sobin, L.H., TNM : Klassifikation maligner TumorenWiley-VCH, 2017.

255. D'Amico, A.V., Whittington, R., Malkowicz, S.B., Schultz, D., Blank, K., Broderick, G.A., et.al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer, JAMA, 1998. 280(11): p. 969-974., http://www.ncbi.nlm.nih.gov/pubmed/9749478

256. Gnanapragasam, VJ, Bratt, O, Muir, K, Lee, LS, Huang, HH, Stattin, P, et.al. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study., BMC Med, 2018. 16 (1)(1): p. 31., https://pubmed.ncbi.nlm.nih.gov/29490658/

257. Parry, MG, Cowling, TE, Sujenthiran, A, Nossiter, J, Berry, B, Cathcart, P, et.al. Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation., BMC Med, 2020. 18 (1)(1): p. 114., https://pubmed.ncbi.nlm.nih.gov/32460859/

258. Karpinski, MJ, Hüsing, J, Claassen, K, Möller, L, Kajüter, H, Oesterling, F, et.al. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study., Lancet Oncol, 2024. 25 (9)(9): p. 1188-1201., https://pubmed.ncbi.nlm.nih.gov/39089299/

259. Hofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P., et.al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA), Lancet, 2020. 395(10231): p. 1208-1216., https://pubmed.ncbi.nlm.nih.gov/32209449/

260. Thompson, I., Thrasher, J.B., Aus, G., Burnett, A.L., Canby-Hagino, E.D., Cookson, M.S., et.al. Guideline for the management of clinically localized prostate cancer: 2007 update (confirmed 2009), J Urol, 2007. 177(6): p. 2106-2131., http://www.ncbi.nlm.nih.gov/pubmed/17509297

261. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Prostate Cancer, Version 1.2025 — December 4, 2024, 2025., https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

262. Cornford, P, van den Bergh, RCN, Briers, E, Van den Broeck, T, Brunckhorst, O, Darraugh, J, et.al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent., Eur Urol, 2024. 86 (2)(2): p. 148-163., https://pubmed.ncbi.nlm.nih.gov/38614820/

263. Chow, KM, So, WZ, Lee, HJ, Lee, A, Yap, DWT, Takwoingi, Y, et.al. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis., Eur Urol, 2023. 84 (1)(1): p. 36-48., https://pubmed.ncbi.nlm.nih.gov/37032189/

264. Wang, YF, Lo, CY, Chen, LY, Chang, CW, Huang, YT, Huang, YY, et.al. Comparing the Detection Performance Between Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen PET/CT in Patients With Localized Prostate Cancer: A Systematic Review and Meta-analysis., Clin Nucl Med, 2023. 48 (7)(7): p. e321-e331., https://pubmed.ncbi.nlm.nih.gov/37145456/

265. Luining, WI, Boevé, LMS, Hagens, MJ, Meijer, D, de Weijer, T, Ettema, RH, et.al. A Comparison of Globally Applied Prognostic Risk Groups and the Prevalence of Metastatic Disease on Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer., Eur Urol Oncol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/38693019/

266. Zhao, R, Li, Y, Nie, L, Qin, K, Zhang, H, Shi, H, The meta-analysis of the effect of 68Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan., Medicine (Baltimore), 2021. 100 (15)(15): p. e25417., https://pubmed.ncbi.nlm.nih.gov/33847640/

267. Briganti, A., Chun, F.K., Salonia, A., Gallina, A., Farina, E., Da Pozzo, L.F., et.al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer, BJU Int, 2006. 98(4): p. 788-793., http://www.ncbi.nlm.nih.gov/pubmed/16796698

268. Chun, F.K., Briganti, A., Graefen, M., Montorsi, F., Porter, C., Scattoni, V., et.al. Development and external validation of an extended 10-core biopsy nomogram, Eur Urol, 2007. 52(2): p. 436-444., http://www.ncbi.nlm.nih.gov/pubmed/17010505

269. Steuber, T., Graefen, M., Haese, A., Erbersdobler, A., Chun, F.K., Schlom, T., et.al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy, J Urol, 2006. 175(3 Pt 1): p. 939-944., http://www.ncbi.nlm.nih.gov/pubmed/16469587

270. Exterkate, L, Hermsen, R, Küsters-Vandevelde, HVN, Prette, JF, Baas, DJH, Somford, DM, et.al. Head-to-Head Comparison of , Eur Urol Oncol, 2023. 6 (6)(6): p. 574-581., https://pubmed.ncbi.nlm.nih.gov/37230883/

271. Ravi, P, Xie, W, Buyse, M, Halabi, S, Kantoff, PW, Sartor, O, et.al. Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials., Eur Urol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/38777647/

272. Tu, X., Zhang, C., Liu, Z., Shen, G., Wu, X., Nie, L., et.al. The Role of (68)Ga-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Intermediate/High Risk Patients With Prostate Cancer, Front Oncol, 2020. 10(1365): p. 1-11., https://pubmed.ncbi.nlm.nih.gov/33014777/

273. Evangelista, L., Zattoni, F., Cassarino, G., Artioli, P., Cecchin, D., Dal Moro, F., et.al. PET/MRI in prostate cancer, Eur J Nucl Med Mol Imaging, 2021. 3: p. 859 - 873., https://pubmed.ncbi.nlm.nih.gov/32901351/

274. Scher, HI, Morris, MJ, Stadler, WM, Higano, C, Basch, E, Fizazi, K, et.al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3., J Clin Oncol, 2016. 34 (12)(12): p. 1402-18., https://pubmed.ncbi.nlm.nih.gov/26903579/

275. Hope, TA, Eiber, M, Armstrong, WR, Juarez, R, Murthy, V, Lawhn-Heath, C, et.al. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial., JAMA Oncol, 2021. 7 (11)(11): p. 1635-1642., https://pubmed.ncbi.nlm.nih.gov/34529005/

276. Pienta, KJ, Gorin, MA, Rowe, SP, Carroll, PR, Pouliot, F, Probst, S, et.al. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with , J Urol, 2021. 206 (1)(1): p. 52-61., https://pubmed.ncbi.nlm.nih.gov/33634707/

277. Surasi, DS, Eiber, M, Maurer, T, Preston, MA, Helfand, BT, Josephson, D, et.al. Diagnostic Performance and Safety of Positron Emission Tomography with , Eur Urol, 2023. 84 (4)(4): p. 361-370., https://pubmed.ncbi.nlm.nih.gov/37414702/

278. Kuten, J, Fahoum, I, Savin, Z, Shamni, O, Gitstein, G, Hershkovitz, D, et.al. Head-to-Head Comparison of , J Nucl Med, 2020. 61 (4)(4): p. 527-532., https://pubmed.ncbi.nlm.nih.gov/31562225/

279. Grünig, H, Maurer, A, Thali, Y, Kovacs, Z, Strobel, K, Burger, IA, et.al. Focal unspecific bone uptake on [, Eur J Nucl Med Mol Imaging, 2021. 48 (13)(13): p. 4483-4494., https://pubmed.ncbi.nlm.nih.gov/34120201/

280. Rauscher, I, Krönke, M, König, M, Gafita, A, Maurer, T, Horn, T, et.al. Matched-Pair Comparison of , J Nucl Med, 2020. 61 (1)(1): p. 51-57., https://pubmed.ncbi.nlm.nih.gov/31253741/

281. Seifert, R, Emmett, L, Rowe, SP, Herrmann, K, Hadaschik, B, Calais, J, et.al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)., Eur Urol, 2023. 83 (5)(5): p. 405-412., https://pubmed.ncbi.nlm.nih.gov/36935345/

282. Fendler, Prognostic PSMA-PET PROMISE Nomograms for Patients with Prostate Cancer, ASCO 2024., www.urotoday.com/conference-highlights/asco-2024/asco-2024-prostate-cancer/152616-asco-2024-prognostic-psma-pet-promise-nomograms-for-patients-with-prostate-cancer.html

283. Sung, D, Schmidt, B, Tward, JD, The Ability of the STAR-CAP Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 Prostate Cancer., Clin Genitourin Cancer, 2024. 22 (2)(2): p. 426-433.e5., https://pubmed.ncbi.nlm.nih.gov/38290900/

284. Dess, RT, Suresh, K, Zelefsky, MJ, Freedland, SJ, Mahal, BA, Cooperberg, MR, et.al. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate., JAMA Oncol, 2020. 6 (12)(12): p. 1912-1920., https://pubmed.ncbi.nlm.nih.gov/33090219/

285. Diamand, R, Oderda, M, Albisinni, S, Fourcade, A, Fournier, G, Benamran, D, et.al. External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter study., Urol Oncol, 2020. 38 (11)(11): p. 847.e9-847.e16., https://pubmed.ncbi.nlm.nih.gov/32466877/

286. Gandaglia, G, Ploussard, G, Valerio, M, Mattei, A, Fiori, C, Fossati, N, et.al. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies., Eur Urol, 2019. 75 (3)(3): p. 506-514., https://pubmed.ncbi.nlm.nih.gov/30342844/

287. Martini, A, Wever, L, Soeterik, TFW, Rakauskas, A, Fankhauser, CD, Grogg, JB, et.al. An updated model for predicting side-specific extraprostatic extension in the era of MRI-targeted biopsy., Prostate Cancer Prostatic Dis, 2024. 27 (3)(3): p. 520-524., https://pubmed.ncbi.nlm.nih.gov/38182804/

288. Kench, JG, Judge, M, Delahunt, B, Humphrey, PA, Kristiansen, G, Oxley, J, et.al. Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting., Virchows Arch, 2019. 475 (3)(3): p. 263-277., https://pubmed.ncbi.nlm.nih.gov/31098802/

289. Richter, C, Mezger, E, Schüffler, PJ, Sommer, W, Fusco, F, Hauner, K, et.al. Pathological Reporting of Radical Prostatectomy Specimens Following ICCR Recommendation: Impact of Electronic Reporting Tool Implementation on Quality and Interdisciplinary Communication in a Large University Hospital., Curr Oncol, 2022. 29 (10)(10): p. 7245-7256., https://pubmed.ncbi.nlm.nih.gov/36290848/

290. Brawer, M.K., Peehl, D.M., Stamey, T.A., Bostwick, D.G., Keratin immunoreactivity in the benign and neoplastic human prostate, Cancer Res, 1985. 45(8): p. 3663-3667., http://www.ncbi.nlm.nih.gov/pubmed/2410099

291. Moll, R., Franke, W.W., Schiller, D.L., Geiger, B., Krepler, R., The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells, Cell, 1982. 31(1): p. 11-24., http://www.ncbi.nlm.nih.gov/pubmed/6186379

292. Shah, R.B., Zhou, M., LeBlanc, M., Snyder, M., Rubin, M.A., Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer, Am J Surg Pathol, 2002. 26(9): p. 1161-1168., https://www.ncbi.nlm.nih.gov/pubmed/12218572

293. Wernert, N., Seitz, G., Achtstatter, T., Immunohistochemical investigation of different cytokeratins and vimentin in the prostate from the fetal period up to adulthood and in prostate carcinoma, Pathol Res Pract, 1987. 182(5): p. 617-626., http://www.ncbi.nlm.nih.gov/pubmed/2446293

294. Jiang, Z., Wu, C.L., Woda, B.A., Iczkowski, K.A., Chu, P.G., Tretiakova, M.S., et.al. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker, Histopathology, 2004. 45(3): p. 218-225., http://www.ncbi.nlm.nih.gov/pubmed/15330799

295. Kristiansen, I., Stephan, C., Jung, K., Dietel, M., Rieger, A., Tolkach, Y., et.al. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA, Int J Mol Sci, 2017. 18(6):, http://www.ncbi.nlm.nih.gov/pubmed/28555048

296. Kristiansen, G., Diagnostic and prognostic molecular biomarkers for prostate cancer, Histopathology, 2012. 60(1): p. 125-141., http://www.ncbi.nlm.nih.gov/pubmed/22212082

297. Epstein, J.I., PSA and PAP as immunohistochemical markers in prostate cancer, Urol Clin North Am, 1993. 20(4): p. 757-770., http://www.ncbi.nlm.nih.gov/pubmed/7505984

298. Magi-Galluzzi, C., Xu, X., Hlatky, L., Hahnfeldt, P., Kaplan, I., Hsiao, P., et.al. Heterogeneity of androgen receptor content in advanced prostate cancer, Mod Pathol, 1997. 10(8): p. 839-845., http://www.ncbi.nlm.nih.gov/pubmed/9267828

299. Murphy, G.P., Elgamal, A.A., Su, S.L., Bostwick, D.G., Holmes, E.H., Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen, Cancer, 1998. 83(11): p. 2259-2269., http://www.ncbi.nlm.nih.gov/pubmed/9840525

300. Amin, MB, Epstein, JI, Ulbright, TM, Humphrey, PA, Egevad, L, Montironi, R, et.al. Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the International Society of Urological Pathology consensus conference., Am J Surg Pathol, 2014. 38 (8)(8): p. 1017-22., https://pubmed.ncbi.nlm.nih.gov/25025364/

301. Hameed, O, Humphrey, PA, Immunohistochemistry in diagnostic surgical pathology of the prostate., Semin Diagn Pathol, 2005. 22 (1)(1): p. 88-104., https://pubmed.ncbi.nlm.nih.gov/16512601/

302. International Agency for Research on Cancer, WHO classification of tumours of the urinary system and male genital organsMoch, H., 2022. 5th edition:

303. O'Connor, E, Dowling, C, Casey, M, O'Connor, D, McHale, T, Implications of a diagnosis of atypical small acinar proliferation (ASAP) and high-grade prostatic intraepithelial neoplasia (HGPIN) on prostate biopsy: a 5-year follow-up study., Ir J Med Sci, 2022. 191 (5)(5): p. 2035-2040., https://pubmed.ncbi.nlm.nih.gov/34799794/

304. Bostwick, D.G., Amin, M.B., Dundore, P., Marsh, W., Schultz, D.S., Architectural patterns of high-grade prostatic intraepithelial neoplasia, Hum Pathol, 1993. 24(3): p. 298-310., http://www.ncbi.nlm.nih.gov/pubmed/8454275

305. Bostwick, D.G., Qian, J., High-grade prostatic intraepithelial neoplasia, Mod Pathol, 2004. 17(3): p. 360-379., http://www.ncbi.nlm.nih.gov/pubmed/14739906

306. Moore, C.K., Karikehalli, S., Nazeer, T., Fisher, H.A., Kaufman, R.P., Jr., Mian, B.M., Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era, J Urol, 2005. 173(1): p. 70-72., http://www.ncbi.nlm.nih.gov/pubmed/15592031

307. Qian, J., Wollan, P., Bostwick, D.G., The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma, Hum Pathol, 1997. 28(2): p. 143-148., http://www.ncbi.nlm.nih.gov/pubmed/9023393

308. Keetch, D.W., Humphrey, P., Stahl, D., Smith, D.S., Catalona, W.J., Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate, J Urol, 1995. 154(2 Pt 1): p. 347-351., http://www.ncbi.nlm.nih.gov/pubmed/7541850

309. van Leenders, GJLH, van der Kwast, TH, Grignon, DJ, Evans, AJ, Kristiansen, G, Kweldam, CF, et.al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma., Am J Surg Pathol, 2020. 44 (8)(8): p. e87-e99., https://pubmed.ncbi.nlm.nih.gov/32459716/

310. Zhang, YC, Sun, GL, Ma, DL, Wei, C, Shang, HJ, Liu, Z, et.al. The presence of intraductal carcinoma of the prostate is closely associated with poor prognosis: a systematic review and meta-analysis., Asian J Androl, 2021. 23 (1)(1): p. 103-108., https://pubmed.ncbi.nlm.nih.gov/32496222/

311. Wang, B, Fu, Y, Chen, M, Peng, S, Marra, G, Zhuang, J, et.al. The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy., Urol Oncol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/38233262/

312. Miyajima, K, Sato, S, Uchida, N, Suzuki, H, Iwatani, K, Imai, Y, et.al. Clinical Significance of Intraductal Carcinoma of the Prostate After High-Dose Brachytherapy With External Beam Radiation Therapy: A Single Institution Series and an Updated Meta-Analysis., Clin Genitourin Cancer, 2023. ():, https://pubmed.ncbi.nlm.nih.gov/38007354/

313. Zhu, S, Zhao, J, Nie, L, Yin, W, Zhang, Y, Zhao, F, et.al. Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)., BMC Med, 2022. 20 (1)(1): p. 237., https://pubmed.ncbi.nlm.nih.gov/35864546/

314. Bernhardt, M, Kristiansen, G, Molecular Alterations in Intraductal Carcinoma of the Prostate., Cancers (Basel), 2023. 15 (23)(23):, https://pubmed.ncbi.nlm.nih.gov/38067216/

315. Kweldam, CF, Wildhagen, MF, Steyerberg, EW, Bangma, CH, van der Kwast, TH, van Leenders, GJ, Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer., Mod Pathol, 2015. 28 (3)(3): p. 457-64., https://pubmed.ncbi.nlm.nih.gov/25189638/

316. Kweldam, CF, Kümmerlin, IP, Nieboer, D, Verhoef, EI, Steyerberg, EW, van der Kwast, TH, et.al. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy., Mod Pathol, 2016. 29 (6)(6): p. 630-6., https://pubmed.ncbi.nlm.nih.gov/26939875/

317. Hollemans, E, Verhoef, EI, Bangma, CH, Rietbergen, J, Helleman, J, Roobol, MJ, et.al. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis., Mod Pathol, 2019. 32 (1)(1): p. 139-146., https://pubmed.ncbi.nlm.nih.gov/30349027/

318. Seyrek, N, Hollemans, E, Osanto, S, Pelger, RCM, van der Poel, HG, Bekers, E, et.al. Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients., Histopathology, 2022. 80 (3)(3): p. 558-565., https://pubmed.ncbi.nlm.nih.gov/34706119/

319. Tohi, Y, Ishikawa, R, Kato, T, Miyakawa, J, Matsumoto, R, Mori, K, et.al. Clinical outcomes of intraductal carcinoma or cribriform in radical prostatectomy specimens of men opting for active surveillance: data from the PRIAS-JAPAN study., Int J Clin Oncol, 2023. 28 (2)(2): p. 299-305., https://pubmed.ncbi.nlm.nih.gov/36472710/

320. Okubo, Y, Sato, S, Hasegawa, C, Koizumi, M, Suzuki, T, Yamamoto, Y, et.al. Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores., Hum Pathol, 2023. 135 (): p. 99-107., https://pubmed.ncbi.nlm.nih.gov/36738975/

321. Shah, RB, Cai, Q, Aron, M, Berney, DM, Cheville, JC, Deng, FM, et.al. Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations., Am J Cancer Res, 2021. 11 (8)(8): p. 3990-4001., https://pubmed.ncbi.nlm.nih.gov/34522463/

322. van der Kwast, TH, van Leenders, GJ, Berney, DM, Delahunt, B, Evans, AJ, Iczkowski, KA, et.al. ISUP Consensus Definition of Cribriform Pattern Prostate Cancer., Am J Surg Pathol, 2021. 45 (8)(8): p. 1118-1126., https://pubmed.ncbi.nlm.nih.gov/33999555/

323. Egevad, L, Delahunt, B, Iczkowski, KA, van der Kwast, T, van Leenders, GJLH, Leite, KRM, et.al. Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria., Histopathology, 2023. 82 (6)(6): p. 837-845., https://pubmed.ncbi.nlm.nih.gov/36645163/

324. Wolters, T., Roobol, M.J., van Leeuwen, P.J., van den Bergh, R.C., Hoedemaeker, R.F., van Leenders, G.J., et.al. Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer, Eur Urol, 2010. 57(5): p. 821-829., http://www.ncbi.nlm.nih.gov/pubmed/19664875

325. Marks, R.A., Lin, H., Koch, M.O., Cheng, L., Positive-block ratio in radical prostatectomy specimens is an independent predictor of prostate-specific antigen recurrence, Am J Surg Pathol, 2007. 31(6): p. 877-881., http://www.ncbi.nlm.nih.gov/pubmed/17527074

326. Epstein, J.I., Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens, J Urol, 2011. 186(3): p. 790-797., http://www.ncbi.nlm.nih.gov/pubmed/21788055

327. Amin, M., Boccon-Gibod, L., Egevad, L., Epstein, J.I., Humphrey, P.A., Mikuz, G., et.al. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens, Scand J Urol Nephrol Suppl, 2005. p. 20-33., http://www.ncbi.nlm.nih.gov/pubmed/16019757

328. Bostwick, D.G., Egbert, B.M., Fajardo, L.F., Radiation injury of the normal and neoplastic prostate, Am J Surg Pathol, 1982. 6(6): p. 541-551., http://www.ncbi.nlm.nih.gov/pubmed/7149094

329. Helpap, B., Kollermann, J., Therapieinduzierte Tumorregression des Prostatakarzinoms, Pathologe, 2004. 25(6): p. 461-468., http://www.ncbi.nlm.nih.gov/pubmed/15221282

330. Vailancourt, L., Ttu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., et.al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study, Am. J Surg. Pathol, 1996. 20(1): p. 86-93., http://www.ncbi.nlm.nih.gov/pubmed/8540613

331. Dhom, G., Degro, S., Therapy of prostatic cancer and histopathologic follow-up, Prostate, 1982. 3(6): p. 531-542., http://www.ncbi.nlm.nih.gov/pubmed/7155986

332. McNeal, J.E., Normal histology of the prostate, Am. J. Surg. Pathol, 1988. 12(8): p. 619-633., http://www.ncbi.nlm.nih.gov/pubmed/2456702

333. McNeal, J.E., The zonal anatomy of the prostate, Prostate, 1981. 2(1): p. 35-49., http://www.ncbi.nlm.nih.gov/pubmed/7279811

334. Bostwick, D.G., Grignon, D.J., Hammond, M.E., Amin, M.B., Cohen, M., Crawford, D., et.al. Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999, Arch Pathol Lab Med, 2000. 124(7): p. 995-1000., http://www.ncbi.nlm.nih.gov/pubmed/10888774

335. Epstein, J.I., Partin, A.W., Sauvageot, J., Walsh, P.C., Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up, Am J Surg Pathol, 1996. 20(3): p. 286-292., http://www.ncbi.nlm.nih.gov/pubmed/8772781

336. Wise, A.M., Stamey, T.A., McNeal, J.E., Clayton, J.L., Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens, Urology, 2002. 60(2): p. 264-269., http://www.ncbi.nlm.nih.gov/pubmed/12137824

337. Arora, R., Koch, M.O., Eble, J.N., Ulbright, T.M., Li, L., Cheng, L., Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate, Cancer, 2004. 100(11): p. 2362-2366., http://www.ncbi.nlm.nih.gov/pubmed/15160339

338. Mehra, R., Han, B., Tomlins, S.A., Wang, L., Menon, A., Wasco, M.J., et.al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases, Cancer Res, 2007. 67(17): p. 7991-7995., http://www.ncbi.nlm.nih.gov/pubmed/17804708

339. Desai, A., Wu, H., Sun, L., Sesterhenn, I.A., Mostofi, F.K., McLeod, D., et.al. Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients, Prostate Cancer Prostatic Dis, 2002. 5(3): p. 212-218., http://www.ncbi.nlm.nih.gov/pubmed/12496984

340. Llanos, CA, Blieden, C, Vernon, SE, Processing radical prostatectomies: an alternate-slice method is comparable with total embedding., Ann Diagn Pathol, 2012. 16 (4)(4): p. 284-7., https://pubmed.ncbi.nlm.nih.gov/22115537/

341. Vainer, B, Toft, BG, Olsen, KE, Jacobsen, GK, Marcussen, N, Handling of radical prostatectomy specimens: total or partial embedding?, Histopathology, 2011. 58 (2)(2): p. 211-6., https://pubmed.ncbi.nlm.nih.gov/21323948/

342. Fadul, LC, da Silva, MT, de Freitas, LA, Athanazio, DA, Assessment of the circumferential margins, extraprostatic extension and Gleason score in radical prostatectomy specimens: Comparison of a partial embedding method with supplemental total inclusion of peripheral tissues., Pathol Res Pract, 2016. 212 (3)(3): p. 217-21., https://pubmed.ncbi.nlm.nih.gov/26774290/

343. Collette, ERP, den Bakker, MA, Klaver, SO, Vis, AN, Kliffen, M, Partial versus complete prostatectomy specimen sampling: prospective non-inferiority study for pT3a tumours and surgical margin involvement., BMJ Open, 2019. 9 (4)(4): p. e024524., https://pubmed.ncbi.nlm.nih.gov/30975668/

344. Bernhardt, M, Hommerding, O, Kreft, T, Weinhold, L, Schmid, M, Kristiansen, G, Prospective selective embedding of radical prostatectomy specimens is not inferior to full embedding regarding established and new prognostic parameters., Virchows Arch, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/39349666/

345. Epstein, J.I., Carmichael, M., Partin, A.W., Walsh, P.C., Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup, J Urol, 1993. 149(6): p. 1478-1481., http://www.ncbi.nlm.nih.gov/pubmed/8501792

346. Fromont, G., Cathelineau, X., Rozet, F., Prapotnich, D., Validire, P., Vallancien, G., Impact of margin size on the incidence of local residual tumor after laparoscopic radical prostatectomy, J Urol, 2004. 172(5 Pt 1): p. 1845-1847., http://www.ncbi.nlm.nih.gov/pubmed/15540735

347. Fromont, G., Baumert, H., Cathelineau, X., Rozet, F., Validire, P., Vallancien, G., Intraoperative frozen section analysis during nerve sparing laparoscopic radical prostatectomy: feasibility study, J Urol, 2003. 170(5): p. 1843-1846., http://www.ncbi.nlm.nih.gov/pubmed/14532789

348. Newman, A.J., Jr., Graham, M.A., Carlton, C.E., Jr., Lieman, S., Incidental carcinoma of the prostate at the time of transurethral resection: importance of evaluating every chip, J. Urol, 1982. 128(5): p. 948-950., http://www.ncbi.nlm.nih.gov/pubmed/6184491

349. Martino, P., Palazzo, S., Battaglia, M., Lucarelli, G., Selvaggi, F.P., Incidental prostatic cancer: repeat TURP or biopsy?, Urol. Int, 2004. 73(3): p. 193-197., http://www.ncbi.nlm.nih.gov/pubmed/15539835

350. van Andel, G., Vleeming, R., Kurth, K., de Reijke, T.M., Incidental carcinoma of the prostate, Semin. Surg. Oncol, 1995. 11(1): p. 36-45., http://www.ncbi.nlm.nih.gov/pubmed/7538693

351. Murphy, W.M., Dean, P.J., Brasfield, J.A., Tatum, L., Incidental carcinoma of the prostate. How much sampling is adequate?, Am. J. Surg. Pathol, 1986. 10(3): p. 170-174., http://www.ncbi.nlm.nih.gov/pubmed/3513636

352. Köllermann, J, Hoeh, B, Ruppel, D, Smith, K, Reis, H, Wenzel, M, et.al. The significance of the extent of tissue embedding for the detection of incidental prostate carcinoma on transurethral prostate resection material: the more, the better?, Virchows Arch, 2022. 481 (3)(3): p. 387-396., https://pubmed.ncbi.nlm.nih.gov/35710851/

353. Epstein, J.I., Amin, M., Boccon-Gibod, L., Egevad, L., Humphrey, P.A., Mikuz, G., et.al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens, Scand J Urol Nephrol Suppl, 2005. p. 34-63., http://www.ncbi.nlm.nih.gov/pubmed/16019758

354. Prendeville, S, Berney, DM, Bubendorf, L, Compérat, E, Egevad, L, Hes, O, et.al. Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a web-based survey by the European Network of Uropathology., Histopathology, 2019. 74 (6)(6): p. 844-852., https://pubmed.ncbi.nlm.nih.gov/30604878/

355. Ni Mhaolcatha, S, Power, E, Mayer, N, Prendeville, S, Optimal sampling of pelvic lymphadenectomy specimens following radical prostatectomy: is complete tissue submission justified?, J Clin Pathol, 2019. 72 (10)(10): p. 712-715., https://pubmed.ncbi.nlm.nih.gov/31154422/

356. Gafeer, MM, Arriola, AGP, The Hunt for Lymph Nodes: Is Total Submission of Standard-Template and Extended-Template Pelvic Lymph Node Dissections Necessary for Detecting Metastatic Prostate Cancer?, Arch Pathol Lab Med, 2023. 147 (12)(12): p. 1466-1470., https://pubmed.ncbi.nlm.nih.gov/36881767/

357. Berney, D.M., Wheeler, T.M., Grignon, D.J., Epstein, J.I., Griffiths, D.F., Humphrey, P.A., et.al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes, Mod. Pathol, 2011. 24(1): p. 39-47., http://www.ncbi.nlm.nih.gov/pubmed/20818343

358. Boormans, J.L., Wildhagen, M.F., Bangma, C.H., Verhagen, P.C., van Leenders, G.J., Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer, BJU. Int, 2008. 102(11): p. 1589-1593., http://www.ncbi.nlm.nih.gov/pubmed/18710447

359. Cheng, L., Bergstralh, E.J., Cheville, J.C., Slezak, J., Corica, F.A., Zincke, H., et.al. Cancer volume of lymph node metastasis predicts progression in prostate cancer, Am J Surg Pathol, 1998. 22(12): p. 1491-1500., http://www.ncbi.nlm.nih.gov/pubmed/9850175

360. Roehl, K.A., Han, M., Ramos, C.G., Antenor, J.A., Catalona, W.J., Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results, J Urol, 2004. 172(3): p. 910-914., http://www.ncbi.nlm.nih.gov/pubmed/15310996

361. Lopez-Beltran, A., Mikuz, G., Luque, R.J., Mazzucchelli, R., Montironi, R., Current practice of Gleason grading of prostate carcinoma, Virchows Arch, 2006. 448(2): p. 111-118., http://www.ncbi.nlm.nih.gov/pubmed/16328356

362. Partin, A.W., Mangold, L.A., Lamm, D.M., Walsh, P.C., Epstein, J.I., Pearson, J.D., Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium, Urology, 2001. 58(6): p. 843-848., http://www.ncbi.nlm.nih.gov/pubmed/11744442

363. Svanholm, H., Mygind, H., Prostatic carcinoma reproducibility of histologic grading, Acta Pathol Microbiol. Immunol. Scand A, 1985. 93(2): p. 67-71., http://www.ncbi.nlm.nih.gov/pubmed/3984736

364. Makarov, D.V., Trock, B.J., Humphreys, E.B., Mangold, L.A., Walsh, P.C., Epstein, J.I., et.al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005, Urology, 2007. 69(6): p. 1095-1101., http://www.ncbi.nlm.nih.gov/pubmed/17572194

365. Kattan, M.W., Eastham, J., Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer, Clin Prostate Cancer, 2003. 1(4): p. 221-226., http://www.ncbi.nlm.nih.gov/pubmed/15040880

366. Lotan, TL, Tomlins, SA, Bismar, TA, Van der Kwast, TH, Grignon, D, Egevad, L, et.al. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer., Am J Surg Pathol, 2020. 44 (7)(7): p. e15-e29., https://pubmed.ncbi.nlm.nih.gov/32044806/

367. Kristiansen, G, Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer., Mod Pathol, 2018. 31 (S1)(S1): p. S143-155., https://pubmed.ncbi.nlm.nih.gov/29297492/

368. Lokeshwar, SD, Syed, JS, Segal, D, Rahman, SN, Sprenkle, PC, Optimal Use of Tumor-Based Molecular Assays for Localized Prostate Cancer., Curr Oncol Rep, 2022. 24 (2)(2): p. 249-256., https://pubmed.ncbi.nlm.nih.gov/35080739/

369. Eggener, SE, Rumble, RB, Armstrong, AJ, Morgan, TM, Crispino, T, Cornford, P, et.al. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline., J Clin Oncol, 2020. 38 (13)(13): p. 1474-1494., https://pubmed.ncbi.nlm.nih.gov/31829902/

370. Berlin, A, Murgic, J, Hosni, A, Pintilie, M, Salcedo, A, Fraser, M, et.al. Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy., Int J Radiat Oncol Biol Phys, 2019. 103 (1)(1): p. 84-91., https://pubmed.ncbi.nlm.nih.gov/30170099/

371. Wei, L, Wang, J, Lampert, E, Schlanger, S, DePriest, AD, Hu, Q, et.al. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators., Eur Urol, 2017. 71 (2)(2): p. 183-192., https://pubmed.ncbi.nlm.nih.gov/27451135/

372. Salami, SS, Hovelson, DH, Kaplan, JB, Mathieu, R, Udager, AM, Curci, NE, et.al. Transcriptomic heterogeneity in multifocal prostate cancer., JCI Insight, 2018. 3 (21)(21):, https://pubmed.ncbi.nlm.nih.gov/30385730/

373. Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., et.al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer, N Engl J Med, 2020. 383(24): p. 2345-2357., https://pubmed.ncbi.nlm.nih.gov/32955174/

374. Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., et.al. Olaparib for Metastatic Castration-Resistant Prostate Cancer, N Engl J Med, 2020. 382(22): p. 2091-2102., https://pubmed.ncbi.nlm.nih.gov/32343890/

375. Mehra, N, Kloots, I, Vlaming, M, Aluwini, S, Dewulf, E, Oprea-Lager, DE, et.al. Genetic Aspects and Molecular Testing in Prostate Cancer: A Report from a Dutch Multidisciplinary Consensus Meeting., Eur Urol Open Sci, 2023. 49 (): p. 23-31., https://pubmed.ncbi.nlm.nih.gov/36874601/

376. Schostak, M, Bradbury, A, Briganti, A, Gonzalez, D, Gomella, L, Mateo, J, et.al. Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer., Eur Urol Oncol, 2023. ():, https://pubmed.ncbi.nlm.nih.gov/37714762/

377. Segal, NH, Parsons, DW, Peggs, KS, Velculescu, V, Kinzler, KW, Vogelstein, B, et.al. Epitope landscape in breast and colorectal cancer., Cancer Res, 2008. 68 (3)(3): p. 889-92., https://pubmed.ncbi.nlm.nih.gov/18245491/

378. Le, DT, Durham, JN, Smith, KN, Wang, H, Bartlett, BR, Aulakh, LK, et.al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade., Science, 2017. 357 (6349)(6349): p. 409-413., https://pubmed.ncbi.nlm.nih.gov/28596308/

379. Graham, LS, Schweizer, MT, Mismatch repair deficiency and clinical implications in prostate cancer., Prostate, 2022. 82 Suppl 1 (): p. S37-S44., https://pubmed.ncbi.nlm.nih.gov/35358351/

380. Bill-Axelson, A., Holmberg, L., Ruutu, M., Garmo, H., Stark, J.R., Busch, C., et.al. Radical prostatectomy versus watchful waiting in early prostate cancer, N Engl J Med, 2011. 364(18): p. 1708-1717., http://www.ncbi.nlm.nih.gov/pubmed/21542742

381. Wilt, T.J., Brawer, M.K., Jones, K.M., Barry, M.J., Aronson, W.J., Fox, S., et.al. Radical prostatectomy versus observation for localized prostate cancer, N. Engl. J Med, 2012. 367(3): p. 203-213., http://www.ncbi.nlm.nih.gov/pubmed/22808955

382. Ip, S., Dahabreh, I.J., Chung, M., Yu, W.W., Balk, E.M., Iovin, R.C., et.al. An evidence review of active surveillance in men with localized prostate cancer, Evid Rep. Technol. Assess. (Full. Rep. ), 2011. p. 1-341., http://www.ncbi.nlm.nih.gov/pubmed/23126653

383. Dale, W., Bilir, P., Han, M., Meltzer, D., The role of anxiety in prostate carcinoma: a structured review of the literature, Cancer, 2005. 104(3): p. 467-478., http://www.ncbi.nlm.nih.gov/pubmed/15959911

384. Klotz, L., Active Surveillance, Quality of Life, and Cancer-related Anxiety, Eur Urol, 2013. 64(1): p. 37-39., http://www.ncbi.nlm.nih.gov/pubmed/23433806

385. Kronenwetter, C., Weidner, G., Pettengill, E., Marlin, R., Crutchfield, L., McCormac, P., et.al. A qualitative analysis of interviews of men with early stage prostate cancer: the Prostate Cancer Lifestyle Trial, Cancer Nurs, 2005. 28(2): p. 99-107., http://www.ncbi.nlm.nih.gov/pubmed/15815179

386. Oliffe, J.L., Davison, B.J., Pickles, T., Mroz, L., The self-management of uncertainty among men undertaking active surveillance for low-risk prostate cancer, Qual Health Res, 2009. 19(4): p. 432-443., http://www.ncbi.nlm.nih.gov/pubmed/19229061

387. Boon, H., Brown, J.B., Gavin, A., Westlake, K., Men with prostate cancer: making decisions about complementary/alternative medicine, Med Decis. Making, 2003. 23(6): p. 471-479., http://www.ncbi.nlm.nih.gov/pubmed/14672107

388. van den Bergh, R.C., Korfage, I.J., Bangma, C.H., Psychological aspects of active surveillance, Curr. Opin. Urol, 2012. 22(3): p. 237-242., http://www.ncbi.nlm.nih.gov/pubmed/22357407

389. van den Bergh, R.C., Korfage, I.J., Borsboom, G.J., Steyerberg, E.W., Essink-Bot, M.L., Prostate cancer-specific anxiety in Dutch patients on active surveillance: validation of the memorial anxiety scale for prostate cancer, Qual Life Res, 2009. 18(8): p. 1061-1066., http://www.ncbi.nlm.nih.gov/pubmed/19669670

390. Pickles, T., Ruether, J.D., Weir, L., Carlson, L., Jakulj, F., Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance, BJU Int, 2007. 100(3): p. 544-551., http://www.ncbi.nlm.nih.gov/pubmed/17532857

391. van den Bergh, R.C., Essink-Bot, M.L., Roobol, M.J., Wolters, T., Schroder, F.H., Bangma, C.H., et.al. Anxiety and distress during active surveillance for early prostate cancer, Cancer, 2009. 115(17): p. 3868-3878., http://www.ncbi.nlm.nih.gov/pubmed/19637245

392. van den Bergh, R.C., Essink-Bot, M.L., Roobol, M.J., Schroder, F.H., Bangma, C.H., Steyerberg, E.W., Do anxiety and distress increase during active surveillance for low risk prostate cancer?, J Urol, 2010. 183(5): p. 1786-1791., http://www.ncbi.nlm.nih.gov/pubmed/20299064

393. Gorin, M.A., Soloway, C.T., Eldefrawy, A., Soloway, M.S., Factors That Influence Patient Enrollment in Active Surveillance for Low-risk Prostate Cancer, Urology, 2011., http://www.ncbi.nlm.nih.gov/pubmed/21215429

394. Pickles, T., Keyes, M., Morris, W.J., Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis, Int J Radiat Oncol Biol Phys, 2010. 76(1): p. 43-49., http://www.ncbi.nlm.nih.gov/pubmed/19570619

395. Burnet, K.L., Parker, C., Dearnaley, D., Brewin, C.R., Watson, M., Does active surveillance for men with localized prostate cancer carry psychological morbidity?, BJU Int, 2007. 100(3): p. 540-543., http://www.ncbi.nlm.nih.gov/pubmed/17550414

396. Thong, M.S., Mols, F., Kil, P.J., Korfage, I.J., LV, van de Poll-Franse, Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-term quality of life and symptom burden, BJU Int, 2010. 105(5): p. 652-658., http://www.ncbi.nlm.nih.gov/pubmed/19747357

397. Parker, C., Active surveillance: towards a new paradigm in the management of early prostate cancer, Lancet Oncol, 2004. 5(2): p. 101-106., http://www.ncbi.nlm.nih.gov/pubmed/14761814

398. Barry, M.J., Andriole, G.L., Culkin, D.J., Fox, S.H., Jones, K.M., Carlyle, M.H., et.al. Ascertaining cause of death among men in the Prostate Cancer Intervention Versus Observation Trial, Clin Trials, 2013. 10(6): p. 907-914., http://www.ncbi.nlm.nih.gov/pubmed/23988464

399. Bul, M., Zhu, X., Rannikko, A., Staerman, F., Valdagni, R., Pickles, T., et.al. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study, Eur Urol, 2012. 62(2): p. 195-200., http://www.ncbi.nlm.nih.gov/pubmed/22342775

400. Wilt, T.J., MacDonald, R., Rutks, I., Shamliyan, T.A., Taylor, B.C., Kane, R.L., Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer, Ann. Intern. Med, 2008. 148(6): p. 435-448., http://www.ncbi.nlm.nih.gov/pubmed/18252677

401. U.S.Preventive Services Task Force, Screening for prostate cancer: recommendation and rationale, Annals of Internal Medicine, 2002. 137(11): p. 915-916.

402. Mambourg, F., van den Bruel, A., Devries, S., Leys, M., Vinck, I., Lona, M., et.al. HTA of prostate cancer screeningBelgian Health Care Knowledge Centre (KCE), 2006.

403. van den Bergh, R.C., Korfage, I.J., Roobol, M.J., Bangma, C.H., de Koning, H.J., Steyerberg, E.W., et.al. Sexual function with localized prostate cancer: active surveillance vs radical therapy, BJU. Int, 2012. 110(7): p. 1032-1039., http://www.ncbi.nlm.nih.gov/pubmed/22260273

404. Talcott, J.A., Manola, J., Clark, J.A., Kaplan, I., Beard, C.J., Mitchell, S.P., et.al. Time course and predictors of symptoms after primary prostate cancer therapy, J. Clin. Oncol, 2003. 21(21): p. 3979-3986., http://www.ncbi.nlm.nih.gov/pubmed/14581420

405. Heidenreich, A., Aus, G., Abbou, C.C., Bolla, M., Joniau, S., Matveev, V., et.al. EAU guidelines on prostate cancerEAU, 2007.

406. Hoffman, R.M., Hunt, W.C., Gilliland, F.D., Stephenson, R.A., Potosky, A.L., Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study, Cancer, 2003. 97(7): p. 1653-1662., http://www.ncbi.nlm.nih.gov/pubmed/12655522

407. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Nutzenbewertung der interstitiellen Brachytherapie beim lokal begrenzten Prostatakarzinom. Abschlussbericht N04-02IQWiG, 2007., http://www.iqwig.de/download/N04-02_Abschlussbericht_Brachytherapie.pdf

408. Vargas, C., Ghilezan, M., Hollander, M., Gustafson, G., Korman, H., Gonzalez, J., et.al. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy, J Urol, 2005. 174(3): p. 882-887., http://www.ncbi.nlm.nih.gov/pubmed/16093980

409. Baxter, N.N., Tepper, J.E., Durham, S.B., Rothenberger, D.A., Virnig, B.A., Increased risk of rectal cancer after prostate radiation: a population-based study, Gastroenterology, 2005. 128(4): p. 819-824., http://www.ncbi.nlm.nih.gov/pubmed/15825064

410. Brenner, D.J., Curtis, R.E., Hall, E.J., Ron, E., Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery, Cancer, 2000. 88(2): p. 398-406., http://www.ncbi.nlm.nih.gov/pubmed/10640974

411. Ojha, R.P., Fischbach, L.A., Zhou, Y., Felini, M.J., Singh, K.P., Thertulien, R., Acute myeloid leukemia incidence following radiation therapy for localized or locally advanced prostate adenocarcinoma, Cancer Epidemiol, 2010. 34(3): p. 274-278., http://www.ncbi.nlm.nih.gov/pubmed/20427255

412. Liauw, S.L., Sylvester, J.E., Morris, C.G., Blasko, J.C., Grimm, P.D., Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up, Int J Radiat Oncol Biol Phys, 2006. 66(3): p. 669-673., http://www.ncbi.nlm.nih.gov/pubmed/16887293

413. Abdel-Wahab, M., Reis, I.M., Hamilton, K., Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy, Int J Radiat Oncol Biol Phys, 2008. 72(1): p. 58-68., http://www.ncbi.nlm.nih.gov/pubmed/18374503

414. Bellardita, L., Rancati, T., Alvisi, M.F., Villani, D., Magnani, T., Marenghi, C., et.al. Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance, Eur Urol, 2013., http://www.ncbi.nlm.nih.gov/pubmed/23357351

415. Heidenreich, A., Bolla, M., Joniau, S., Mason, M.D., Matveev, V., Mottet, N., et.al. EAU guidelines on prostate cancer, 2013., https://uroweb.org/wp-content/uploads/09_Prostate_Cancer_LR.pdf

416. Charlson, M.E., Pompei, P., Ales, K.L., MacKenzie, C.R., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic. Dis, 1987. 40(5): p. 373-383., http://www.ncbi.nlm.nih.gov/pubmed/3558716

417. Walz, J., Gallina, A., Saad, F., Montorsi, F., Perrotte, P., Shariat, S.F., et.al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer, J Clin Oncol, 2007. 25(24): p. 3576-3581., http://www.ncbi.nlm.nih.gov/pubmed/17704404

418. Kunz, I., Musch, M., Roggenbuck, U., Klevecka, V., Kroepfl, D., Tumour characteristics, oncological and functional outcomes in patients aged >/= 70 years undergoing radical prostatectomy, BJU. Int, 2013. 111(3 Pt B): p. E24-E29., http://www.ncbi.nlm.nih.gov/pubmed/22947135

419. American Society of Anesthesiologists (ASA), ASA Physical Status Classification System, 2014., https://www.asahq.org/-/media/sites/asahq/files/public/resources/standards-guidelines/asa-physical-status-classification-system.pdf

420. Froehner, M., Koch, R., Litz, R.J., Hakenberg, O.W., Wirth, M.P., Which patients are at the highest risk of dying from competing causes , BJU. Int, 2012. 110(2): p. 206-210., http://www.ncbi.nlm.nih.gov/pubmed/22044591

421. Doblhammer, G., Kreft, D., Dethloff, A., Gewonnene Lebensjahre. Langfristige Trends der Sterblichkeit nach Todesursachen in Deutschland und im internationalen Vergleich, Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2012. 55(4): p. 448-458., http://www.ncbi.nlm.nih.gov/pubmed/22441514

422. Christensen, K., Doblhammer, G., Rau, R., Vaupel, J.W., Ageing populations: the challenges ahead, Lancet, 2009. 374(9696): p. 1196-1208., http://www.ncbi.nlm.nih.gov/pubmed/19801098

423. Louie-Johnsun, M., Neill, M., Treurnicht, K., Jarmulowicz, M., Eden, C., Final outcomes of patients with low-risk prostate cancer suitable for active surveillance but treated surgically, BJU Int, 2009. 104(10): p. 1501-1504., http://www.ncbi.nlm.nih.gov/pubmed/19426187

424. Choo, R., Danjoux, C., Morton, G., Szumacher, E., Sugar, L., Gardner, S., et.al. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer?, Prostate, 2007. 67(15): p. 1614-1620., http://www.ncbi.nlm.nih.gov/pubmed/17823923

425. Griffin, C.R., Yu, X., Loeb, S., Desireddi, V.N., Han, M., Graif, T., et.al. Pathological features after radical prostatectomy in potential candidates for active monitoring, J Urol, 2007. 178(3 Pt 1): p. 860-863., http://www.ncbi.nlm.nih.gov/pubmed/17631347

426. Suardi, N., Capitanio, U., Chun, F.K., Graefen, M., Perrotte, P., Schlomm, T., et.al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features, Cancer, 2008. 113(8): p. 2068-2072., http://www.ncbi.nlm.nih.gov/pubmed/18792067

427. Conti, S.L., Dall'era, M., Fradet, V., Cowan, J.E., Simko, J., Carroll, P.R., Pathological outcomes of candidates for active surveillance of prostate cancer, J Urol, 2009. 181(4): p. 1628-1633., http://www.ncbi.nlm.nih.gov/pubmed/19233388

428. Thaxton, C.S., Loeb, S., Roehl, K.A., Kan, D., Catalona, W.J., Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols, Urology, 2010. 75(2): p. 414-418., http://www.ncbi.nlm.nih.gov/pubmed/19963249

429. Tosoian, JJ, Mamawala, M, Epstein, JI, Landis, P, Macura, KJ, Simopoulos, DN, et.al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort., Eur Urol, 2020. 77 (6)(6): p. 675-682., https://pubmed.ncbi.nlm.nih.gov/31918957/

430. Lam, TBL, MacLennan, S, Willemse, PM, Mason, MD, Plass, K, Shepherd, R, et.al. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)., Eur Urol, 2019. 76 (6)(6): p. 790-813., https://pubmed.ncbi.nlm.nih.gov/31587989/

431. Willemse, PM, Davis, NF, Grivas, N, Zattoni, F, Lardas, M, Briers, E, et.al. Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy., Eur Urol, 2022. 81 (4)(4): p. 337-346., https://pubmed.ncbi.nlm.nih.gov/34980492/

432. Thomsen, FB, Brasso, K, Klotz, LH, Røder, MA, Berg, KD, Iversen, P, Active surveillance for clinically localized prostate cancer--a systematic review., J Surg Oncol, 2014. 109 (8)(8): p. 830-5., https://pubmed.ncbi.nlm.nih.gov/24610744/

433. Loeb, S, Bruinsma, SM, Nicholson, J, Briganti, A, Pickles, T, Kakehi, Y, et.al. Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification., Eur Urol, 2015. 67 (4)(4): p. 619-26., https://pubmed.ncbi.nlm.nih.gov/25457014/

434. Sakr, W.A., Haas, G.P., Cassin, B.F., Pontes, J.E., Crissman, J.D., The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients, J. Urol, 1993. 150(2 Pt 1): p. 379-385., http://www.ncbi.nlm.nih.gov/pubmed/8326560

435. Lu-Yao, G.L., Yao, S.L., Population-based study of long-term survival in patients with clinically localised prostate cancer, Lancet, 1997. 349(9056): p. 906-910., http://www.ncbi.nlm.nih.gov/pubmed/9093251

436. Aus, G., Robinson, D., Rosell, J., Sandblom, G., Varenhorst, E., Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden, Cancer, 2005. 103(5): p. 943-951., http://www.ncbi.nlm.nih.gov/pubmed/15651057

437. Klotz, L, Overdiagnosis in urologic cancer : For World Journal of Urology Symposium on active surveillance in prostate and renal cancer., World J Urol, 2022. 40 (1)(1): p. 1-8., https://pubmed.ncbi.nlm.nih.gov/33492425/

438. Johansson, JE, Adami, HO, Andersson, SO, Bergström, R, Krusemo, UB, Kraaz, W, Natural history of localised prostatic cancer. A population-based study in 223 untreated patients., Lancet, 1989. 1 (8642)(8642): p. 799-803., https://pubmed.ncbi.nlm.nih.gov/2564901/

439. Bill-Axelson, A., Holmberg, L., Ruutu, M., Haggman, M., Andersson, S.O., Bratell, S., et.al. Radical prostatectomy versus watchful waiting in early prostate cancer, N Engl J Med, 2005. 352(19): p. 1977-1984., http://www.ncbi.nlm.nih.gov/pubmed/15888698

440. Adolfsson, J, Tribukait, B, Levitt, S, The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity., Eur Urol, 2007. 52 (4)(4): p. 1028-35., https://pubmed.ncbi.nlm.nih.gov/17467883/

441. Jonsson, E, Sigbjarnarson, HP, Tomasson, J, Benediktsdottir, KR, Tryggvadottir, L, Hrafnkelsson, J, et.al. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987., Scand J Urol Nephrol, 2006. 40 (4)(4): p. 265-71., https://pubmed.ncbi.nlm.nih.gov/16916765/

442. Lu-Yao, GL, Albertsen, PC, Moore, DF, Shih, W, Lin, Y, DiPaola, RS, et.al. Outcomes of localized prostate cancer following conservative management., JAMA, 2009. 302 (11)(11): p. 1202-9., https://pubmed.ncbi.nlm.nih.gov/19755699/

443. Timilshina, N, Alibhai, SMH, Tomlinson, G, Sander, B, Cheung, DC, Finelli, A, Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach., J Urol, 2023. 209 (3)(3): p. 540-548., https://pubmed.ncbi.nlm.nih.gov/36475730/

444. Carter, H.B., Epstein, J.I., Chan, D.W., Fozard, J.L., Pearson, J.D., Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer, JAMA, 1997. 277(18): p. 1456-1460., http://www.ncbi.nlm.nih.gov/pubmed/9145718

445. Chan, T.Y., Chan, D.Y., Stutzman, K.L., Epstein, J.I., Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors?, J Urol, 2001. 166(6): p. 2181-2184., http://www.ncbi.nlm.nih.gov/pubmed/11696731

446. Dong, F., Kattan, M.W., Steyerberg, E.W., Jones, J.S., Stephenson, A.J., Schroder, F.H., et.al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice, J Urol, 2008. 180(1): p. 150-154., http://www.ncbi.nlm.nih.gov/pubmed/18485398

447. Elgamal, A.A., Van Poppel, H.P., Van de Voorde, W.M., Van Dorpe, J.A., Oyen, R.H., Baert, L.V., Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens--a different view, J Urol, 1997. 157(1): p. 244-250., http://www.ncbi.nlm.nih.gov/pubmed/8976263

448. Epstein, J.I., Walsh, P.C., Carmichael, M., Brendler, C.B., Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer, JAMA, 1994. 271(5): p. 368-374., http://www.ncbi.nlm.nih.gov/pubmed/7506797

449. Epstein, J.I., Walsh, P.C., Akingba, G., Carter, H.B., The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer, J Urol, 1999. 162(5): p. 1649-1652., http://www.ncbi.nlm.nih.gov/pubmed/10524890

450. Goto, Y., Ohori, M., Arakawa, A., Kattan, M.W., Wheeler, T.M., Scardino, P.T., Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies, J Urol, 1996. 156(3): p. 1059-1063., http://www.ncbi.nlm.nih.gov/pubmed/8709307

451. Irwin, M.B., Trapasso, J.G., Identification of insignificant prostate cancers: analysis of preoperative parameters, Urology, 1994. 44(6): p. 862-867., http://www.ncbi.nlm.nih.gov/pubmed/7527167

452. Kattan, M.W., Eastham, J.A., Wheeler, T.M., Maru, N., Scardino, P.T., Erbersdobler, A., et.al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors, J Urol, 2003. 170(5): p. 1792-1797., https://www.ncbi.nlm.nih.gov/pubmed/14532778

453. Loeb, S., Roehl, K.A., Thaxton, C.S., Catalona, W.J., Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer, Urology, 2008. 72(1): p. 143-147., http://www.ncbi.nlm.nih.gov/pubmed/18436287

454. Roehl, K.A., Antenor, J.A., Catalona, W.J., Serial biopsy results in prostate cancer screening study, J. Urol, 2002. 167(6): p. 2435-2439., http://www.ncbi.nlm.nih.gov/pubmed/11992052

455. Steyerberg, E.W., Roobol, M.J., Kattan, M.W., van der Kwast, T.H., de Koning, H.J., Schroder, F.H., Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram, J. Urol, 2007. 177(1): p. 107-112., http://www.ncbi.nlm.nih.gov/pubmed/17162015

456. Augustin, H., Hammerer, P.G., Graefen, M., Erbersdobler, A., Blonski, J., Palisaar, J., et.al. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction, Eur Urol, 2003. 43(5): p. 455-460., http://www.ncbi.nlm.nih.gov/pubmed/12705986

457. Ghavamian, R., Blute, M.L., Bergstralh, E.J., Slezak, J., Zincke, H., Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy, Urology, 1999. 54(1): p. 105-110., http://www.ncbi.nlm.nih.gov/pubmed/10414735

458. Horninger, W., Rogatsch, H., Reissigl, A., Volgger, H., Klocker, H., Hobisch, A., et.al. Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA-based screening, Prostate, 1999. 40(1): p. 56-61., http://www.ncbi.nlm.nih.gov/pubmed/10344724

459. Ochiai, A., Troncoso, P., Chen, M.E., Lloreta, J., Babaian, R.J., The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management, J. Urol, 2005. 174(6): p. 2164-8, discussion., http://www.ncbi.nlm.nih.gov/pubmed/16280756

460. Recker, F., Kwiatkowski, M.K., Huber, A., Stamm, B., Lehmann, K., Tscholl, R., Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience, J. Urol, 2001. 166(3): p. 851-855., http://www.ncbi.nlm.nih.gov/pubmed/11490232

461. Sokoloff, M.H., Yang, X.J., Fumo, M., Mhoon, D., Brendler, C.B., Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of < 4.0 ng/mL, BJU. Int, 2004. 93(4): p. 499-502., http://www.ncbi.nlm.nih.gov/pubmed/15008717

462. Cupp, M.R., Bostwick, D.G., Myers, R.P., Oesterling, J.E., The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis, J Urol, 1995. 153(5): p. 1543-1548., http://www.ncbi.nlm.nih.gov/pubmed/7714976

463. Jack, G.S., Cookson, M.S., Coffey, C.S., Vader, V., Roberts, R.L., Chang, S.S., et.al. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors, J Urol, 2002. 168(2): p. 519-524., http://www.ncbi.nlm.nih.gov/pubmed/12131301

464. Lee, A.K., Doytchinova, T., Chen, M.H., Renshaw, A.A., Weinstein, M., Richie, J.P., et.al. Can the core length involved with prostate cancer identify clinically insignificant disease in low risk patients diagnosed on the basis of a single positive core?, Urol Oncol, 2003. 21(2): p. 123-127., http://www.ncbi.nlm.nih.gov/pubmed/12856640

465. Miyake, H., Sakai, I., Harada, K., Hara, I., Eto, H., Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease, Int. J. Urol, 2005. 12(3): p. 270-274., http://www.ncbi.nlm.nih.gov/pubmed/15828954

466. Noguchi, M., Stamey, T.A., McNeal, J.E., Yemoto, C.M., Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer, J. Urol, 2001. 166(1): p. 104-109., http://www.ncbi.nlm.nih.gov/pubmed/11435833

467. Spitz, M.R., Strom, S.S., Yamamura, Y., Troncoso, P., Babaian, R.J., Scardino, P.T., et.al. Epidemiologic determinants of clinically relevant prostate cancer, Int. J. Cancer, 2000. 89(3): p. 259-264., http://www.ncbi.nlm.nih.gov/pubmed/10861502

468. Stamey, T.A., Freiha, F.S., McNeal, J.E., Redwine, E.A., Whittemore, A.S., Schmid, H.P., Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer, Cancer, 1993. 71(3 Suppl): p. 933-938., http://www.ncbi.nlm.nih.gov/pubmed/7679045

469. Terris, M.K., McNeal, J.E., Stamey, T.A., Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies, J. Urol, 1992. 148(3): p. 829-832., http://www.ncbi.nlm.nih.gov/pubmed/1380991

470. Terris, M.K., Haney, D.J., Johnstone, I.M., McNeal, J.E., Stamey, T.A., Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies, Urology, 1995. 45(1): p. 75-80., http://www.ncbi.nlm.nih.gov/pubmed/7529450

471. Hirano, D., Werahera, P.N., Crawford, E.D., Lucia, M.S., DeAntoni, E.P., Miller, G.J., Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: analysis of tumor volume, grade, tumor doubling time and life expectancy, J Urol, 1998. 159(4): p. 1265-1269., http://www.ncbi.nlm.nih.gov/pubmed/9507849

472. Bruinsma, SM, Roobol, MJ, Carroll, PR, Klotz, L, Pickles, T, Moore, CM, et.al. Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure., Nat Rev Urol, 2017. 14 (5)(5): p. 312-322., https://pubmed.ncbi.nlm.nih.gov/28290462/

473. Hamdy, FC, Donovan, JL, Lane, JA, Metcalfe, C, Davis, M, Turner, EL, et.al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer., N Engl J Med, 2023. 388 (17)(17): p. 1547-1558., https://pubmed.ncbi.nlm.nih.gov/36912538/

474. Stephenson, A.J., Kattan, M.W., Eastham, J.A., Bianco, F.J., Jr., Yossepowitch, O., Vickers, A.J., et.al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era, J Clin Oncol, 2009. 27(26): p. 4300-4305., http://www.ncbi.nlm.nih.gov/pubmed/19636023

475. Guzzo, T.J., Dluzniewski, P., Orosco, R., Platz, E.A., Partin, A.W., Han, M., Prediction of mortality after radical prostatectomy by Charlson comorbidity index, Urology, 2010. 76(3): p. 553-557., http://www.ncbi.nlm.nih.gov/pubmed/20627284

476. Tosoian, JJ, Mamawala, M, Epstein, JI, Landis, P, Wolf, S, Trock, BJ, et.al. Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer., J Clin Oncol, 2015. 33 (30)(30): p. 3379-85., https://pubmed.ncbi.nlm.nih.gov/26324359/

477. van As, NJ, Norman, AR, Thomas, K, Khoo, VS, Thompson, A, Huddart, RA, et.al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance., Eur Urol, 2008. 54 (6)(6): p. 1297-305., https://pubmed.ncbi.nlm.nih.gov/18342430/

478. Carter, HB, Kettermann, A, Warlick, C, Metter, EJ, Landis, P, Walsh, PC, et.al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience., J Urol, 2007. 178 (6)(6): p. 2359-64; discussion 2364-5., https://pubmed.ncbi.nlm.nih.gov/17936806/

479. Adamy, A, Yee, DS, Matsushita, K, Maschino, A, Cronin, A, Vickers, A, et.al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer., J Urol, 2011. 185 (2)(2): p. 477-82., https://pubmed.ncbi.nlm.nih.gov/21167529/

480. Soloway, MS, Soloway, CT, Eldefrawy, A, Acosta, K, Kava, B, Manoharan, M, Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment., Eur Urol, 2010. 58 (6)(6): p. 831-5., https://pubmed.ncbi.nlm.nih.gov/20800964/

481. Roemeling, S, Roobol, MJ, de Vries, SH, Wolters, T, Gosselaar, C, van Leenders, GJ, et.al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome., Eur Urol, 2007. 51 (5)(5): p. 1244-50; discussion 1251., https://pubmed.ncbi.nlm.nih.gov/17161520/

482. Godtman, RA, Holmberg, E, Khatami, A, Stranne, J, Hugosson, J, Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial., Eur Urol, 2013. 63 (1)(1): p. 101-7., https://pubmed.ncbi.nlm.nih.gov/22980443/

483. Klotz, L, Vesprini, D, Sethukavalan, P, Jethava, V, Zhang, L, Jain, S, et.al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer., J Clin Oncol, 2015. 33 (3)(3): p. 272-7., https://pubmed.ncbi.nlm.nih.gov/25512465/

484. Carlsson, S, Benfante, N, Alvim, R, Sjoberg, DD, Vickers, A, Reuter, VE, et.al. Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience., J Urol, 2020. 203 (6)(6): p. 1122-1127., https://pubmed.ncbi.nlm.nih.gov/31868556/

485. Hamdy, F.C., Donovan, J.L., Lane, J.A., Mason, M., Metcalfe, C., Holding, P., et.al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer, N Engl J Med, 2016. 375(15): p. 1415-1424., http://www.ncbi.nlm.nih.gov/pubmed/27626136

486. Bryant, RJ, Oxley, J, Young, GJ, Lane, JA, Metcalfe, C, Davis, M, et.al. The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression., BJU Int, 2020. 125 (4)(4): p. 506-514., https://pubmed.ncbi.nlm.nih.gov/31900963/

487. Groeben, C, Ihrig, A, Hölscher, T, Krones, T, Kessler, E, Kliesch, S, et.al. [Evaluation of the decision aid "Entscheidungshilfe Prostatakrebs" from the patients' view : Results from the first three months]., Urologe A, 2016. 55 (12)(12): p. 1586-1594., https://pubmed.ncbi.nlm.nih.gov/27826660/

488. Dall'Era, M.A., Konety, B.R., Cowan, J.E., Shinohara, K., Stauf, F., Cooperberg, M.R., et.al. Active surveillance for the management of prostate cancer in a contemporary cohort, Cancer, 2008. 112(12): p. 2664-2670., http://www.ncbi.nlm.nih.gov/pubmed/18433013

489. Sugimoto, M, Shiraishi, T, Tsunemori, H, Demura, T, Saito, Y, Kamoto, T, et.al. Pathological findings at radical prostatectomy in Japanese prospective active surveillance cohort., Jpn J Clin Oncol, 2010. 40 (10)(10): p. 973-9., https://pubmed.ncbi.nlm.nih.gov/20534686⁠/

490. van den Bergh, R.C., Vasarainen, H., van der Poel, H.G., Vis-Maters, J.J., Rietbergen, J.B., Pickles, T., et.al. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study, BJU Int, 2010. 105(7): p. 956-962., http://www.ncbi.nlm.nih.gov/pubmed/19817747

491. Eggener, S.E., Mueller, A., Berglund, R.K., Ayyathurai, R., Soloway, C., Soloway, M.S., et.al. A multi-institutional evaluation of active surveillance for low risk prostate cancer, J Urol, 2009. 181(4): p. 1635-1641., http://www.ncbi.nlm.nih.gov/pubmed/19233410

492. Bokhorst, LP, Valdagni, R, Rannikko, A, Kakehi, Y, Pickles, T, Bangma, CH, et.al. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment., Eur Urol, 2016. 70 (6)(6): p. 954-960., https://pubmed.ncbi.nlm.nih.gov/27329565/

493. Burton, AJ, Martin, RM, Donovan, JL, Lane, JA, Davis, M, Hamdy, FC, et.al. Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring., Cancer Epidemiol Biomarkers Prev, 2012. 21 (10)(10): p. 1877-85., https://pubmed.ncbi.nlm.nih.gov/22859401/

494. Ehdaie, B, Poon, BY, Sjoberg, DD, Recabal, P, Laudone, V, Touijer, K, et.al. Variation in serum prostate-specific antigen levels in men with prostate cancer managed with active surveillance., BJU Int, 2016. 118 (4)(4): p. 535-40., https://pubmed.ncbi.nlm.nih.gov/26385021/

495. Soeterik, TFW, van Melick, HHE, Dijksman, LM, Biesma, DH, Witjes, JA, van Basten, JA, Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients., Eur Urol Oncol, 2018. 1 (3)(3): p. 231-237., https://pubmed.ncbi.nlm.nih.gov/31102626/

496. Cooperberg, MR, Brooks, JD, Faino, AV, Newcomb, LF, Kearns, JT, Carroll, PR, et.al. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes., Eur Urol, 2018. 74 (2)(2): p. 211-217., https://pubmed.ncbi.nlm.nih.gov/29433975/

497. Schoots, IG, Nieboer, D, Giganti, F, Moore, CM, Bangma, CH, Roobol, MJ, Is magnetic resonance imaging-targeted biopsy a useful addition to systematic confirmatory biopsy in men on active surveillance for low-risk prostate cancer? A systematic review and meta-analysis., BJU Int, 2018. 122 (6)(6): p. 946-958., https://pubmed.ncbi.nlm.nih.gov/29679430/

498. Klotz, L., Pond, G., Loblaw, A., Sugar, L., Moussa, M., Berman, D., et.al. Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST), European urology, 2020. 77(3): p. 311-317., https://pubmed.ncbi.nlm.nih.gov/31708295/

499. Chiam, K, Carle, C, Hughes, S, Kench, JG, Woo, HH, Lord, S, et.al. Use of multiparametric magnetic resonance imaging (mpMRI) in active surveillance for low-risk prostate cancer: a scoping review on the benefits and harm of mpMRI in different biopsy scenarios., Prostate Cancer Prostatic Dis, 2021. 24 (3)(3): p. 662-673., https://pubmed.ncbi.nlm.nih.gov/33654249/

500. Bratt, O, Carlsson, S, Fransson, P, Thellenberg Karlsson, C, Stranne, J, Kindblom, J, The Swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease., Scand J Urol, 2022. 56 (4)(4): p. 265-273., https://pubmed.ncbi.nlm.nih.gov/35811480/

501. Osses, DF, Drost, FH, Verbeek, JFM, Luiting, HB, van Leenders, GJLH, Bangma, CH, et.al. Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?, BJU Int, 2020. 126 (1)(1): p. 124-132., https://pubmed.ncbi.nlm.nih.gov/32232921/

502. Luiting, HB, Remmers, S, Boevé, ER, Valdagni, R, Chiu, PK, Semjonow, A, et.al. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study., Eur Urol Oncol, 2022. 5 (6)(6): p. 651-658., https://pubmed.ncbi.nlm.nih.gov/35437217/

503. Moore, C. M., Giganti, F., Albertsen, P., Allen, C., Bangma, C., Briganti, A., et.al. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer, European urology, 2017. 71(4): p. 648-655., https://pubmed.ncbi.nlm.nih.gov/27349615/

504. Giganti, F, Stavrinides, V, Stabile, A, Osinibi, E, Orczyk, C, Radtke, JP, et.al. Prostate cancer measurements on serial MRI during active surveillance: it's time to be PRECISE., Br J Radiol, 2020. 93 (1116)(1116): p. 20200819., https://pubmed.ncbi.nlm.nih.gov/32955923/

505. Giganti, F., Stabile, A., Stavrinides, V., Osinibi, E., Retter, A., Orczyk, C., et.al. Natural history of prostate cancer on active surveillance, European radiology, 2021. 31(3): p. 1644-1655., https://pubmed.ncbi.nlm.nih.gov/33000302/

506. Yerram, NK, Long, L, O'Connor, LP, Wang, AZ, Ahdoot, M, Lebastchi, AH, et.al. Magnetic Resonance Imaging-Targeted and Systematic Biopsy for Detection of Grade Progression in Patients on Active Surveillance for Prostate Cancer., J Urol, 2021. 205 (5)(5): p. 1352-1360., https://pubmed.ncbi.nlm.nih.gov/33356479/

507. Rajwa, P, Pradere, B, Mori, K, Ploussard, G, Leapman, MS, Shariat, SF, Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis., J Urol, 2021. 205 (6)(6): p. 1559-1568., https://pubmed.ncbi.nlm.nih.gov/33683937/

508. Guo, R, Cai, L, Fan, Y, Jin, J, Zhou, L, Zhang, K, Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis., Prostate Cancer Prostatic Dis, 2015. 18 (3)(3): p. 221-8., https://pubmed.ncbi.nlm.nih.gov/25986915⁠/

509. Radtke, J.P., Kuru, T.H., Bonekamp, D., Freitag, M.T., Wolf, M.B., Alt, C.D., et.al. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance, Prostate Cancer Prostatic. Dis, 2016. 19(3): p. 283-291., http://www.ncbi.nlm.nih.gov/pubmed/27184812

510. Schoots, IG, Moore, CM, Rouvière, O, Role of MRI in low-risk prostate cancer: finding the wolf in sheep's clothing or the sheep in wolf's clothing?, Curr Opin Urol, 2017. 27 (3)(3): p. 238-245., https://pubmed.ncbi.nlm.nih.gov/28306604/

511. Chu, CE, Cowan, JE, Lonergan, PE, Washington, SL, Fasulo, V, de la Calle, CM, et.al. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer., Eur Urol Oncol, 2022. 5 (5)(5): p. 537-543., https://pubmed.ncbi.nlm.nih.gov/33483265/

512. Rajwa, P, Pradere, B, Quhal, F, Mori, K, Laukhtina, E, Huebner, NA, et.al. Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis., Eur Urol, 2021. 80 (5)(5): p. 549-563., https://pubmed.ncbi.nlm.nih.gov/34020828/

513. Greenberg, JW, Koller, CR, Lightfoot, C, Brinkley, GJ, Leinwand, G, Wang, J, et.al. Annual mpMRI surveillance: PI-RADS upgrading and increasing trend correlated with patients who harbor clinically significant disease., Urol Oncol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/38365461/

514. Valentin, B, Arsov, C, Ullrich, T, Al-Monajjed, R, Boschheidgen, M, Hadaschik, BA, et.al. Magnetic Resonance Imaging-guided Active Surveillance Without Annual Rebiopsy in Patients with Grade Group 1 or 2 Prostate Cancer: The Prospective PROMM-AS Study., Eur Urol Open Sci, 2024. 59 (): p. 30-38., https://pubmed.ncbi.nlm.nih.gov/38298772/

515. Stavrinides, V, Papageorgiou, G, Danks, D, Giganti, F, Pashayan, N, Trock, B, et.al. Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models., Prostate Cancer Prostatic Dis, 2021. 24 (4)(4): p. 1028-1031., https://pubmed.ncbi.nlm.nih.gov/33958731/

516. Klotz, L., Zhang, L., Lam, A., Nam, R., Mamedov, A., Loblaw, A., Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer, J Clin Oncol, 2010. 28(1): p. 126-131., http://www.ncbi.nlm.nih.gov/pubmed/19917860

517. Klotz, L., Active surveillance for prostate cancer: for whom?, J Clin Oncol, 2005. 23(32): p. 8165-8169., http://www.ncbi.nlm.nih.gov/pubmed/16278468

518. McLaren, D.B., McKenzie, M., Duncan, G., Pickles, T., Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma, Cancer, 1998. 82(2): p. 342-348., http://www.ncbi.nlm.nih.gov/pubmed/9445192

519. Khatami, A., Aus, G., Damber, J.E., Lilja, H., Lodding, P., Hugosson, J., PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section, Int J Cancer, 2007. 120(1): p. 170-174., http://www.ncbi.nlm.nih.gov/pubmed/17013897

520. Ross, A.E., Loeb, S., Landis, P., Partin, A.W., Epstein, J.I., Kettermann, A., et.al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program, J Clin Oncol, 2010. 28(17): p. 2810-2816., http://www.ncbi.nlm.nih.gov/pubmed/20439642

521. Stephenson, A.J., Aprikian, A.G., Souhami, L., Behlouli, H., Jacobson, A.I., Begin, L.R., et.al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer, Urology, 2002. 59(5): p. 652-656., http://www.ncbi.nlm.nih.gov/pubmed/11992834

522. O'Connor, LP, Wang, AZ, Yerram, NK, Long, L, Ahdoot, M, Lebastchi, AH, et.al. Changes in Magnetic Resonance Imaging Using the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation Criteria to Detect Prostate Cancer Progression for Men on Active Surveillance., Eur Urol Oncol, 2021. 4 (2)(2): p. 227-234., https://pubmed.ncbi.nlm.nih.gov/33867045/

523. Stevens, E, Truong, M, Bullen, JA, Ward, RD, Purysko, AS, Klein, EA, Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer., Urol Oncol, 2020. 38 (11)(11): p. 846.e9-846.e16., https://pubmed.ncbi.nlm.nih.gov/32576527/

524. Sushentsev, N, Abrego, L, Colarieti, A, Sanmugalingam, N, Stanzione, A, Zawaideh, JP, et.al. Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance., Eur Urol Open Sci, 2023. 52 (): p. 36-39., https://pubmed.ncbi.nlm.nih.gov/37182116/

525. Kawase, M, Ebara, S, Tatenuma, T, Sasaki, T, Ikehata, Y, Nakayama, A, et.al. A Nomogram for Predicting Prostate Cancer with Lymph Node Involvement in Robot-Assisted Radical Prostatectomy Era: A Retrospective Multicenter Cohort Study in Japan (The MSUG94 Group)., Diagnostics (Basel), 2022. 12 (10)(10):, https://pubmed.ncbi.nlm.nih.gov/36292234/

526. Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, Bianchi M, Sun M, Freschi M, Salonia A, Karakiewicz PI, Rigatti P, Montorsi F. Briganti 2012 Nomogram: "Prediction of Lymph Node Involvement in patients with prostate cancer" Available at website: https://www.evidencio.com/models/show/670/de (aufgerufen am 25.06.2024)., 2012.

527. Eastham, JA, Auffenberg, GB, Barocas, DA, Chou, R, Crispino, T, Davis, JW, et.al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management., J Urol, 2022. 208 (1)(1): p. 10-18., https://pubmed.ncbi.nlm.nih.gov/35536144/

528. National Institute for Healt and Care Excellence (NICE), Prostate cancer: diagnosis and management, 2021., www.nice.org.uk/guidance/ng131

529. Mottet, N., Cornford, P., van den Bergh, R. C. N., Briers, E., UOMO), Expert Patient Advocate (European Prostate Cancer Coalition/Europa, Eberli, D., et.al. EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate CancerEAU Guideline, 2023.

530. Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., et.al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 2023. 21(10): p. 1067-1096.

531. Enikeev, D, Morozov, A, Taratkin, M, Barret, E, Kozlov, V, Singla, N, et.al. Active Surveillance for Intermediate-Risk Prostate Cancer: Systematic Review and Meta-analysis of Current Protocols and Outcomes., Clin Genitourin Cancer, 2020. 18 (6)(6): p. e739-e753., https://pubmed.ncbi.nlm.nih.gov/32768356/

532. Baboudjian, M, Breda, A, Rajwa, P, Gallioli, A, Gondran-Tellier, B, Sanguedolce, F, et.al. Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression., Eur Urol Oncol, 2022. 5 (6)(6): p. 617-627., https://pubmed.ncbi.nlm.nih.gov/35934625/

533. Mukherjee, S, Papadopoulos, D, Norris, JM, Wani, M, Madaan, S, Comparison of Outcomes of Active Surveillance in Intermediate-Risk Versus Low-Risk Localised Prostate Cancer Patients: A Systematic Review and Meta-Analysis., J Clin Med, 2023. 12 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/37048815/

534. Chen, RC, Rumble, RB, Loblaw, DA, Finelli, A, Ehdaie, B, Cooperberg, MR, et.al. Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement., J Clin Oncol, 2016. 34 (18)(18): p. 2182-90., https://pubmed.ncbi.nlm.nih.gov/26884580/

535. Berney, DM, Beltran, L, Sandu, H, Soosay, G, Møller, H, Scardino, P, et.al. The percentage of high-grade prostatic adenocarcinoma in prostate biopsies significantly improves on Grade Groups in the prediction of prostate cancer death., Histopathology, 2019. 75 (4)(4): p. 589-597., https://pubmed.ncbi.nlm.nih.gov/31032963/

536. Sauter, G, Steurer, S, Clauditz, TS, Krech, T, Wittmer, C, Lutz, F, et.al. Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens., Eur Urol, 2016. 69 (4)(4): p. 592-598., https://pubmed.ncbi.nlm.nih.gov/26542947/

537. Marks, RA, Koch, MO, Lopez-Beltran, A, Montironi, R, Juliar, BE, Cheng, L, The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens., Hum Pathol, 2007. 38 (8)(8): p. 1207-11., https://pubmed.ncbi.nlm.nih.gov/17490720/

538. Moreira, DM, Fleshner, NE, Freedland, SJ, Baseline Perineural Invasion is Associated with Shorter Time to Progression in Men with Prostate Cancer Undergoing Active Surveillance: Results from the REDEEM Study., J Urol, 2015. 194 (5)(5): p. 1258-63., https://pubmed.ncbi.nlm.nih.gov/25988518/

539. Morash, C, Tey, R, Agbassi, C, Klotz, L, McGowan, T, Srigley, J, et.al. Active surveillance for the management of localized prostate cancer: Guideline recommendations., Can Urol Assoc J, 2015. 9 (5-6)(5-6): p. 171-8., https://pubmed.ncbi.nlm.nih.gov/26225165/

540. Musunuru, HB, Yamamoto, T, Klotz, L, Ghanem, G, Mamedov, A, Sethukavalan, P, et.al. Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience., J Urol, 2016. 196 (6)(6): p. 1651-1658., https://pubmed.ncbi.nlm.nih.gov/27569437/

541. Raldow, AC, Zhang, D, Chen, MH, Braccioforte, MH, Moran, BJ, D'Amico, AV, Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer., JAMA Oncol, 2015. 1 (3)(3): p. 334-40., https://pubmed.ncbi.nlm.nih.gov/26181182/

542. Lane, JA, Donovan, JL, Davis, M, Walsh, E, Dedman, D, Down, L, et.al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial., Lancet Oncol, 2014. 15 (10)(10): p. 1109-18., https://pubmed.ncbi.nlm.nih.gov/25163905/

543. National Prostate Cancer Audit, Using the Cambridge Prognostic Groups for risk stratification of prostate cancer in the National Prostate Cancer Audit: How could it impact our estimates of potential "over-treatment"?, NPCA: Short Report, 2021.

544. Lophatananon, A, Byrne, MHV, Barrett, T, Warren, A, Muir, K, Dokubo, I, et.al. Assessing the impact of MRI based diagnostics on pre-treatment disease classification and prognostic model performance in men diagnosed with new prostate cancer from an unscreened population., BMC Cancer, 2022. 22 (1)(1): p. 878., https://pubmed.ncbi.nlm.nih.gov/35953766/

545. Chan, VW, Tan, WS, Asif, A, Ng, A, Gbolahan, O, Dinneen, E, et.al. Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer-A Systematic Review and Meta-Analysis., Cancers (Basel), 2021. 13 (13)(13):, https://pubmed.ncbi.nlm.nih.gov/34208888/

546. Nahas, WC, Rodrigues, GJ, Rodrigues Gonçalves, FA, Sawczyn, GV, Barros, GG, Cardili, L, et.al. Perioperative, Oncological, and Functional Outcomes Between Robot-Assisted Laparoscopic Prostatectomy and Open Radical Retropubic Prostatectomy: A Randomized Clinical Trial., J Urol, 2024. 212 (1)(1): p. 32-40., https://pubmed.ncbi.nlm.nih.gov/38723593/

547. Checcucci, E, De Cillis, S, Alladio, E, Piramide, F, Volpi, G, Granato, S, et.al. Ten-year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot-assisted radical prostatectomy., Prostate, 2024. 84 (9)(9): p. 832-841., https://pubmed.ncbi.nlm.nih.gov/38572570/

548. van As, N, Yasar, B, Griffin, C, Patel, J, Tree, AC, Ostler, P, et.al. Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial., Eur Urol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/39266383/

549. Donovan, JL, Hamdy, FC, Lane, JA, Mason, M, Metcalfe, C, Walsh, E, et.al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer., N Engl J Med, 2016. 375 (15)(15): p. 1425-1437., https://pubmed.ncbi.nlm.nih.gov/27626365/

550. Yu, T., Zhang, Q., Zheng, T., Shi, H., Liu, Y., Feng, S., et.al. The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: A Meta-Analysis of the Literatures, PLoS One, 2016. 11(5): p. e0154499., https://www.ncbi.nlm.nih.gov/pubmed/27171271

551. Viani, GA, Viana, BS, Martin, JE, Rossi, BT, Zuliani, G, Stefano, EJ, Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial., Cancer, 2016. 122 (13)(13): p. 2004-11., https://pubmed.ncbi.nlm.nih.gov/27028170/

552. Peeters, S.T., Lebesque, J.V., Heemsbergen, W.D., van Putten, W.L., Slot, A., Dielwart, M.F., et.al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer, Int. J. Radiat. Oncol. Biol. Phys, 2006. 64(4): p. 1151-1161., http://www.ncbi.nlm.nih.gov/pubmed/16414208

553. Zietman, A.L., DeSilvio, M.L., Slater, J.D., Rossi, C.J., Jr., Miller, D.W., Adams, J.A., et.al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial, JAMA, 2005. 294(10): p. 1233-1239., https://www.ncbi.nlm.nih.gov/pubmed/16160131

554. Dearnaley, D.P., Sydes, M.R., Graham, J.D., Aird, E.G., Bottomley, D., Cowan, R.A., et.al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial, Lancet Oncol, 2007. 8(6): p. 475-487., http://www.ncbi.nlm.nih.gov/pubmed/17482880

555. Kuban, D.A., Tucker, S.L., Dong, L., Starkschall, G., Huang, E.H., Cheung, M.R., et.al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer, Int J Radiat Oncol Biol Phys, 2008. 70(1): p. 67-74., http://www.ncbi.nlm.nih.gov/pubmed/17765406

556. Pasalic, D, Kuban, DA, Allen, PK, Tang, C, Mesko, SM, Grant, SR, et.al. Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial., Int J Radiat Oncol Biol Phys, 2019. 104 (4)(4): p. 790-797., https://pubmed.ncbi.nlm.nih.gov/30836166/

557. Michalski, JM, Moughan, J, Purdy, J, Bosch, W, Bruner, DW, Bahary, JP, et.al. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial., JAMA Oncol, 2018. 4 (6)(6): p. e180039., https://pubmed.ncbi.nlm.nih.gov/29543933/

558. Kim, S, Kong, JH, Lee, Y, Lee, JY, Kang, TW, Kong, TH, et.al. Dose-escalated radiotherapy for clinically localized and locally advanced prostate cancer., Cochrane Database Syst Rev, 2023. 3 (3)(3): p. CD012817., https://pubmed.ncbi.nlm.nih.gov/36884035/

559. Al-Mamgani, A, Heemsbergen, WD, Peeters, ST, Lebesque, JV, Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer., Int J Radiat Oncol Biol Phys, 2009. 73 (3)(3): p. 685-91., https://pubmed.ncbi.nlm.nih.gov/18718725/

560. Catton, CN, Lukka, H, Gu, CS, Martin, JM, Supiot, S, Chung, PWM, et.al. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer., J Clin Oncol, 2017. 35 (17)(17): p. 1884-1890., https://pubmed.ncbi.nlm.nih.gov/28296582/

561. de Crevoisier, R, Bayar, MA, Pommier, P, Muracciole, X, Pêne, F, Dudouet, P, et.al. Daily Versus Weekly Prostate Cancer Image Guided Radiation Therapy: Phase 3 Multicenter Randomized Trial., Int J Radiat Oncol Biol Phys, 2018. 102 (5)(5): p. 1420-1429., https://pubmed.ncbi.nlm.nih.gov/30071296/

562. Dearnaley, D., Syndikus, I., Mossop, H., Khoo, V., Birtle, A., Bloomfield, D., et.al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial, Lancet Oncol, 2016. 17(8): p. 1047-1060., http://www.ncbi.nlm.nih.gov/pubmed/27339115

563. Vogelius, IR, Bentzen, SM, Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer., Int J Radiat Oncol Biol Phys, 2020. 107 (2)(2): p. 299-304., https://pubmed.ncbi.nlm.nih.gov/31987958/

564. Jones, C.U., Hunt, D., McGowan, D.G., Amin, M.B., Chetner, M.P., Bruner, D.W., et.al. Radiotherapy and short-term androgen deprivation for localized prostate cancer, N Engl J Med, 2011. 365(2): p. 107-118., http://www.ncbi.nlm.nih.gov/pubmed/21751904

565. Pisansky, TM, Hunt, D, Gomella, LG, Amin, MB, Balogh, AG, Chinn, DM, et.al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910., J Clin Oncol, 2015. 33 (4)(4): p. 332-9., https://pubmed.ncbi.nlm.nih.gov/25534388/

566. Hickey, BE, James, ML, Daly, T, Soh, FY, Jeffery, M, Hypofractionation for clinically localized prostate cancer., Cochrane Database Syst Rev, 2019. 9 (9)(9): p. CD011462., https://pubmed.ncbi.nlm.nih.gov/31476800/

567. Kishan, AU, Sun, Y, Hartman, H, Pisansky, TM, Bolla, M, Neven, A, et.al. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis., Lancet Oncol, 2022. 23 (2)(2): p. 304-316., https://pubmed.ncbi.nlm.nih.gov/35051385/

568. Fransson, P, Nilsson, P, Gunnlaugsson, A, Beckman, L, Tavelin, B, Norman, D, et.al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial., Lancet Oncol, 2021. 22 (2)(2): p. 235-245., https://pubmed.ncbi.nlm.nih.gov/33444529/

569. Widmark, A, Gunnlaugsson, A, Beckman, L, Thellenberg-Karlsson, C, Hoyer, M, Lagerlund, M, et.al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial., Lancet, 2019. 394 (10196)(10196): p. 385-395., https://pubmed.ncbi.nlm.nih.gov/31227373/

570. Brand, DH, Tree, AC, Ostler, P, van der Voet, H, Loblaw, A, Chu, W, et.al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial., Lancet Oncol, 2019. 20 (11)(11): p. 1531-1543., https://pubmed.ncbi.nlm.nih.gov/31540791/

571. Ratnakumaran, R, Hinder, V, Brand, D, Staffurth, J, Hall, E, van As, N, et.al. The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B Study., Cancers (Basel), 2023. 15 (4)(4):, https://pubmed.ncbi.nlm.nih.gov/36831631/

572. Tree, AC, Ostler, P, van der Voet, H, Chu, W, Loblaw, A, Ford, D, et.al. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial., Lancet Oncol, 2022. 23 (10)(10): p. 1308-1320., https://pubmed.ncbi.nlm.nih.gov/36113498/

573. Gemeinsamer Bundesausschuss (G-BA), Protonentherapie Indikation: Prostatakarzinom. Abschlussbericht des Unterausschusses „Methodenbewertung" des Gemeinsamen Bundesausschusses (3. Update-Recherche), 2008., http://www.g-ba.de/downloads/40-268-739/2008-06-19_Abschluss_Protonen-Prostatakarzinom.pdf

574. Bolla, M., Maingon, P., Carrie, C., Villa, S., Kitsios, P., Poortmans, P.M., et.al. Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991, J Clin Oncol, 2016. 34(15): p. 1748-1756., http://www.ncbi.nlm.nih.gov/pubmed/26976418

575. Krauss, DJ, Karrison, T, Martinez, AA, Morton, G, Yan, D, Bruner, DW, et.al. Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial., J Clin Oncol, 2023. 41 (17)(17): p. 3203-3216., https://pubmed.ncbi.nlm.nih.gov/37104748/

576. Malone, S, Roy, S, Eapen, L, E, C, MacRae, R, Perry, G, et.al. Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial., J Clin Oncol, 2020. 38 (6)(6): p. 593-601., https://pubmed.ncbi.nlm.nih.gov/31829912/

577. Spratt, DE, Malone, S, Roy, S, Grimes, S, Eapen, L, Morgan, SC, et.al. Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis., J Clin Oncol, 2021. 39 (2)(2): p. 136-144., https://pubmed.ncbi.nlm.nih.gov/33275486/

578. Ma, TM, Sun, Y, Malone, S, Roach, M, Dearnaley, D, Pisansky, TM, et.al. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials., J Clin Oncol, 2023. 41 (4)(4): p. 881-892., https://pubmed.ncbi.nlm.nih.gov/36269935/

579. Incrocci, L., Wortel, R.C., Alemayehu, W.G., Aluwini, S., Schimmel, E., Krol, S., et.al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, 2016. 17(8): p. 1061-1069., http://www.ncbi.nlm.nih.gov/pubmed/27339116

580. Morgan, SC, Hoffman, K, Loblaw, DA, Buyyounouski, MK, Patton, C, Barocas, D, et.al. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline., J Urol, 2019. 201 (3)(3): p. 528-534., https://pubmed.ncbi.nlm.nih.gov/30759696/

581. Lilleby, O, Meidahl Petersen, P, Daugaard, G, Anne Perell, K, Current evidence for moderate and ultra-hypofractionated radiation therapy in prostate cancer: a summary of the results from phase 3 randomised trials., Scand J Urol, 2023. 58 (): p. 21-27., https://pubmed.ncbi.nlm.nih.gov/37338209/

582. Gemeinsamer Bundesausschuss (G-BA), Protonentherapie bei Prostatakarzinom (§ 137c SGB V), 2021., https://www.g-ba.de/bewertungsverfahren/methodenbewertung/116/#einstellen-der-methodenbewertung

583. Toesca, DAS, Hartsell, WF, DeWees, TA, Chang, JH, Laughlin, BS, Voss, MM, et.al. Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial., Int J Radiat Oncol Biol Phys, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/38972465/

584. Grewal, AS, Schonewolf, C, Min, EJ, Chao, HH, Both, S, Lam, S, et.al. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer., Int J Radiat Oncol Biol Phys, 2019. 105 (4)(4): p. 713-722., https://pubmed.ncbi.nlm.nih.gov/31199994/

585. Ha, B, Cho, KH, Lee, KH, Joung, JY, Kim, YJ, Lee, SU, et.al. Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation., Radiat Oncol, 2019. 14 (1)(1): p. 4., https://pubmed.ncbi.nlm.nih.gov/30630500/

586. Henderson, RH, Bryant, CM, Nichols, RC, Mendenhall, WM, Hoppe, BS, Su, Z, et.al. Five- and seven-year outcomes for image-guided moderately accelerated hypofractionated proton therapy for prostate cancer., Acta Oncol, 2022. 61 (4)(4): p. 468-477., https://pubmed.ncbi.nlm.nih.gov/34965846/

587. Slater, JM, Slater, JD, Kang, JI, Namihas, IC, Jabola, BR, Brown, K, et.al. Hypofractionated Proton Therapy in Early Prostate Cancer: Results of a Phase I/II Trial at Loma Linda University., Int J Part Ther, 2019. 6 (1)(1): p. 1-9., https://pubmed.ncbi.nlm.nih.gov/31773043/

588. Vapiwala, N, Wong, JK, Handorf, E, Paly, J, Grewal, A, Tendulkar, R, et.al. A Pooled Toxicity Analysis of Moderately Hypofractionated Proton Beam Therapy and Intensity Modulated Radiation Therapy in Early-Stage Prostate Cancer Patients., Int J Radiat Oncol Biol Phys, 2021. 110 (4)(4): p. 1082-1089., https://pubmed.ncbi.nlm.nih.gov/33539968/

589. Pan, HY, Jiang, J, Hoffman, KE, Tang, C, Choi, SL, Nguyen, QN, et.al. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer., J Clin Oncol, 2018. 36 (18)(18): p. 1823-1830., https://pubmed.ncbi.nlm.nih.gov/29561693/

590. Liu, Y, Patel, SA, Jani, AB, Gillespie, TW, Patel, PR, Godette, KD, et.al. Overall Survival After Treatment of Localized Prostate Cancer With Proton Beam Therapy, External-Beam Photon Therapy, or Brachytherapy., Clin Genitourin Cancer, 2021. 19 (3)(3): p. 255-266.e7., https://pubmed.ncbi.nlm.nih.gov/32972877/

591. Corrao, G, Marvaso, G, Mastroleo, F, Biffi, A, Pellegrini, G, Minari, S, et.al. Photon vs proton hypofractionation in prostate cancer: A systematic review and meta-analysis., Radiother Oncol, 2024. 195 (): p. 110264., https://pubmed.ncbi.nlm.nih.gov/38561122/

592. Kupelian, P.A., Potters, L., Khuntia, D., Ciezki, J.P., Reddy, C.A., Reuther, A.M., et.al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer, Int J Radiat Oncol Biol Phys, 2004. 58(1): p. 25-33., http://www.ncbi.nlm.nih.gov/pubmed/14697417

593. Bolla, M., Van, Tienhoven G., Warde, P., Dubois, J.B., Mirimanoff, R.O., Storme, G., et.al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study, Lancet Oncol, 2010. 11(11): p. 1066-1073., http://www.ncbi.nlm.nih.gov/pubmed/20933466

594. Horwitz, E.M., Bae, K., Hanks, G.E., Porter, A., Grignon, D.J., Brereton, H.D., et.al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer, J Clin Oncol, 2008. 26(15): p. 2497-2504., http://www.ncbi.nlm.nih.gov/pubmed/18413638

595. Lawton, C.A.F., Lin, X., Hanks, G.E., Lepor, H., Grignon, D.J., Brereton, H.D., et.al. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202, Int J Radiat Oncol Biol Phys, 2017. 98(2): p. 296-303., http://www.ncbi.nlm.nih.gov/pubmed/28463149

596. Bolla, M., de Reijke, T.M., van Tienhoven, G., Van Den Bergh, A.C., Oddens, J., Poortmans, P.M., et.al. Duration of androgen suppression in the treatment of prostate cancer, N Engl J Med, 2009. 360(24): p. 2516-2527., http://www.ncbi.nlm.nih.gov/pubmed/19516032

597. Nabid, A, Carrier, N, Martin, AG, Bahary, JP, Lemaire, C, Vass, S, et.al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial., Eur Urol, 2018. 74 (4)(4): p. 432-441., https://pubmed.ncbi.nlm.nih.gov/29980331/

598. Kerkmeijer, LGW, Groen, VH, Pos, FJ, Haustermans, K, Monninkhof, EM, Smeenk, RJ, et.al. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial., J Clin Oncol, 2021. 39 (7)(7): p. 787-796., https://pubmed.ncbi.nlm.nih.gov/33471548/

599. Zapatero, A., Guerrero, A., Maldonado, X., Alvarez, A., Gonzalez San, Segundo C., Cabeza Rodriguez, M.A., et.al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial, Lancet Oncol, 2015. 16(3): p. 320-327., https://www.ncbi.nlm.nih.gov/pubmed/25702876

600. de Vries, KC, Wortel, RC, Oomen-de Hoop, E, Heemsbergen, WD, Pos, FJ, Incrocci, L, Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial., Int J Radiat Oncol Biol Phys, 2020. 106 (1)(1): p. 108-115., https://pubmed.ncbi.nlm.nih.gov/31593756/

601. Arcangeli, G, Saracino, B, Arcangeli, S, Gomellini, S, Petrongari, MG, Sanguineti, G, et.al. Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial., J Clin Oncol, 2017. 35 (17)(17): p. 1891-1897., https://pubmed.ncbi.nlm.nih.gov/28355113/

602. Niazi, T, Nabid, A, Malagon, T, Tisseverasinghe, S, Bettahar, R, Dahmane, R, et.al. Hypofractionated Dose Escalation Radiotherapy for High-risk Prostate Cancer: The Survival Analysis of the Prostate Cancer Study 5, a Groupe de Radio-oncologie Génito-urinaire du Quebec-led Phase 3 Trial., Eur Urol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/39271420/

603. Zapatero, A, Castro, P, Roch, M, Carnero, PR, Carroceda, S, Rosciupchin, AES, et.al. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial., Radiat Oncol, 2024. 19 (1)(1): p. 54., https://pubmed.ncbi.nlm.nih.gov/38702761/

604. Henry, A, Pieters, BR, André Siebert, F, Hoskin, P, GEC-ESTRO ACROP prostate brachytherapy guidelines., Radiother Oncol, 2022. 167 (): p. 244-251., https://pubmed.ncbi.nlm.nih.gov/34999134/

605. Yamada, Y, Rogers, L, Demanes, DJ, Morton, G, Prestidge, BR, Pouliot, J, et.al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy., Brachytherapy, 2012. 11 (1)(1): p. 20-32., https://pubmed.ncbi.nlm.nih.gov/22265435/

606. Bittner, NHJ, Cox, BW, Davis, B, King, M, Lawton, CAF, Merrick, GS, et.al. ACR-ABS-ASTRO Practice Parameter for Transperineal Permanent Brachytherapy of Prostate Cancer., Am J Clin Oncol, 2022. 45 (6)(6): p. 249-257., https://pubmed.ncbi.nlm.nih.gov/35588224/

607. Gemeinsamer, Bundesausschuss, Qualitätssicherungs-​Richtlinie zur interstitiellen LDR-​Brachytherapie beim lokal begrenzten Prostatakarzinom mit niedrigem Risikoprofil, 2020., https://www.g-ba.de/beschluesse/4476/

608. Galalae, R.M., Kovacs, G., Schultze, J., Loch, T., Rzehak, P., Wilhelm, R., et.al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer, Int J Radiat Oncol Biol Phys, 2002. 52(1): p. 81-90., http://www.ncbi.nlm.nih.gov/pubmed/11777625

609. Hoskin, PJ, Rojas, AM, Ostler, PJ, Bryant, L, Lowe, GJ, Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results., Radiother Oncol, 2021. 154 (): p. 214-219., https://pubmed.ncbi.nlm.nih.gov/33011207/

610. Morton, G, Chung, HT, McGuffin, M, Helou, J, D'Alimonte, L, Ravi, A, et.al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy., Radiother Oncol, 2017. 122 (1)(1): p. 87-92., https://pubmed.ncbi.nlm.nih.gov/27823821/

611. Stone, NN, Stock, RG, Prostate brachytherapy in men with gland volume of 100cc or greater: Technique, cancer control, and morbidity., Brachytherapy, 2013. 12 (3)(3): p. 217-21., https://pubmed.ncbi.nlm.nih.gov/23384439/

612. Le, H, Rojas, A, Alonzi, R, Hughes, R, Ostler, P, Lowe, G, et.al. The influence of prostate volume on outcome after high-dose-rate brachytherapy alone for localized prostate cancer., Int J Radiat Oncol Biol Phys, 2013. 87 (2)(2): p. 270-4., https://pubmed.ncbi.nlm.nih.gov/23849693/

613. Salembier, C, Henry, A, Pieters, BR, Hoskin, P, A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate , J Contemp Brachytherapy, 2020. 12 (1)(1): p. 1-5., https://pubmed.ncbi.nlm.nih.gov/32190063/

614. Salembier, C, Rijnders, A, Henry, A, Niehoff, P, André Siebert, F, Hoskin, P, Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection., J Contemp Brachytherapy, 2013. 5 (2)(2): p. 63-9., https://pubmed.ncbi.nlm.nih.gov/23878549/

615. Awad, M.A., Gaither, T.W., Osterberg, E.C., Murphy, G.P., Baradaran, N., Breyer, B.N., Prostate cancer radiation and urethral strictures, Prostate cancer and prostatic diseases, 2018. 21(2): p. 168-174., www.ncbi.nlm.nih.gov/pubmed/29296018

616. Lardas, M., Liew, M., van den Bergh, R. C., Santis, M., Bellmunt, J., van den Broeck, T., et.al. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer, Eur Urol, 2017. 72(6): p. 869-885., https://pubmed.ncbi.nlm.nih.gov/28757301/

617. Ramsay, C.R., Adewuyi, T.E., Gray, J., Hislop, J., Shirley, M.D., Jayakody, S., et.al. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation, Health Technol Assess, 2015. 19(49): p. 1-490., http://www.ncbi.nlm.nih.gov/pubmed/26140518

618. Eade, T.N., Horwitz, E.M., Ruth, K., Buyyounouski, M.K., D'Ambrosio, D.J., Feigenberg, S.J., et.al. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant, Int J Radiat. Oncol Biol Phys, 2008. 71(2): p. 338-345., http://www.ncbi.nlm.nih.gov/pubmed/18207665

619. Michalski, JM, Winter, KA, Prestidge, BR, Sanda, MG, Amin, M, Bice, WS, et.al. Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial., J Clin Oncol, 2023. 41 (24)(24): p. 4035-4044., https://pubmed.ncbi.nlm.nih.gov/37315297/

620. Joseph, D, Denham, JW, Steigler, A, Lamb, DS, Spry, NA, Stanley, J, et.al. Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial., Int J Radiat Oncol Biol Phys, 2020. 106 (4)(4): p. 693-702., https://pubmed.ncbi.nlm.nih.gov/32092343/

621. Giberti, C., Chiono, L., Gallo, F., Schenone, M., Gastaldi, E., Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer, World J Urol, 2009. 27(5): p. 607-612., https://pubmed.ncbi.nlm.nih.gov/19455340/

622. Giberti, C., Gallo, F., Schenone, M., Gastaldi, E., Cortese, P., Ninotta, G., et.al. Robotic prostatectomy versus brachytherapy for the treatment of low risk prostate cancer, The Canadian journal of urology, 2017. 24(2): p. 8728-8733., https://pubmed.ncbi.nlm.nih.gov/28436359/

623. Morris, W. J., Tyldesley, S., Rodda, S., Halperin, R., Pai, H., McKenzie, M., et.al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial), Int J Radiat Oncol Biol Phys, 2017. 98(2): p. 275-285., https://pubmed.ncbi.nlm.nih.gov/28262473/

624. Rodda, S., Tyldesley, S., Morris, W. J., Keyes, M., Halperin, R., Pai, H., et.al. ASCENDE-RT, Int J Radiat Oncol Biol Phys, 2017. 98(2): p. 286-295., https://pubmed.ncbi.nlm.nih.gov/28433432/

625. Yorozu, A, Namiki, M, Saito, S, Egawa, S, Yaegashi, H, Konaka, H, et.al. Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907)., Int J Radiat Oncol Biol Phys, 2024. 118 (2)(2): p. 390-401., https://pubmed.ncbi.nlm.nih.gov/37802225/

626. Sathya, J.R., Davis, I.R., Julian, J.A., Guo, Q., Daya, D., Dayes, I.S., et.al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate, J. Clin. Oncol, 2005. 23(6): p. 1192-1199., http://www.ncbi.nlm.nih.gov/pubmed/15718316

627. Merrick, GS, Wallner, KE, Galbreath, RW, Butler, WM, Adamovich, E, Is supplemental external beam radiation therapy essential to maximize brachytherapy outcomes in patients with unfavorable intermediate-risk disease?, Brachytherapy, 2016. 15 (1)(1): p. 79-84., https://pubmed.ncbi.nlm.nih.gov/26525214/

628. Merrick, GS, Wallner, KE, Galbreath, RW, Butler, WM, Fiano, R, Orio, PF, et.al. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials., Brachytherapy, 2015. 14 (5)(5): p. 677-85., https://pubmed.ncbi.nlm.nih.gov/26051802/

629. Crook, J. M., Gomez-Iturriaga, A., Wallace, K., Ma, C., Fung, S., Alibhai, S., et.al. Comparison of health-related quality of life 5 years after SPIRIT, Journal of clinical oncology, 2011. 29(4): p. 362-368., https://pubmed.ncbi.nlm.nih.gov/21149658/

630. Eccles, B. K., Cross, W., Rosario, D. J., Doble, A., Parker, C., Logue, J., et.al. SABRE 1 (Surgery Against Brachytherapy - a Randomised Evaluation), BJU international, 2013. 112(3): p. 330-337., https://pubmed.ncbi.nlm.nih.gov/23826842/

631. Wiegel, T., Albers, P., Bartkowiak, D., Bussar-Maatz, R., Härter, M., Kristiansen, G., et.al. Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial), J Cancer Res Clin Oncol, 2021. 147(1): p. 235-242., www.ncbi.nlm.nih.gov/pubmed/32886212

632. Sanmamed, N, Locke, G, Crook, J, Liu, A, Raman, S, Glicksman, R, et.al. Long-Term Biochemical Control of a Prospective Cohort of Prostate Cancer Patients Treated With Interstitial Brachytherapy Versus Radical Prostatectomy., Clin Oncol (R Coll Radiol), 2023. 35 (4)(4): p. 262-268., https://pubmed.ncbi.nlm.nih.gov/36737311/

633. Moran, BJ, Koroulakis, A, Decesaris, C, Braccioforte, MH, Amin, N, Agarwal, M, Long-term outcomes of a prospective randomized trial of , Brachytherapy, 2021. 20 (1)(1): p. 38-43., https://pubmed.ncbi.nlm.nih.gov/33059997/

634. Beyer, D.C., Brachman, D.G., Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy, Radiother Oncol, 2000. 57(3): p. 263-267., http://www.ncbi.nlm.nih.gov/pubmed/11104883

635. Sharkey, J., Cantor, A., Solc, Z., Huff, W., Chovnick, S.D., Behar, R.J., et.al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice, Brachytherapy, 2005. 4(1): p. 34-44., http://www.ncbi.nlm.nih.gov/pubmed/15737905

636. Zaorsky, N.G., Doyle, L.A., Hurwitz, M.D., Dicker, A.P., Den, R.B., Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?, Expert review of anticancer therapy, 2014. 14(1): p. 39-50., www.ncbi.nlm.nih.gov/pubmed/24124755

637. Hinnen, K.A., Battermann, J.J., van Roermund, J.G., Moerland, M.A., Jurgenliemk-Schulz, I.M., Frank, S.J., et.al. Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy, Int J Radiat Oncol Biol Phys, 2010. 76(5): p. 1433-1438., http://www.ncbi.nlm.nih.gov/pubmed/19540075

638. Sylvester, JE, Grimm, PD, Wong, J, Galbreath, RW, Merrick, G, Blasko, JC, Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience., Int J Radiat Oncol Biol Phys, 2011. 81 (2)(2): p. 376-81., https://pubmed.ncbi.nlm.nih.gov/20864269/

639. Potters, L., Morgenstern, C., Calugaru, E., Fearn, P., Jassal, A., Presser, J., et.al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer, J Urol, 2005. 173(5): p. 1562-1566., http://www.ncbi.nlm.nih.gov/pubmed/15821486

640. Stone, NN, Stock, RG, Unger, P, Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer., J Urol, 2005. 173 (3)(3): p. 803-7., https://pubmed.ncbi.nlm.nih.gov/15711273/

641. Zelefsky, M.J., Kuban, D.A., Levy, L.B., Potters, L., Beyer, D.C., Blasko, J.C., et.al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation, Int. J Radiat. Oncol. Biol. Phys, 2007. 67(2): p. 327-333., http://www.ncbi.nlm.nih.gov/pubmed/17084558

642. Lawton, CA, DeSilvio, M, Lee, WR, Gomella, L, Grignon, D, Gillin, M, et.al. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05)., Int J Radiat Oncol Biol Phys, 2007. 67 (1)(1): p. 39-47., https://pubmed.ncbi.nlm.nih.gov/17084551/

643. Stock, RG, Stone, NN, Importance of post-implant dosimetry in permanent prostate brachytherapy., Eur Urol, 2002. 41 (4)(4): p. 434-9., https://pubmed.ncbi.nlm.nih.gov/12074816/

644. Crook, JM, Tang, C, Thames, H, Blanchard, P, Sanders, J, Ciezki, J, et.al. A biochemical definition of cure after brachytherapy for prostate cancer., Radiother Oncol, 2020. 149 (): p. 64-69., https://pubmed.ncbi.nlm.nih.gov/32442822/

645. Frank, SJ, Pugh, TJ, Blanchard, P, Mahmood, U, Graber, WJ, Kudchadker, RJ, et.al. Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes., Int J Radiat Oncol Biol Phys, 2018. 100 (2)(2): p. 374-382., https://pubmed.ncbi.nlm.nih.gov/29229325/

646. Ito, K, Saito, S, Yorozu, A, Kojima, S, Kikuchi, T, Higashide, S, et.al. Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival., Int J Clin Oncol, 2018. 23 (6)(6): p. 1148-1159., https://pubmed.ncbi.nlm.nih.gov/29934842/

647. Koontz, B.F., Chino, J., Lee, W.R., Hahn, C.A., Buckley, N., Huang, S., et.al. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer, Brachytherapy, 2009. 8(2): p. 191-196., http://www.ncbi.nlm.nih.gov/pubmed/19433320

648. Stock, R.G., Yalamanchi, S., Hall, S.J., Stone, N.N., Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation, J Urol, 2010. 183(2): p. 546-550., http://www.ncbi.nlm.nih.gov/pubmed/20006854

649. Jani, A.B., Feinstein, J.M., Pasciak, R., Krengel, S., Weichselbaum, R.R., Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer, Urology, 2006. 67(5): p. 1007-1011., http://www.ncbi.nlm.nih.gov/pubmed/16635512

650. King, MT, Keyes, M, Frank, SJ, Crook, JM, Butler, WM, Rossi, PJ, et.al. Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement., Brachytherapy, 2021. 20 (6)(6): p. 1114-1129., https://pubmed.ncbi.nlm.nih.gov/34509378/

651. Corkum, M, Loblaw, A, Hasan, Y, Chung, HT, Tseng, CL, McGuffin, M, et.al. Prostate high dose-rate brachytherapy as monotherapy for prostate cancer: Late toxicity and patient reported outcomes from a randomized phase II clinical trial., Radiother Oncol, 2021. 156 (): p. 160-165., https://pubmed.ncbi.nlm.nih.gov/33359269/

652. Hudson, JM, Loblaw, A, McGuffin, M, Chung, HT, Tseng, CL, Helou, J, et.al. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update., Radiother Oncol, 2024. 198 (): p. 110381., https://pubmed.ncbi.nlm.nih.gov/38879130/

653. Grills, I.S., Martinez, A.A., Hollander, M., Huang, R., Goldman, K., Chen, P.Y., et.al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds, J Urol, 2004. 171(3): p. 1098-1104., http://www.ncbi.nlm.nih.gov/pubmed/14767279

654. Yoshioka, Y., Nose, T., Yoshida, K., Inoue, T., Yamazaki, H., Tanaka, E., et.al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial, Int. J Radiat. Oncol. Biol. Phys, 2000. 48(3): p. 675-681., http://www.ncbi.nlm.nih.gov/pubmed/11020563

655. Corner, C., Rojas, A.M., Bryant, L., Ostler, P., Hoskin, P., A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer, Int J Radiat Oncol Biol Phys, 2008. 72(2): p. 441-446., http://www.ncbi.nlm.nih.gov/pubmed/18249501

656. Martin, T., Baltas, D., Kurek, R., Roddiger, S., Kontova, M., Anagnostopoulos, G., et.al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study, Strahlenther. Onkol, 2004. 180(4): p. 225-232., http://www.ncbi.nlm.nih.gov/pubmed/15057433

657. Martinez, A.A., Pataki, I., Edmundson, G., Sebastian, E., Brabbins, D., Gustafson, G., Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report, Int. J. Radiat. Oncol. Biol. Phys, 2001. 49(1): p. 61-69., http://www.ncbi.nlm.nih.gov/pubmed/11163498

658. Viani, GA, Arruda, CV, Assis Pellizzon, AC, De Fendi, LI, HDR brachytherapy as monotherapy for prostate cancer: A systematic review with meta-analysis., Brachytherapy, 2021. 20 (2)(2): p. 307-314., https://pubmed.ncbi.nlm.nih.gov/33461894/

659. Keyes, M, Merrick, G, Frank, SJ, Grimm, P, Zelefsky, MJ, American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review., Brachytherapy, 2017. 16 (2)(2): p. 245-265., https://pubmed.ncbi.nlm.nih.gov/28110898/

660. Oh, J, Tyldesley, S, Pai, H, McKenzie, M, Halperin, R, Duncan, G, et.al. An Updated Analysis of the Survival Endpoints of ASCENDE-RT., Int J Radiat Oncol Biol Phys, 2023. 115 (5)(5): p. 1061-1070., https://pubmed.ncbi.nlm.nih.gov/36528488/

661. Kee, DLC, Gal, J, Falk, AT, Schiappa, R, Chand, ME, Gautier, M, et.al. Brachytherapy versus external beam radiotherapy boost for prostate cancer: Systematic review with meta-analysis of randomized trials., Cancer Treat Rev, 2018. 70 (): p. 265-271., https://pubmed.ncbi.nlm.nih.gov/30326422/

662. Martinez, A.A., Demanes, D.J., Galalae, R., Vargas, C., Bertermann, H., Rodriguez, R., et.al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime, Int. J. Radiat. Oncol. Biol. Phys, 2005. 62(5): p. 1322-1331., http://www.ncbi.nlm.nih.gov/pubmed/16029788

663. Galalae, R.M., Martinez, A., Mate, T., Mitchell, C., Edmundson, G., Nuernberg, N., et.al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer, Int J Radiat Oncol Biol Phys, 2004. 58(4): p. 1048-1055., http://www.ncbi.nlm.nih.gov/pubmed/15001244

664. Galalae, R.M., Martinez, A., Nuernberg, N., Edmundson, G., Gustafson, G., Gonzalez, J., et.al. Hypofractionated conformal HDR brachytherapy in hormone naive men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?, Strahlenther Onkol, 2006. 182(3): p. 135-141., http://www.ncbi.nlm.nih.gov/pubmed/16520907

665. Martinez, A.A., Gustafson, G., Gonzalez, J., Armour, E., Mitchell, C., Edmundson, G., et.al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer, Int. J. Radiat. Oncol. Biol. Phys, 2002. 53(2): p. 316-327., http://www.ncbi.nlm.nih.gov/pubmed/12023135

666. Deger, S., Boehmer, D., Roigas, J., Schink, T., Wernecke, K.D., Wiegel, T., et.al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer, Eur Urol, 2005. 47(4): p. 441-448., http://www.ncbi.nlm.nih.gov/pubmed/15774239

667. Brenner, D.J., Martinez, A.A., Edmundson, G.K., Mitchell, C., Thames, H.D., Armour, E.P., Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue, Int J Radiat Oncol Biol Phys, 2002. 52(1): p. 6-13., http://www.ncbi.nlm.nih.gov/pubmed/11777617

668. Koukourakis, G., Kelekis, N., Armonis, V., Kouloulias, V., Brachytherapy for prostate cancer: a systematic review, Adv Urol, 2009. p. 327945., http://www.ncbi.nlm.nih.gov/pubmed/19730753

669. Henry, A.M., Al-Qaisieh, B., Gould, K., Bownes, P., Smith, J., Carey, B., et.al. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience, Int J Radiat. Oncol Biol Phys, 2010. 76(1): p. 50-56., http://www.ncbi.nlm.nih.gov/pubmed/20005453

670. Sylvester, J.E., Grimm, P.D., Blasko, J.C., Millar, J., Orio, P.F., III, Skoglund, S., et.al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience, Int J Radiat. Oncol Biol Phys, 2007. 67(1): p. 57-64., http://www.ncbi.nlm.nih.gov/pubmed/17084544

671. Merrick, G.S., Butler, W.M., Wallner, K.E., Galbreath, R.W., Allen, Z., Lief, J.H., et.al. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy, Urology, 2005. 65(1): p. 95-100., http://www.ncbi.nlm.nih.gov/pubmed/15667872

672. Prada, P.J., Juan, G., Gonzalez-Suarez, H., Fernandez, J., Jimenez, I., Amon, J., et.al. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants, BJU Int, 2010. 106(1): p. 32-36., http://www.ncbi.nlm.nih.gov/pubmed/20067460

673. Wong, W.W., Vora, S.A., Schild, S.E., Ezzell, G.A., Andrews, P.E., Ferrigni, R.G., et.al. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy, Cancer, 2009. 115(23): p. 5596-5606., http://www.ncbi.nlm.nih.gov/pubmed/19670452

674. Stone, N.N., Stone, M.M., Rosenstein, B.S., Unger, P., Stock, R.G., Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy, J Urol, 2011. 185(2): p. 495-500., http://www.ncbi.nlm.nih.gov/pubmed/21167528

675. Ho, A.Y., Burri, R.J., Cesaretti, J.A., Stone, N.N., Stock, R.G., Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy, Int J Radiat Oncol Biol Phys, 2009. 75(1): p. 16-22., http://www.ncbi.nlm.nih.gov/pubmed/19289266

676. Vassil AD, Murphy ES, Reddy CA, Angermeier KW, Altman A, Chehade N, Ulchaker J, Klein EA,, Ciezki JP, Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation, 2010., http://www.ncbi.nlm.nih.gov/pubmed/20378156

677. Miszczyk, M, Magrowski, Ł, Krzysztofiak, T, Stando, R, Majewski, W, Stawiski, K, et.al. Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients., Radiother Oncol, 2023. 183 (): p. 109632., https://pubmed.ncbi.nlm.nih.gov/36963442/

678. Parry, MG, Nossiter, J, Sujenthiran, A, Cowling, TE, Patel, RN, Morris, M, et.al. Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study., Int J Radiat Oncol Biol Phys, 2021. 109 (5)(5): p. 1219-1229., https://pubmed.ncbi.nlm.nih.gov/33279595/

679. Pieters, BR, de Back, DZ, Koning, CC, Zwinderman, AH, Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review., Radiother Oncol, 2009. 93 (2)(2): p. 168-73., https://pubmed.ncbi.nlm.nih.gov/19748692/

680. Jackson, W. C., Hartman, H. E., Dess, R. T., Birer, S. R., Soni, P. D., Hearn, J. W. D., et.al. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer, J Clin Oncol, 2020. 38(26): p. 3024-3031., https://pubmed.ncbi.nlm.nih.gov/32396488/

681. Attard, G, Murphy, L, Clarke, NW, Cross, W, Jones, RJ, Parker, CC, et.al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol., Lancet, 2022. 399 (10323)(10323): p. 447-460., https://pubmed.ncbi.nlm.nih.gov/34953525/

682. Widmark, A., Klepp, O., Solberg, A., Damber, J.E., Angelsen, A., Fransson, P., et.al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial, Lancet, 2009. 373(9660): p. 301-308., http://www.ncbi.nlm.nih.gov/pubmed/19091394

683. Shelley, M.D., Kumar, S., Wilt, T., Staffurth, J., Coles, B., Mason, M.D., A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma, Cancer Treat Rev, 2009. 35(1): p. 9-17., http://www.ncbi.nlm.nih.gov/pubmed/18926640

684. Shelley, M.D., Kumar, S., Coles, B., Wilt, T., Staffurth, J., Mason, M.D., Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials, Cancer Treat. Rev, 2009. 35(7): p. 540-546., http://www.ncbi.nlm.nih.gov/pubmed/19493624

685. Cuppone, F., Bria, E., Giannarelli, D., Vaccaro, V., Milella, M., Nistico, C., et.al. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials, BMC Cancer, 2010. 10: p. 675., https://www.ncbi.nlm.nih.gov/pubmed/21143897

686. Bria, E., Cuppone, F., Giannarelli, D., Milella, M., Ruggeri, E.M., Sperduti, I., et.al. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials, Cancer, 2009. 115(15): p. 3446-3456., http://www.ncbi.nlm.nih.gov/pubmed/19484790

687. Pommier, P., Chabaud, S., Lagrange, J.L., Richaud, P., Lesaunier, F., Le, Prise E., et.al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01, J. Clin. Oncol, 2007. 25(34): p. 5366-5373., http://www.ncbi.nlm.nih.gov/pubmed/18048817

688. Blanchard, P, Faivre, L, Lesaunier, F, Salem, N, Mesgouez-Nebout, N, Deniau-Alexandre, E, et.al. Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial., Int J Radiat Oncol Biol Phys, 2016. 94 (1)(1): p. 85-92., https://pubmed.ncbi.nlm.nih.gov/26576711/

689. Gongora, M, Stranne, J, Johansson, E, Bottai, M, Thellenberg Karlsson, C, Brasso, K, et.al. Characteristics of Patients in SPCG-15-A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer., Eur Urol Open Sci, 2022. 41 (): p. 63-73., https://pubmed.ncbi.nlm.nih.gov/35813256/

690. Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J.B., Mirimanoff, R.O., et.al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial, Lancet, 2002. 360(9327): p. 103-106., http://www.ncbi.nlm.nih.gov/pubmed/12126818

691. Denham, J.W., Steigler, A., Lamb, D.S., Joseph, D., Mameghan, H., Turner, S., et.al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial, Lancet Oncol, 2005. 6(11): p. 841-850., http://www.ncbi.nlm.nih.gov/pubmed/16257791

692. Laverdiere, J., Nabid, A., De Bedoya, L.D., Ebacher, A., Fortin, A., Wang, C.S., et.al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer, J Urol, 2004. 171(3): p. 1137-1140., http://www.ncbi.nlm.nih.gov/pubmed/14767287

693. Pilepich, M.V., Winter, K., Lawton, C.A., Krisch, R.E., Wolkov, H.B., Movsas, B., et.al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31, Int. J. Radiat. Oncol. Biol. Phys, 2005. 61(5): p. 1285-1290., https://www.ncbi.nlm.nih.gov/pubmed/15817329

694. Zagars, G.K., Johnson, D.E., von Eschenbach, A.C., Hussey, D.H., Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study, Int. J Radiat. Oncol. Biol. Phys, 1988. 14(6): p. 1085-1091., https://www.ncbi.nlm.nih.gov/pubmed/3133327

695. Tyrrell, C.J., Payne, H., See, W.A., McLeod, D.G., Wirth, M.P., Iversen, P., et.al. Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme, Radiother. Oncol, 2005. 76(1): p. 4-10., http://www.ncbi.nlm.nih.gov/pubmed/16145740

696. Granfors, T., Modig, H., Damber, J.E., Tomic, R., Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone, J Urol, 2006. 176(2): p. 544-547., http://www.ncbi.nlm.nih.gov/pubmed/16813885

697. Roach, M., III, Bae, K., Speight, J., Wolkov, H.B., Rubin, P., Lee, R.J., et.al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610, J. Clin. Oncol, 2008. 26(4): p. 585-591., http://www.ncbi.nlm.nih.gov/pubmed/18172188

698. Hanks, G.E., Pajak, T.F., Porter, A., Grignon, D., Brereton, H., Venkatesan, V., et.al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02, J Clin Oncol, 2003. 21(21): p. 3972-3978., http://www.ncbi.nlm.nih.gov/pubmed/14581419

699. Roach, M, Moughan, J, Lawton, CAF, Dicker, AP, Zeitzer, KL, Gore, EM, et.al. Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial., Lancet Oncol, 2018. 19 (11)(11): p. 1504-1515., https://pubmed.ncbi.nlm.nih.gov/30316827/

700. Murakami, M, Ishikawa, H, Sekino, Y, Nishiyama, H, Suzuki, H, Sugahara, S, et.al. Moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial., J Radiat Res, 2024. 65 (3)(3): p. 402-407., https://pubmed.ncbi.nlm.nih.gov/38739903/

701. Takagi, M, Demizu, Y, Fujii, O, Terashima, K, Niwa, Y, Daimon, T, et.al. Proton Therapy for Localized Prostate Cancer: Long-Term Results From a Single-Center Experience., Int J Radiat Oncol Biol Phys, 2021. 109 (4)(4): p. 964-974., https://pubmed.ncbi.nlm.nih.gov/33186616/

702. Choo, R, Hillman, DW, Mitchell, C, Daniels, T, Vargas, C, Rwigema, JC, et.al. Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate Cancer., Int J Radiat Oncol Biol Phys, 2023. 115 (5)(5): p. 1085-1094., https://pubmed.ncbi.nlm.nih.gov/36427645/

703. Hoskin, PJ, Rojas, AM, Bownes, PJ, Lowe, GJ, Ostler, PJ, Bryant, L, Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer., Radiother Oncol, 2012. 103 (2)(2): p. 217-22., https://pubmed.ncbi.nlm.nih.gov/22341794/

704. Olarte, A, Cambeiro, M, Moreno-Jiménez, M, Arbea, L, Pérez-Gracia, JL, Gil-Bazo, I, et.al. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes., Brachytherapy, 2016. 15 (2)(2): p. 127-35., https://pubmed.ncbi.nlm.nih.gov/26832677/

705. Fischer-Valuck, BW, Rao, YJ, Brenneman, RJ, Patel, PR, Filson, CP, Jani, AB, et.al. Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer., Brachytherapy, 2020. 19 (5)(5): p. 557-566., https://pubmed.ncbi.nlm.nih.gov/32624405/

706. Corkum, MT, Buyyounouski, MK, Chang, AJ, Chung, HT, Chung, P, Cox, BW, et.al. Salvage prostate brachytherapy in radiorecurrent prostate cancer: An international Delphi consensus study., Radiother Oncol, 2023. 184 (): p. 109672., https://pubmed.ncbi.nlm.nih.gov/37059334/

707. Valle, LF, Lehrer, EJ, Markovic, D, Elashoff, D, Levin-Epstein, R, Karnes, RJ, et.al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)., Eur Urol, 2021. 80 (3)(3): p. 280-292., https://pubmed.ncbi.nlm.nih.gov/33309278/

708. Shen, B, Liu, J, Wu, D, Guo, J, Evaluation of the safety and efficacy of high-dose rate brachytherapy for radiorecurrent prostate cancer: a systematic review and meta-analysis., Strahlenther Onkol, 2024. 200 (8)(8): p. 655-670., https://pubmed.ncbi.nlm.nih.gov/38386054/

709. Swanson, G.P., Thompson, I.M., Basler, J., Treatment options in lymph node-positive prostate cancer, Cancer, 2006. 106(12): p. 2531-2539., http://www.ncbi.nlm.nih.gov/pubmed/16700035

710. Fossati, N., Willemse, P.M., Van den Broeck, T., van den Bergh, R.C.N., Yuan, C.Y., Briers, E., et.al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review, Eur Urol, 2017. 72(1): p. 84-109., http://www.ncbi.nlm.nih.gov/pubmed/28126351

711. Da Pozzo, L.F., Cozzarini, C., Briganti, A., Suardi, N., Salonia, A., Bertini, R., et.al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy, Eur Urol, 2009. 55(5): p. 1003-1011., http://www.ncbi.nlm.nih.gov/pubmed/19211184

712. Briganti, A., Karnes, R.J., Da Pozzo, L.F., Cozzarini, C., Capitanio, U., Gallina, A., et.al. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis, Eur Urol, 2011. 59(5): p. 832-840., http://www.ncbi.nlm.nih.gov/pubmed/21354694

713. Abdollah, F., Karnes, R.J., Suardi, N., Cozzarini, C., Gandaglia, G., Fossati, N., et.al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer, J Clin Oncol, 2014. 32(35): p. 3939-3947., http://www.ncbi.nlm.nih.gov/pubmed/25245445

714. Tilki, D., Preisser, F., Tennstedt, P., Tober, P., Mandel, P., Schlomm, T., et.al. Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy, BJU Int, 2016., http://www.ncbi.nlm.nih.gov/pubmed/27743493

715. Jegadeesh, N., Liu, Y., Zhang, C., Zhong, J., Cassidy, R.J., Gillespie, T., et.al. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer, Cancer, 2017. 123(3): p. 512-520., http://www.ncbi.nlm.nih.gov/pubmed/27859018

716. Schröder, F.H., Kurth, K.H., Fossa, S.D., Hoekstra, W., Karthaus, P.P., de Prijck, L., et.al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial), Eur. Urol, 2009. 55(1): p. 14-22., http://www.ncbi.nlm.nih.gov/pubmed/18823693

717. Lawton, C.A., Winter, K., Grignon, D., Pilepich, M.V., Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31, J Clin Oncol, 2005. 23(4): p. 800-807., http://www.ncbi.nlm.nih.gov/pubmed/15681524

718. Lawton, C.A., Winter, K., Murray, K., Machtay, M., Mesic, J.B., Hanks, G.E., et.al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate, Int J Radiat Oncol Biol Phys, 2001. 49(4): p. 937-946., http://www.ncbi.nlm.nih.gov/pubmed/11240234

719. Kleeberg, U.R., Endokrine Therapie versus Beobachtung nach R0-Resektion nodal positiver Prostatakarzinome, Strahlenther Onkol, 2000. 176(6): p. 293-294., http://www.ncbi.nlm.nih.gov/pubmed/10897259

720. Iversen, P., Wirth, M.P., See, W.A., McLeod, D.G., Klimberg, I., Gleason, D., et.al. Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program, Urology, 2004. 63(5): p. 928-933., http://www.ncbi.nlm.nih.gov/pubmed/15134983

721. Messing, E.M., Manola, J., Yao, J., Kiernan, M., Crawford, D., Wilding, G., et.al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy, Lancet Oncol, 2006. 7(6): p. 472-479., http://www.ncbi.nlm.nih.gov/pubmed/16750497

722. Aus, G., Nordenskjold, K., Robinson, D., Rosell, J., Varenhorst, E., Prognostic factors and survival in node-positive (N1) prostate cancer-a prospective study based on data from a Swedish population-based cohort, Eur Urol, 2003. 43(6): p. 627-631., http://www.ncbi.nlm.nih.gov/pubmed/12767363

723. Schmidt, J.D., Gibbons, R.P., Murphy, G.P., Bartolucci, A., Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project, Prostate, 1996. 28(1): p. 51-57., http://www.ncbi.nlm.nih.gov/pubmed/8545281

724. deVere, White R., Babaian, R.K., Feldman, M., Krane, R.J., Olsson, C.A., Adjunctive therapy with interstitial irradiation for prostate cancer, Urology, 1982. 19(4): p. 395-398., http://www.ncbi.nlm.nih.gov/pubmed/6803419

725. Robnett, T.J., Whittington, R., Malkowicz, S.B., Brereton, H.D., van Arsdalen, K., Drach, G., et.al. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer, Int. J. Radiat. Oncol. Biol. Phys, 2002. 53(5): p. 1146-1151., http://www.ncbi.nlm.nih.gov/pubmed/12128114

726. Briganti, A., Karnes, J.R., Da Pozzo, L.F., Cozzarini, C., Gallina, A., Suardi, N., et.al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy, Eur Urol, 2009. 55(2): p. 261-270., http://www.ncbi.nlm.nih.gov/pubmed/18838212

727. Boorjian, S.A., Thompson, R.H., Siddiqui, S., Bagniewski, S., Bergstralh, E.J., Karnes, R.J., et.al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era, J Urol, 2007. 178(3 Pt 1): p. 864-870., http://www.ncbi.nlm.nih.gov/pubmed/17631342

728. Perera, M, Papa, N, Roberts, M, Williams, M, Udovicich, C, Vela, I, et.al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis., Eur Urol, 2020. 77 (4)(4): p. 403-417., https://pubmed.ncbi.nlm.nih.gov/30773328/

729. Bolla, M., van Poppel, H., Tombal, B., Vekemans, K., Da Pozzo, L., Reijke, T. M., et.al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer, Lancet, 2012. 380(9858): p. 2018-2027., https://pubmed.ncbi.nlm.nih.gov/23084481/

730. Parker, C. C., Clarke, N. W., Cook, A. D., Kynaston, H. G., Petersen, P. M., Catton, C., et.al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT), Lancet, 2020. 396(10260): p. 1413-1421., https://pubmed.ncbi.nlm.nih.gov/33002429/

731. Vale, C.L., Fisher, D., Kneebone, A., Parker, C., Pearse, M., Richaud, P., et.al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer, Lancet, 2020. 396(10260): p. 1422-1431., https://pubmed.ncbi.nlm.nih.gov/33002431/

732. Kneebone, A., Fraser-Browne, C., Duchesne, G. M., Fisher, R., Frydenberg, M., Herschtal, A., et.al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES), Lancet Oncol, 2020. 21(10): p. 1331-1340., https://pubmed.ncbi.nlm.nih.gov/33002437/

733. Thompson, I.M., Tangen, C.M., Paradelo, J., Lucia, M.S., Miller, G., Troyer, D., et.al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial, J Urol, 2009. 181(3): p. 956-962., http://www.ncbi.nlm.nih.gov/pubmed/19167731

734. Sargos, P., Chabaud, S., Latorzeff, I., Magné, N., Benyoucef, A., Supiot, S., et.al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17), Lancet Oncol, 2020. 21(10): p. 1341-1352., https://pubmed.ncbi.nlm.nih.gov/33002438/

735. Wiegel, T., Bartkowiak, D., Bottke, D., Bronner, C., Steiner, U., Siegmann, A., et.al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy, European urology, 2014. 66(2): p. 243-250., www.ncbi.nlm.nih.gov/pubmed/24680359

736. Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., et.al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer, Eur Urol, 2021. 79(2): p. 263-282., https://www.ncbi.nlm.nih.gov/pubmed/33039206

737. Hackman, G., Taari, K., Tammela, T. L., Matikainen, M., Kouri, M., Joensuu, T., et.al. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension, Eur Urol, 2019. 76(5): p. 586-595., https://pubmed.ncbi.nlm.nih.gov/31375279/

738. Sayan, M, Tilki, D, D'Amico, AV, Postoperative Management of Prostate Cancer-Optimizing Prostate Cancer Care., JAMA Oncol, 2024. 10 (9)(9): p. 1169-1170., https://pubmed.ncbi.nlm.nih.gov/38990544/

739. Ghadjar, P., Wiegel, T., Re, European urology, 2021., https://pubmed.ncbi.nlm.nih.gov/33612373/

740. Tilki, D, van den Bergh, RCN, Briers, E, Van den Broeck, T, Brunckhorst, O, Darraugh, J, et.al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer., Eur Urol, 2024. 86 (2)(2): p. 164-182., https://pubmed.ncbi.nlm.nih.gov/38688773/

741. Crouzet, S., Chapelon, J.Y., Rouviere, O., Mege-Lechevallier, F., Colombel, M., Tonoli-Catez, H., et.al. Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients, Eur Urol, 2014. 65(5): p. 907-914., http://www.ncbi.nlm.nih.gov/pubmed/23669165

742. Ganzer, R., Fritsche, H.M., Brandtner, A., Brundl, J., Koch, D., Wieland, W.F., et.al. Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer, BJU Int, 2013. 112(3): p. 322-329., http://www.ncbi.nlm.nih.gov/pubmed/23356910

743. Azzouzi, A.R., Vincendeau, S., Barret, E., Cicco, A., Kleinclauss, F., van der Poel, H.G., et.al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial, Lancet Oncol, 2017. 18(2): p. 181-191., http://www.ncbi.nlm.nih.gov/pubmed/28007457

744. Gill, I. S., Azzouzi, A. R., Emberton, M., Coleman, J. A., Coeytaux, E., Scherz, A., et.al. Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer, The Journal of urology, 2018. 200(4): p. 786-793., https://pubmed.ncbi.nlm.nih.gov/29864437/

745. Rodriguez-Rivera, J. A., Rodriguez-Lay, R., Zegarra-Montes, L., Benzaghou, F., Gaillac, B., Azzouzi, A. R., et.al. Extensión de la indicación de terapia fotodinámica dirigida vascular con padeliporfina (WST11), Actas urologicas espanolas, 2018. 42(10): p. 632-638., https://pubmed.ncbi.nlm.nih.gov/29699883/

746. Aus, G., Current status of HIFU and cryotherapy in prostate cancer--a review, Eur Urol, 2006. 50(5): p. 927-934., http://www.ncbi.nlm.nih.gov/pubmed/16971038

747. Blana, A., Rogenhofer, S., Ganzer, R., Lunz, J.C., Schostak, M., Wieland, W.F., et.al. Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer, Urology, 2008. 72(6): p. 1329-1333., http://www.ncbi.nlm.nih.gov/pubmed/18829078

748. Cordeiro, E.R., Cathelineau, X., Thuroff, S., Marberger, M., Crouzet, S., de la Rosette, J.J., High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer, BJU Int, 2012. 110(9): p. 1228-1242., http://www.ncbi.nlm.nih.gov/pubmed/22672199

749. Golan, R., Bernstein, A. N., McClure, T. D., Sedrakyan, A., Patel, N. A., Parekh, D. J., et.al. Partial Gland Treatment of Prostate Cancer Using High-Intensity Focused Ultrasound in the Primary and Salvage Settings, The Journal of urology, 2017. 198(5): p. 1000-1009., https://pubmed.ncbi.nlm.nih.gov/28433640/

750. Shoji, S., Nakano, M., Fujikawa, H., Endo, K., Hashimoto, A., Tomonaga, T., et.al. Urethra-sparing high-intensity focused ultrasound for localized prostate cancer, International journal of urology : official journal of the Japanese Urological Association, 2015. 22(11): p. 1043-1049., https://pubmed.ncbi.nlm.nih.gov/26251127/

751. Muto, S., Yoshii, T., Saito, K., Kamiyama, Y., Ide, H., Horie, S., Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer, Japanese journal of clinical oncology, 2008. 38(3): p. 192-199., https://pubmed.ncbi.nlm.nih.gov/18281309/

752. Ziglioli, F., Baciarello, M., Maspero, G., Bellini, V., Bocchialini, T., Cavalieri, D., et.al. Oncologic outcome, side effects and comorbidity of high-intensity focused ultrasound (HIFU) for localized prostate cancer. A review, Ann Med Surg (Lond), 2020. 56: p. 110-115., www.ncbi.nlm.nih.gov/pubmed/32637083

753. Uchida, T., Tomonaga, T., Kim, H., Nakano, M., Shoji, S., Nagata, Y., et.al. Improved outcomes with advancements in high intensity focused ultrasound devices for the treatment of localized prostate cancer, J Urol, 2015. 193(1): p. 103-110., http://www.ncbi.nlm.nih.gov/pubmed/25079940

754. Thuroff, S., Chaussy, C., Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years, J Urol, 2013. 190(2): p. 702-710., http://www.ncbi.nlm.nih.gov/pubmed/23415962

755. Dickinson, L., Arya, M., Afzal, N., Cathcart, P., Charman, S.C., Cornaby, A., et.al. Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort, Eur Urol, 2016. 70(4): p. 668-674., http://www.ncbi.nlm.nih.gov/pubmed/26951947

756. Berge, V., Dickinson, L., McCartan, N., Hindley, R.G., Diep, L.M., Emberton, M., et.al. Morbidity associated with primary high intensity focused ultrasound and redo high intensity focused ultrasound for localized prostate cancer, J Urol, 2014. 191(6): p. 1764-1769., http://www.ncbi.nlm.nih.gov/pubmed/24373800

757. Cytron, S., Greene, D., Witzsch, U., Nylund, P., Bjerklund Johansen, T. E., Cryoablation of the prostate, Prostate cancer and prostatic diseases, 2009. 12(4): p. 339-346., https://pubmed.ncbi.nlm.nih.gov/19901934/

758. Donnelly, B. J., Saliken, J. C., Brasher, P. M. A., Ernst, S. D., Rewcastle, J. C., Lau, H., et.al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer, Cancer, 2010. 116(2): p. 323-330., https://pubmed.ncbi.nlm.nih.gov/19937954/

759. Shelley, M., Wilt, T.J., Coles, B., Mason, M.D., Cryotherapy for localised prostate cancer, Cochrane. Database. Syst. Rev, 2007. p. CD005010., http://www.ncbi.nlm.nih.gov/pubmed/17636783

760. Chin, J. L., Al-Zahrani, A. A., Autran-Gomez, A. M., Williams, A. K., Bauman, G., Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b), The Journal of urology, 2012. 188(4): p. 1170-1175., https://pubmed.ncbi.nlm.nih.gov/22901586/

761. Jung, J. H., Risk, M. C., Goldfarb, R., Reddy, B., Coles, B., Dahm, P., Primary cryotherapy for localised or locally advanced prostate cancer, Cochrane Database Syst Rev, 2018. p. CD005010., https://www.cochrane.org/evidence/CD005010_primary-cryotherapy-localised-or-locally-advanced-prostate-cancer

762. Gao, L., Yang, L., Qian, S., Tang, Z., Qin, F., Wei, Q., et.al. Cryosurgery would be An Effective Option for Clinically Localized Prostate Cancer, Scientific reports, 2016. 6: p. 27490., https://pubmed.ncbi.nlm.nih.gov/27271239/

763. Blazevski, A., Scheltema, M. J., Amin, A., Thompson, J. E., Lawrentschuk, N., Stricker, P. D., Irreversible electroporation (IRE), BJU international, 2020. 125(3): p. 369-378., https://pubmed.ncbi.nlm.nih.gov/31725935/

764. Collettini, F., Enders, J., Stephan, C., Fischer, T., Baur, A. D. J., Penzkofer, T., et.al. Image-guided Irreversible Electroporation of Localized Prostate Cancer, Radiology, 2019. 292(1): p. 250-257., https://pubmed.ncbi.nlm.nih.gov/31161973/

765. Blazevski, A., Scheltema, M. J., Yuen, B., Masand, N., Nguyen, T. V., Delprado, W., et.al. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer, European urology oncology, 2020. 3(3): p. 283-290., https://pubmed.ncbi.nlm.nih.gov/31103721/

766. Morozov, A., Taratkin, M., Barret, E., Singla, N., Bezrukov, E., Chinenov, D., et.al. A systematic review of irreversible electroporation in localised prostate cancer treatment, Andrologia, 2020. p. e13789., https://pubmed.ncbi.nlm.nih.gov/32786087/

767. Bill-Axelson, A, Holmberg, L, Garmo, H, Rider, JR, Taari, K, Busch, C, et.al. Radical prostatectomy or watchful waiting in early prostate cancer., N Engl J Med, 2014. 370 (10)(10): p. 932-42., https://pubmed.ncbi.nlm.nih.gov/24597866/

768. Studer, U.E., Whelan, P., Albrecht, W., Casselman, J., de, Reijke T., Hauri, D., et.al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891, J. Clin. Oncol, 2006. 24(12): p. 1868-1876., http://www.ncbi.nlm.nih.gov/pubmed/16622261

769. National Comprehensive Cancer Network, NCCN Distress Thermometer, NCCN Guidelines Version 1.2024 Distress Management, 2024., www.nccn.org/docs/default-source/patient-resources/nccn_distress_thermometer.pdf

770. https://uroweb.org/guidelines/prostate-cancer/chapter/treatment, abgerufen am 24.10.2024, 2024.

771. https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Bevoelkerung/Sterbefaelle-Lebenserwartung/Tabellen/_tabellen-innen-lebenserwartung-sterbetafel.html, abgerufen am 24.10.2024, 2024.

772. CIRS - Cumulative Illness Rating Scale, abgerufen am 31.10.2024, 2024., https://www.anq.ch/fileadmin/redaktion/deutsch/CIRS_V_201303_D.pdf

773. https://pose-trial.org/wp-content/uploads/2017/04/Mini-Cog-deutsch-f%C3%BCr-POSE.pdf, abgerufen am 24.10.2024, 2024.

774. Dutch Urological Association, Prostate Cancer. Nation-wide guideline. Version 1.0Dutch Urological Association, 2007.

775. Amling, C.L., Bergstralh, E.J., Blute, M.L., Slezak, J.M., Zincke, H., Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?, J Urol, 2001. 165(4): p. 1146-1151., http://www.ncbi.nlm.nih.gov/pubmed/11257657

776. Stephenson, A.J., Kattan, M.W., Eastham, J.A., Dotan, Z.A., Bianco, F.J., Jr., Lilja, H., et.al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition, J. Clin. Oncol, 2006. 24(24): p. 3973-3978., http://www.ncbi.nlm.nih.gov/pubmed/16921049

777. Freedland, S.J., Sutter, M.E., Dorey, F., Aronson, W.J., Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen, Urology, 2003. 61(2): p. 365-369., http://www.ncbi.nlm.nih.gov/pubmed/12597949

778. Roach, M., III, Hanks, G., Thames, H., Jr., Schellhammer, P., Shipley, W.U., Sokol, G.H., et.al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference, Int. J. Radiat. Oncol. Biol. Phys, 2006. 65(4): p. 965-974., http://www.ncbi.nlm.nih.gov/pubmed/16798415

779. National Collaborating Centre for Cancer, National Institute for Health and Clinical Excellence (NICE), Prostate Cancer: diagnosis and treatment, 2008., http://www.nice.org.uk/Guidance/CG58

780. Foster, L.S., Jajodia, P., Fournier, G., Jr., Shinohara, K., Carroll, P., Narayan, P., The value of prostate specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy, J Urol, 1993. 149(5): p. 1024-1028., http://www.ncbi.nlm.nih.gov/pubmed/7683341

781. Fowler, J.E., Jr., Brooks, J., Pandey, P., Seaver, L.E., Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy, J Urol, 1995. 153(3 Pt 2): p. 1011-1014., http://www.ncbi.nlm.nih.gov/pubmed/7531783

782. Heidenreich, A., Bolla, M., Joniau, S., van der Kwast, T.H., Matveev, V., Mason, M.D., et.al. EAU guidelines on prostate cancerEAU, 2009.

783. Nguyen, P.L., D'Amico, A.V., Lee, A.K., Suh, W.W., Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature, Cancer, 2007. 110(7): p. 1417-1428., http://www.ncbi.nlm.nih.gov/pubmed/17694553

784. Adler, G., Seufferlein, T., [Hope and disappointment in cancer medicine], Z Arztl Fortbild Qualitatssich, 2007. 101: p. 287-92., http://www.ncbi.nlm.nih.gov/pubmed/17711253

785. Pfister, D., Porres, D., Heidenreich, A., Heidegger, I., Knuechel, R., Steib, F., et.al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with Ga-PSMA-HBED-CC than with F-Fluoroethylcholine PET/CT, Eur J Nucl Med Mol Imaging, 2016., http://www.ncbi.nlm.nih.gov/pubmed/26993315

786. Sterzing, F., Kratochwil, C., Fiedler, H., Katayama, S., Habl, G., Kopka, K., et.al. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients, Eur J Nucl Med Mol Imaging, 2016. 43(1): p. 34-41., http://www.ncbi.nlm.nih.gov/pubmed/26404016

787. Morigi, J.J., Stricker, P.D., van Leeuwen, P.J., Tang, R., Ho, B., Nguyen, Q., et.al. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy, J Nucl Med, 2015. 56(8): p. 1185-1190., http://www.ncbi.nlm.nih.gov/pubmed/26112024

788. Afshar-Oromieh, A., Zechmann, C.M., Malcher, A., Eder, M., Eisenhut, M., Linhart, H.G., et.al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 2014. 41(1): p. 11-20., http://www.ncbi.nlm.nih.gov/pubmed/24072344

789. van Leeuwen, P.J., Stricker, P., Hruby, G., Kneebone, A., Ting, F., Thompson, B., et.al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment, BJU Int, 2016. 117(5): p. 732-739., http://www.ncbi.nlm.nih.gov/pubmed/26683282

790. Shakespeare, T.P., Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists, Radiat Oncol, 2015. 10: p. 233., http://www.ncbi.nlm.nih.gov/pubmed/26582424

791. Emmett, L, Tang, R, Nandurkar, R, Hruby, G, Roach, P, Watts, JA, et.al. 3-Year Freedom from Progression After , J Nucl Med, 2020. 61 (6)(6): p. 866-872., https://pubmed.ncbi.nlm.nih.gov/31676727/

792. Meijer, D, Eppinga, WSC, Mohede, RM, Vanneste, BGL, Meijnen, P, Meijer, OWM, et.al. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Is Associated with Improved Oncological Outcome in Men Treated with Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer., Eur Urol Oncol, 2022. 5 (2)(2): p. 146-152., https://pubmed.ncbi.nlm.nih.gov/35074282/

793. Pound, C.R., Partin, A.W., Eisenberger, M.A., Chan, D.W., Pearson, J.D., Walsh, P.C., Natural history of progression after PSA elevation following radical prostatectomy, JAMA, 1999. 281(17): p. 1591-1597., http://www.ncbi.nlm.nih.gov/pubmed/10235151

794. Horwitz, E.M., Thames, H.D., Kuban, D.A., Levy, L.B., Kupelian, P.A., Martinez, A.A., et.al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis, J Urol, 2005. 173(3): p. 797-802., http://www.ncbi.nlm.nih.gov/pubmed/15711272

795. Fitch, D.L., McGrath, S., Martinez, A.A., Vicini, F.A., Kestin, L.L., Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation, Int J Radiat Oncol Biol Phys, 2006. 66(5): p. 1430-1439., http://www.ncbi.nlm.nih.gov/pubmed/16765527

796. Buyyounouski, M.K., Hanlon, A.L., Eisenberg, D.F., Horwitz, E.M., Feigenberg, S.J., Uzzo, R.G., et.al. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer, Int J Radiat Oncol Biol Phys, 2005. 63(5): p. 1455-1462., http://www.ncbi.nlm.nih.gov/pubmed/16169682

797. Denham, J.W., Kumar, M., Gleeson, P.S., Lamb, D.S., Joseph, D., Atkinson, C., et.al. Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer, Int J Radiat Oncol Biol Phys, 2009. 74(2): p. 404-411., http://www.ncbi.nlm.nih.gov/pubmed/19176272

798. Crook, J., Malone, S., Perry, G., Bahadur, Y., Robertson, S., Abdolell, M., Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients, Int J Radiat Oncol Biol Phys, 2000. 48(2): p. 355-367., http://www.ncbi.nlm.nih.gov/pubmed/10974448

799. Scardino, P.T., The prognostic significance of biopsies after radiotherapy for prostatic cancer, Semin. Urol, 1983. 1(4): p. 243-252., http://www.ncbi.nlm.nih.gov/pubmed/6399610

800. Fendler, WP, Calais, J, Eiber, M, Flavell, RR, Mishoe, A, Feng, FY, et.al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial., JAMA Oncol, 2019. 5 (6)(6): p. 856-863., https://pubmed.ncbi.nlm.nih.gov/30920593/

801. Fendler, WP, Ferdinandus, J, Czernin, J, Eiber, M, Flavell, RR, Behr, SC, et.al. Impact of , J Nucl Med, 2020. 61 (12)(12): p. 1793-1799., https://pubmed.ncbi.nlm.nih.gov/32358094/

802. Morris, MJ, Rowe, SP, Gorin, MA, Saperstein, L, Pouliot, F, Josephson, D, et.al. Diagnostic Performance of , Clin Cancer Res, 2021. 27 (13)(13): p. 3674-3682., https://pubmed.ncbi.nlm.nih.gov/33622706/

803. Fleming, MT, Hermsen, R, Purysko, AS, Chau, A, Davis, P, Chapin, BF, et.al. True-Positive , J Nucl Med, 2024. 65 (7)(7): p. 1080-1086., https://pubmed.ncbi.nlm.nih.gov/38782456/

804. Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M.S., Murphy, D.G., et.al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis, Eur Urol, 2016., http://www.ncbi.nlm.nih.gov/pubmed/27363387

805. EAU - EANM - ESTRO - ESUR - ISUP – SIOG, Prostate Cancer, 2024.

806. Scattoni, V., Picchio, M., Suardi, N., Messa, C., Freschi, M., Roscigno, M., et.al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy, Eur. Urol, 2007. 52(2): p. 423-429., http://www.ncbi.nlm.nih.gov/pubmed/17397992

807. Gomez, P., Manoharan, M., Kim, S.S., Soloway, M.S., Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?, BJU Int, 2004. 94(3): p. 299-302., http://www.ncbi.nlm.nih.gov/pubmed/15291855

808. Tilki, D., Preisser, F., Graefen, M., Huland, H., Pompe, R.S., External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort, Eur Urol, 2019. 75(6): p. 896-900., https://pubmed.ncbi.nlm.nih.gov/30955970/

809. van den Broeck, T., van den Bergh, R.C.N., Arfi, N., Gross, T., Moris, L., Briers, E., et.al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer, Eur Urol, 2019. 75(6): p. 967-987., https://pubmed.ncbi.nlm.nih.gov/30342843/

810. Freedland, SJ, de Almeida Luz, M, De Giorgi, U, Gleave, M, Gotto, GT, Pieczonka, CM, et.al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer., N Engl J Med, 2023. 389 (16)(16): p. 1453-1465., https://pubmed.ncbi.nlm.nih.gov/37851874/

811. Carrie, C., Magné, N., Burban-Provost, P., Sargos, P., Latorzeff, I., Lagrange, J. L., et.al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16), The Lancet. Oncology, 2019. 20(12): p. 1740-1749., https://pubmed.ncbi.nlm.nih.gov/31629656/

812. Goluboff, E.T., Prager, D., Rukstalis, D., Giantonio, B., Madorsky, M., Barken, I., et.al. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy, J Urol, 2001. 166(3): p. 882-886., http://www.ncbi.nlm.nih.gov/pubmed/11490238

813. Moul, J.W., Wu, H., Sun, L., McLeod, D.G., Amling, C., Donahue, T., et.al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy, J. Urol, 2004. 171(3): p. 1141-1147., http://www.ncbi.nlm.nih.gov/pubmed/14767288

814. Tendulkar, R.D., Agrawal, S., Gao, T., Efstathiou, J.A., Pisansky, T.M., Michalski, J.M., et.al. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy, Journal of clinical oncology, 2016. 34(30): p. 3648-3654., https://pubmed.ncbi.nlm.nih.gov/27528718/

815. Bottke, D., Bartkowiak, D., Siegmann, A., Thamm, R., Böhmer, D., Budach, V., et.al. Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer, Prostate cancer and prostatic diseases, 2019. 22(2): p. 344-349., https://pubmed.ncbi.nlm.nih.gov/30487644/

816. Shipley, W.U., Seiferheld, W., Lukka, H.R., Major, P.P., Heney, N.M., Grignon, D.J., et.al. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer, The New England journal of medicine, 2017. 376(5): p. 417-428., https://pubmed.ncbi.nlm.nih.gov/28146658/

817. Wiegel, T., Lohm, G., Bottke, D., Hocht, S., Miller, K., Siegmann, A., et.al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study, Int. J Radiat. Oncol. Biol. Phys, 2009. 73(4): p. 1009-1016., http://www.ncbi.nlm.nih.gov/pubmed/18963539

818. Ghadjar, P., Aebersold, D. M., Albrecht, C., Böhmer, D., Flentje, M., Ganswindt, U., et.al. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy, Strahlenther Onkol, 2018. 194(7): p. 619-626., https://pubmed.ncbi.nlm.nih.gov/29383406/

819. Kishan, A. U., Tendulkar, R.l D., Tran, P. T., Parker, C. C., Nguyen, P. L., Stephenson, A. J., et.al. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer, European urology oncology, 2018. 1(1): p. 3-18., https://pubmed.ncbi.nlm.nih.gov/31100226/

820. Spratt, D.E., Dess, R.T., Zumsteg, Z.S., Lin, D.W., Tran, P.T., Morgan, T.M., et.al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer, European urology, 2018. 73(2): p. 156-165., https://pubmed.ncbi.nlm.nih.gov/28716370/

821. Bartkowiak, D., Thamm, R., Siegmann, A., Böhmer, D., Budach, V., Wiegel, T., Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2020. 154: p. 255-259., https://pubmed.ncbi.nlm.nih.gov/32920006/

822. King, C. R., The dose-response of salvage radiotherapy following radical prostatectomy, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016. 121(2): p. 199-203., https://pubmed.ncbi.nlm.nih.gov/27863963/

823. Preisser, F., Chun, F. K. H., Pompe, R. S., Heinze, A., Salomon, G., Graefen, M., et.al. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes, European urology, 2019. 76(1): p. 106-114., https://pubmed.ncbi.nlm.nih.gov/30772034/

824. Ploussard, G., Fossati, N., Wiegel, T., D'Amico, A., Hofman, M. S., Gillessen, S., et.al. Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy, European urology oncology, 2021. p. [Epub ahead of print]., https://pubmed.ncbi.nlm.nih.gov/33574012/

825. Wiegel, T., Bartkowiak, D., Bottke, D., Thamm, R., Hinke, A., Stöckle, M., et.al. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival, International journal of radiation oncology, biology, physics, 2015. 91(2): p. 288-294., www.ncbi.nlm.nih.gov/pubmed/25445556

826. Bartkowiak, D., Siegmann, A., Böhmer, D., Budach, V., Wiegel, T., The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer, BJU international, 2019. 124(5): p. 785-791., https://pubmed.ncbi.nlm.nih.gov/31220400/

827. Dess, R. T., Sun, Y., Jackson, W. C., Jairath, N. K., Kishan, A. U., Wallington, D. G., et.al. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer, JAMA oncology, 2020. 6(5): p. 735-743., https://pubmed.ncbi.nlm.nih.gov/32215583/

828. Trock, B.J., Han, M., Freedland, S.J., Humphreys, E.B., DeWeese, T.L., Partin, A.W., et.al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy, JAMA, 2008. 299(23): p. 2760-2769., http://www.ncbi.nlm.nih.gov/pubmed/18560003

829. van den Broeck, T., van den Bergh, R.C.N., Briers, E., Cornford, P., Cumberbatch, M., Tilki, D., et.al. Biochemical Recurrence in Prostate Cancer, European urology focus, 2020. 6(2): p. 231-234., https://pubmed.ncbi.nlm.nih.gov/31248850/

830. Ghadjar, P., Hayoz, S., Bernhard, J., Zwahlen, D. R., Hölscher, T., Gut, P., et.al. Acute Toxicity and Quality of Life After Dose-Intensified Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer After Prostatectomy, Journal of clinical oncology, 2015. 33(35): p. 4158-4166., https://pubmed.ncbi.nlm.nih.gov/26527774/

831. Heidenreich, A., Richter, S., Thuer, D., Pfister, D., Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy, Eur Urol, 2010. 57(3): p. 437-443., http://www.ncbi.nlm.nih.gov/pubmed/19303197

832. Parekh, A., Graham, P.L., Nguyen, P.L., Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: a systematic review, Semin Radiat Oncol, 2013. 23(3): p. 222-234., http://www.ncbi.nlm.nih.gov/pubmed/23763889

833. Crouzet, S., Blana, A., Murat, F.J., Pasticier, G., Brown, S.C., Conti, G.N., et.al. Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients, BJU Int, 2017. 119(6): p. 896-904., http://www.ncbi.nlm.nih.gov/pubmed/28063191

834. Kanthabalan, A., Peters, M., van Vulpen, M., McCartan, N., Hindley, R.G., Emara, A., et.al. Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer, BJU Int, 2017. 120(2): p. 246-256., http://www.ncbi.nlm.nih.gov/pubmed/28258616

835. Leonardo, C., Simone, G., Papalia, R., Franco, G., Guaglianone, S., Gallucci, M., Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy, Int J Urol, 2009. 16(6): p. 584-586., http://www.ncbi.nlm.nih.gov/pubmed/19453762

836. Murat, F.J., Poissonnier, L., Rabilloud, M., Belot, A., Bouvier, R., Rouviere, O., et.al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer, Eur Urol, 2009. 55(3): p. 640-647., http://www.ncbi.nlm.nih.gov/pubmed/18508188

837. Heidenreich, A., Bolla, M., Joniau, S., Mason, M.D., Matveev, V., Mottet, N., et.al. EAU guidelines on prostate cancerEAU, 2011.

838. Bianco, F.J., Jr., Scardino, P.T., Stephenson, A.J., Diblasio, C.J., Fearn, P.A., Eastham, J.A., Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy, Int J Radiat Oncol Biol Phys, 2005. 62(2): p. 448-453., http://www.ncbi.nlm.nih.gov/pubmed/15890586

839. Heidenreich, A., Semrau, R., Thuer, D., Pfister, D., Die radikale Salvageprostatektomie: Therapie der lokalen Prostatarezidivs nach Strahlentherapie, Urologe A, 2008. 47(11): p. 1441-1446., http://www.ncbi.nlm.nih.gov/pubmed/18806991

840. Kunath, F., Jensen, K., Pinart, M., Kahlmeyer, A., Schmidt, S., Price, C. L., et.al. Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer, The Cochrane database of systematic reviews, 2019. 6: p. CD003506., https://pubmed.ncbi.nlm.nih.gov/31194882/

841. Fizazi, K., Tran, N.P., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., et.al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE), Lancet Oncol, 2019. 20(5): p. 686-700., https://pubmed.ncbi.nlm.nih.gov/30987939/

842. Fizazi, K., Tran, N. P., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., et.al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer, The New England journal of medicine, 2017. 377(4): p. 352-360., https://pubmed.ncbi.nlm.nih.gov/28578607/

843. Sweeney, C.J., Chen, Y.H., Carducci, M., Liu, G., Jarrard, D.F., Eisenberger, M., et.al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, N Engl J Med, 2015. 373(8): p. 737-746., http://www.ncbi.nlm.nih.gov/pubmed/26244877

844. Iversen, P., Johansson, J.E., Lodding, P., Kylmala, T., Lundmo, P., Klarskov, P., et.al. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years, Scand J Urol Nephrol, 2006. 40(6): p. 441-452., http://www.ncbi.nlm.nih.gov/pubmed/17130095

845. The Medical Research Council Prostate Cancer Working Party Investigators Group, Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial., Br. J. Urol, 1997. 79(2): p. 235-246., http://www.ncbi.nlm.nih.gov/pubmed/9052476

846. Boustead, G., Edwards, S.J., Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials, BJU Int, 2007. 99(6): p. 1383-1389., http://www.ncbi.nlm.nih.gov/pubmed/17346269

847. Agarwal, N., McQuarrie, K., Bjartell, A., Chowdhury, S., Pereira de Santana Gomes, A.J., Chung, B.H., et.al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN), Lancet Oncol, 2019. 20(11): p. 1518-1530., https://pubmed.ncbi.nlm.nih.gov/31578173/

848. Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., et.al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer, N Engl J Med, 2019. 381(1): p. 13-24., https://pubmed.ncbi.nlm.nih.gov/31150574/

849. Armstrong, A.J., Szmulewitz, R.Z., Petrylak, D.P., Holzbeierlein, J., Villers, A., Azad, A., et.al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer, J Clin Oncol, 2019. 37(32): p. 2974-2986., https://pubmed.ncbi.nlm.nih.gov/31329516/

850. Smith, MR, Hussain, M, Saad, F, Fizazi, K, Sternberg, CN, Crawford, ED, et.al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer., N Engl J Med, 2022. 386 (12)(12): p. 1132-1142., https://pubmed.ncbi.nlm.nih.gov/35179323/

851. Hussain, M, Tombal, B, Saad, F, Fizazi, K, Sternberg, CN, Crawford, ED, et.al. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial., J Clin Oncol, 2023. 41 (20)(20): p. 3595-3607., https://pubmed.ncbi.nlm.nih.gov/36795843/

852. Fizazi, K, Foulon, S, Carles, J, Roubaud, G, McDermott, R, Fléchon, A, et.al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design., Lancet, 2022. 399 (10336)(10336): p. 1695-1707., https://pubmed.ncbi.nlm.nih.gov/35405085/

853. Mourey, L., Boyle, H.J., Roubaud, G., McDermott, R. S., Supiot, S., Tombal, B. F., et.al. Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (‡70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1 trial, ASCO GU, 2023.

854. Saad, F, Vjaters, E, Shore, N, Olmos, D, Xing, N, Pereira de Santana Gomes, AJ, et.al. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial., J Clin Oncol, 2024. (): p. JCO2401798., https://pubmed.ncbi.nlm.nih.gov/39279580/

855. Clarke, N. W., Ali, A., Ingleby, F. C., Hoyle, A., Amos, C. L., Attard, G., et.al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer, Annals of oncology : official journal of the European Society for Medical Oncology, 2019. 30(12): p. 1992-2003., https://pubmed.ncbi.nlm.nih.gov/31560068/

856. Wilt, T.J., air, B., MacDonald, R., Rutks, I., Early versus deferred androgen suppression in the treatment of advanced prostatic cancer, Cochrane. Database. Syst. Rev, 2001. p. CD003506., http://www.ncbi.nlm.nih.gov/pubmed/11869665

857. Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B.Y., et.al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer, N Engl J Med, 2017. 377(4): p. 352-360., http://www.ncbi.nlm.nih.gov/pubmed/28578607

858. James, ND, Clarke, NW, Cook, A, Ali, A, Hoyle, AP, Attard, G, et.al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)., Int J Cancer, 2022. 151 (3)(3): p. 422-434., https://pubmed.ncbi.nlm.nih.gov/35411939/

859. European Medicines Agency, Erleada: Zusammenfassung der Merkmale des Arzneimittels, 2024., https://www.ema.europa.eu/de/documents/product-information/erleada-epar-product-information_de.pdf

860. European Medicines Agency, Xtandi: Zusammenfassung der Merkmale des Arzneimittels, 2024., www.ema.europa.eu/de/documents/product-information/xtandi-epar-product-information_de.pdf

861. European Medicines Agency, Zytiga: Zusammenfassung der Merkmale des Arzneimittels, 2024., https://www.ema.europa.eu/de/documents/product-information/zytiga-epar-product-information_de.pdf

862. European Medicines Agency, Nubeqa: Zusammenfassung der Merkmale des Arzneimittels, 2024., http://www.ema.europa.eu/de/documents/product-information/nubeqa-epar-product-information_de.pdf

863. Walsh, PC, Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group., J Urol, 1997. 158 (4)(4): p. 1623-4., https://pubmed.ncbi.nlm.nih.gov/9302187/

864. Byar, D.P., Corle, D.K., Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies, NCI. Monogr, 1988. p. 165-170., http://www.ncbi.nlm.nih.gov/pubmed/3050535

865. Zengerling, F, Jakob, JJ, Schmidt, S, Meerpohl, JJ, Blümle, A, Schmucker, C, et.al. Degarelix for treating advanced hormone-sensitive prostate cancer., Cochrane Database Syst Rev, 2021. 8 (8)(8): p. CD012548., https://pubmed.ncbi.nlm.nih.gov/34350976/

866. Kunath, F, Grobe, HR, Rücker, G, Motschall, E, Antes, G, Dahm, P, et.al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer., Cochrane Database Syst Rev, 2014. (6)(6): p. CD009266., https://pubmed.ncbi.nlm.nih.gov/24979481/

867. Yanagisawa, T, Kawada, T, Mori, K, Shim, SR, Mostafaei, H, Sari Motlagh, R, et.al. Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis., BJU Int, 2023. 132 (4)(4): p. 365-379., https://pubmed.ncbi.nlm.nih.gov/37395151/

868. Rajwa, P, Yanagisawa, T, Heidegger, I, Zattoni, F, Marra, G, Soeterik, TFW, et.al. Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis., Prostate Cancer Prostatic Dis, 2023. 26 (1)(1): p. 170-179., https://pubmed.ncbi.nlm.nih.gov/36284192/

869. Chi, KN, Chowdhury, S, Bjartell, A, Chung, BH, Pereira de Santana Gomes, AJ, Given, R, et.al. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study., J Clin Oncol, 2021. 39 (20)(20): p. 2294-2303., https://pubmed.ncbi.nlm.nih.gov/33914595/

870. Institut für Qualität und Wirtschaftlichkeit im, Gesundheitswesen, Apalutamid (Prostatakarzinom). Nutzenbewertung gemäß § 35a SGB V, IQWiG-Berichte, 2020., https://www.iqwig.de/download/a20-20_apalutamid_nutzenbewertung-35a-sgb-v_v1-0.pdf

871. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, Apalutamid (Prostatakarzinom). Addendum zum Auftrag A20-20. Version: 1.0, IQWiG-Berichte, 2020., https://www.iqwig.de/download/a20-62_apalutamid_addendum-zum-auftrag-a20-20_v1-0.pdf

872. Gemeinsamer Bundesausschuss (G-BA), Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel Richtlinie: Anlage XII – Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V Apalutamid (neues Anwendungsgebiet: metastasiertes, hormonsensitives Prostata-karzinom (mHSPC)), 2020., https://www.g-ba.de/downloads/40-268-6793/2020-08-20_AM-RL-XII_Apalutamid_D-532_TrG.pdf

873. Armstrong, AJ, Azad, AA, Iguchi, T, Szmulewitz, RZ, Petrylak, DP, Holzbeierlein, J, et.al. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer., J Clin Oncol, 2022. 40 (15)(15): p. 1616-1622., https://pubmed.ncbi.nlm.nih.gov/35420921/

874. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Dossierbewertung A21-77: Enzalutamid (Prostatakarzinom), Kurzfassung der Nutzenbewertung, 2021. 1.0:, https://www.iqwig.de/download/a21-77_enzalutamid_kurzfassung_nutzenbewertung-35a-sgb-v_v1-0.pdf

875. Gemeinsamer Bundesausschuss (G-BA), Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie: Anlage XII – Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V: Enzalutamid (Neues Anwendungsgebiet: Prostatakarzinom, metastasiert, hormonsensitiv, Kombination mit Androgenentzugstherapie), 2021., https://www.g-ba.de/downloads/39-261-5129/2021-11-19_AM-RL-XII_Enzalutamid_D-691_BAnz.pdf

876. James, N.D., de Bono, J.S., Spears, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., et.al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy, N Engl J Med, 2017. 377(4): p. 338-351., http://www.ncbi.nlm.nih.gov/pubmed/28578639

877. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Abirateronacetat (Prostatakarzinom) – Nutzenbewertung gemäß § 35a SGB V, IQWiG-Berichte – Nr. 605, 2018. 1.0:, https://www.g-ba.de/downloads/92-975-2220/2017-12-15_Nutzenbewertung-IQWiG_Abirateronacetat-D-337.pdf

878. Gemeinsamer Bundesausschuss (G-BA), Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel Richtlinie: Anlage XII – Beschlüsse über die Nutzenbewer-tung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V – Abirateronacetat (neues Anwendungsgebiet: metastasiertes hormonsensitives Prostatakarzinom (mHSPC)), 2018., https://www.g-ba.de/downloads/40-268-5049/2018-06-07_AM-RL-XII_Abirateronacetat-nAWG_D-337_TrG.pdf

879. James, N.D., Sydes, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., Spears, M.R., et.al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, Lancet, 2016. 387(10024): p. 1163-1177., http://www.ncbi.nlm.nih.gov/pubmed/26719232

880. Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., et.al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial, Lancet Oncol, 2013. 14(2): p. 149-158., http://www.ncbi.nlm.nih.gov/pubmed/23306100

881. Gravis, G., Boher, J. M., Chen, Y. H., Liu, G., Fizazi, K., Carducci, M. A., et.al. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel, European urology, 2018. 73(6): p. 847-855., https://pubmed.ncbi.nlm.nih.gov/29475737/

882. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Darolutamid (Prostatakarzinom) – Nutzenbewertung gemäß § 35a SGB V, IQWiG-Berichte – Nr. 1584, 2023. 1.0:, https://www.g-ba.de/downloads/92-975-6523/2023-04-01_Nutzenbewertung-IQWIG_Darolutamid-D-928.pdf

883. Gemeinsamer Bundesausschuss (G-BA), Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel Richtlinie: Anlage XII – Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Darolutamid (neues Anwendungsgebiet: Prostatakarzinom, metastasiert, hormonsensitiv,, 2023., https://www.g-ba.de/downloads/40-268-9782/2023-09-21_AM-RL-XII_Darolutamid_D-928_TrG.pdf

884. Loblaw, D.A., Mendelson, D.S., Talcott, J.A., Virgo, K.S., Somerfield, M.R., Ben-Josef, E., et.al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer, J. Clin. Oncol, 2004. 22(14): p. 2927-2941., http://www.ncbi.nlm.nih.gov/pubmed/15184404

885. Morote, J, Aguilar, A, Planas, J, Trilla, E, Definition of Castrate Resistant Prostate Cancer: New Insights., Biomedicines, 2022. 10 (3)(3):, https://pubmed.ncbi.nlm.nih.gov/35327491/

886. Oefelein, MG, Feng, A, Scolieri, MJ, Ricchiutti, D, Resnick, MI, Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making., Urology, 2000. 56 (6)(6): p. 1021-4., https://pubmed.ncbi.nlm.nih.gov/11113751/

887. Morote, J, Planas, J, Salvador, C, Raventós, CX, Catalán, R, Reventós, J, Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy., BJU Int, 2009. 103 (3)(3): p. 332-5; discussion 335., https://pubmed.ncbi.nlm.nih.gov/19007366/

888. Pickles, T, Hamm, J, Morris, WJ, Schreiber, WE, Tyldesley, S, Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?, BJU Int, 2012. 110 (11 Pt B)(11 Pt B): p. E500-7., https://pubmed.ncbi.nlm.nih.gov/22564197/

889. Klotz, Laurence, O'Callaghan, Chris, Higano, Tia, Goldenberg, Larry, Ding, Keyue, Crook, Juanita, MP74-01 NADIR TESTOSTERONE ON ADT PREDICTS FOR TIME TO CASTRATE RESISTANT PROGRESSION: A SECONDARY ANALYSIS OF THE PR-7 INTERMITTENT VS CONTINUOUS ADT TRIAL, Journal of Urology, 2014. 191(4S): p. e855-e856., https://www.auajournals.org/doi/abs/10.1016/j.juro.2014.02.2334

890. Eisenhauer, EA, Therasse, P, Bogaerts, J, Schwartz, LH, Sargent, D, Ford, R, et.al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)., Eur J Cancer, 2009. 45 (2)(2): p. 228-47., https://pubmed.ncbi.nlm.nih.gov/19097774/

891. AMWF online, S3-Leitlinie Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, https://register.awmf.org/de/leitlinien/detail/128-001OL

892. AMWF online, S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen - interdisziplinäre Querschnittsleitlinie, https://register.awmf.org/de/leitlinien/detail/032-054OL

893. Boyle, HJ, Alibhai, S, Decoster, L, Efstathiou, E, Fizazi, K, Mottet, N, et.al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients., Eur J Cancer, 2019. 116 (): p. 116-136., https://pubmed.ncbi.nlm.nih.gov/31195356/

894. AMWF online, S1-Leitlinie Geriatrisches Assessment der Stufe 2 - Living Guideline, https://register.awmf.org/de/leitlinien/detail/084-002LG

895. Smith, M.R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B.A., Graff, J.N., et.al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer, N Engl J Med, 2018. 378(15): p. 1408-1418., https://pubmed.ncbi.nlm.nih.gov/29420164/

896. Small, E.J., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B.A., Graff, J.N., et.al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer, Ann Oncol, 2019. 30(11): p. 1813-1820., https://pubmed.ncbi.nlm.nih.gov/31560066/

897. Smith, M.R., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B.A., Graff, J.N., et.al. Apalutamide and Overall Survival in Prostate Cancer, Eur Urol, 2020. 79(1): p. 150-158., https://pubmed.ncbi.nlm.nih.gov/32907777/

898. Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., et.al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer, N Engl J Med, 2019. 380(13): p. 1235-1246., https://pubmed.ncbi.nlm.nih.gov/30763142/

899. Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., et.al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide, N Engl J Med, 2020. 383(11): p. 1040-1049., https://pubmed.ncbi.nlm.nih.gov/32905676/

900. Sternberg, C.N., Fizazi, K., Saad, F., Shore, N.D., Giorgi, U., Penson, D.F., et.al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer, N Engl J Med, 2020. 382(23): p. 2197-2206., https://pubmed.ncbi.nlm.nih.gov/32469184/

901. Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., et.al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer, N Engl J Med, 2018. 378(26): p. 2465-2474., https://pubmed.ncbi.nlm.nih.gov/29949494/

902. Tombal, B., Saad, F., Penson, D., Hussain, M., Sternberg, C.N., Morlock, R., et.al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER), Lancet Oncol, 2019. 20(4): p. 556-569., https://pubmed.ncbi.nlm.nih.gov/30770294/

903. Saad, F., Cella, D., Basch, E., Hadaschik, B.A., Mainwaring, P.N., Oudard, S., et.al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer, Lancet Oncol, 2018. 19(10): p. 1404-1416., https://pubmed.ncbi.nlm.nih.gov/30213449/

904. Smith, M.R., Kabbinavar, F., Saad, F., Hussain, A., Gittelman, M.C., Bilhartz, D.L., et.al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer, Journal of clinical oncology, 2005. 23(13): p. 2918-2925., https://pubmed.ncbi.nlm.nih.gov/15860850/

905. ESMO, Talazoparib, https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards/scorecard-383-1

906. Gemeinsamer, Bundesausschuss, Nutzenbewertungsverfahren zum Wirkstoff Apalutamid (Neubewertung nach Fristablauf: Prostatakarzinom, nicht metastasiert, hohes Metastasenrisiko), 2020., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/542/

907. Fizazi, K, Shore, ND, Smith, M, Ramos, R, Jones, R, Niegisch, G, et.al. Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial., Eur J Cancer, 2023. 192 (): p. 113258., https://pubmed.ncbi.nlm.nih.gov/37660438/

908. Gemeinsamer, Bundesausschuss, Nutzenbewertungsverfahren zum Wirkstoff Darolutamid (Prostatakarzinom, nicht metastasiert, hohes Metastasenrisiko), 2020., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/548/

909. ESMO, Enzalutamide: PROSPER, https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards/scorecard-179-1

910. Gemeinsamer Bundesausschuss (G-BA), Nutzenbewertung nach § 35a SGB V: Nutzenbewertungsverfahren zum Wirkstoff Enzalutamid (Neubewertung nach Fristablauf: Prostatakarzinom, nicht metastasiert, Hochrisiko), 2020., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/551/

911. Sokolova, AO, Cheng, HH, Genetic Testing in Prostate Cancer., Curr Oncol Rep, 2020. 22 (1)(1): p. 5., https://pubmed.ncbi.nlm.nih.gov/31974718/

912. Olmos, David, Lorente, David, Alameda, Daniel, Cattrini, Carlo, Romero-Laorden, Nuria, Lozano, Rebeca, et.al. Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first-line (1L) treatment stratified by BRCA status, Journal of Clinical Oncology, 2023. 41(16_suppl): p. 5003-5003., https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.5003

913. Saad, F, Clarke, NW, Oya, M, Shore, N, Procopio, G, Guedes, JD, et.al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial., Lancet Oncol, 2023. 24 (10)(10): p. 1094-1108., https://pubmed.ncbi.nlm.nih.gov/37714168/

914. Chi, KN, Rathkopf, D, Smith, MR, Efstathiou, E, Attard, G, Olmos, D, et.al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer., J Clin Oncol, 2023. 41 (18)(18): p. 3339-3351., https://pubmed.ncbi.nlm.nih.gov/36952634/

915. Agarwal, N, Azad, AA, Carles, J, Fay, AP, Matsubara, N, Heinrich, D, et.al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial., Lancet, 2023. 402 (10398)(10398): p. 291-303., https://pubmed.ncbi.nlm.nih.gov/37285865/

916. Clarke, N, Wiechno, P, Alekseev, B, Sala, N, Jones, R, Kocak, I, et.al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial., Lancet Oncol, 2018. 19 (7)(7): p. 975-986., https://pubmed.ncbi.nlm.nih.gov/29880291/

917. Saad, F, Thiery-Vuillemin, A, Wiechno, P, Alekseev, B, Sala, N, Jones, R, et.al. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial., Lancet Oncol, 2022. 23 (10)(10): p. 1297-1307., https://pubmed.ncbi.nlm.nih.gov/36063830/

918. Clarke, NW, Armstrong, AJ, Thiery-Vuillemin, A, Oya, M, Shore, N, Loredo, E, et.al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer., NEJM Evid, 2022. 1 (9)(9): p. EVIDoa2200043., https://pubmed.ncbi.nlm.nih.gov/38319800/

919. Gemeinsamer Bundesausschuss (G-BA), Nutzenbewertung nach § 35a SGB V: Nutzenbewertungsverfahren zum Wirkstoff Olaparib (Neues Anwendungsgebiet: Prostatakarzinom, metastasiert, kastrationsresistent,Chemotherapie nicht klinisch indiziert, Kombination mit Abirateron und/oder Prednison), 2023., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/917/

920. ESMO, Olaparib, https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards/scorecard-365-1

921. Fizazi, K, Azad, AA, Matsubara, N, Carles, J, Fay, AP, De Giorgi, U, et.al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial., Nat Med, 2024. 30 (1)(1): p. 257-264., https://pubmed.ncbi.nlm.nih.gov/38049622/

922. Fizazi, K, Azad, AA, Matsubara, N, Carles, J, Fay, AP, De Giorgi, U, et.al. Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial., Nat Med, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/38297094/

923. Azad, Arun, Fizazi, Karim, Matsubara, Nobuaki, Saad, Fred, De Giorgi, Ugo, Joung, Jae Young, et.al. Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Safety analyses from the randomized, placebo (PBO)-controlled, phase 3 TALAPRO-2 study.Wolters Kluwer, Journal of Clinical Oncology, 2023. 41(16_suppl): p. 5053 - 5053., https://doi.org/10.1200/JCO.2023.41.16_suppl.5053

924. Chi, KN, Sandhu, S, Smith, MR, Attard, G, Saad, M, Olmos, D, et.al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial., Ann Oncol, 2023. 34 (9)(9): p. 772-782., https://pubmed.ncbi.nlm.nih.gov/37399894/

925. Gemeinsamer Bundesausschuss (G-BA), Nutzenbewertung nach § 35a SGB V: Nutzenbewertungsverfahren zum Wirkstoff Niraparib/Abirateronacetat (Prostatakarzinom, metastasiert, kastrationsresistent, BRCA1/2-Mutationen, Chemotherapie nicht klinisch indiziert, Kombination mit Prednis(ol)on), 2024., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1013/

926. ESMO, Niraparib/abiraterone acetate, https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards/scorecard-395-1

927. Fizazi, K, Piulats, JM, Reaume, MN, Ostler, P, McDermott, R, Gingerich, JR, et.al. Rucaparib or Physician's Choice in Metastatic Prostate Cancer., N Engl J Med, 2023. 388 (8)(8): p. 719-732., https://pubmed.ncbi.nlm.nih.gov/36795891/

928. Ryan, C.J., Smith, M.R., de Bono, J.S., Molina, A., Logothetis, C.J., de, Souza P., et.al. Abiraterone in metastatic prostate cancer without previous chemotherapy, N Engl J Med, 2013. 368(2): p. 138-148., http://www.ncbi.nlm.nih.gov/pubmed/23228172

929. Beer, T.M., Armstrong, A.J., Rathkopf, D.E., Loriot, Y., Sternberg, C.N., Higano, C.S., et.al. Enzalutamide in metastatic prostate cancer before chemotherapy, N Engl J Med, 2014. 371(5): p. 424-433., http://www.ncbi.nlm.nih.gov/pubmed/24881730

930. Tannock, I.F., de, Wit R., Berry, W.R., Horti, J., Pluzanska, A., Chi, K.N., et.al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N. Engl. J. Med, 2004. 351(15): p. 1502-1512., http://www.ncbi.nlm.nih.gov/pubmed/15470213

931. Ryan, C.J., Smith, M.R., Fizazi, K., Saad, F., Mulders, P.F., Sternberg, C.N., et.al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol, 2015. 16(2): p. 152-160., http://www.ncbi.nlm.nih.gov/pubmed/25601341

932. Gemeinsamer Bundesausschuss (G-BA), Nutzenbewertung nach § 35a SGB V: Nutzenbewertungsverfahren zum Wirkstoff Abirateronacetat (Prostatakarzinom, Progredienz während oder nach Docetaxel-haltiger Chemotherapie, Kombination mit Prednison oder Prednisolon), 2011., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/19/

933. Assi, T, Rassy, E, Farhat, F, Kattan, C, Kattan, J, Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review., Oncol Res Treat, 2020. 43 (6)(6): p. 299-306., https://pubmed.ncbi.nlm.nih.gov/32380503/

934. Gemeinsamer Bundesausschuss (G-BA), Nutzenbewertung nach § 35a SGB V: Nutzenbewertungsverfahren zum Wirkstoff Enzalutamid (Prostatakarzinom, Progredienz während oder nach Docetaxel-haltiger Chemotherapie), 2020., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/76/

935. ESMO, Enzalutamide: ENZAMET, https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards/scorecard-178-1

936. Kellokumpu-Lehtinen, P.L., Harmenberg, U., Joensuu, T., McDermott, R., Hervonen, P., Ginman, C., et.al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial, Lancet Oncol, 2013. 14(2): p. 117-124., http://www.ncbi.nlm.nih.gov/pubmed/23294853

937. Morris, MJ, Castellano, D, Herrmann, K, de Bono, JS, Shore, ND, Chi, KN, et.al. None, Lancet, 2024. 404 (10459)(10459): p. 1227-1239., https://pubmed.ncbi.nlm.nih.gov/39293462/

938. de Bono, J.S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.P., Kocak, I., et.al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 2010. 376(9747): p. 1147-1154., http://www.ncbi.nlm.nih.gov/pubmed/20888992

939. Sartor, O, de Bono, J, Chi, KN, Fizazi, K, Herrmann, K, Rahbar, K, et.al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer., N Engl J Med, 2021. 385 (12)(12): p. 1091-1103., https://pubmed.ncbi.nlm.nih.gov/34161051/

940. Hofman, MS, Emmett, L, Sandhu, S, Iravani, A, Joshua, AM, Goh, JC, et.al. [, Lancet, 2021. 397 (10276)(10276): p. 797-804., https://pubmed.ncbi.nlm.nih.gov/33581798/

941. Buteau, JP, Martin, AJ, Emmett, L, Iravani, A, Sandhu, S, Joshua, AM, et.al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [, Lancet Oncol, 2022. 23 (11)(11): p. 1389-1397., https://pubmed.ncbi.nlm.nih.gov/36261050/

942. Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O'Sullivan, J.M., Fossa, S.D., et.al. Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 2013. 369(3): p. 213-223., http://www.ncbi.nlm.nih.gov/pubmed/23863050

943. Smith, M., Parker, C., Saad, F., Miller, K., Tombal, B., Ng, Q.S., et.al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223), Lancet Oncol, 2019. 20(3): p. 408-419., https://pubmed.ncbi.nlm.nih.gov/30738780/

944. Gemeinsamer Bundesausschuss (G-BA), Nutzenbewertung nach § 35a SGB V: Nutzenbewertungsverfahren zum Wirkstoff Cabazitaxel (Prostatakarzinom, Docetaxel-Vorbehandlung, Kombination mit Prednison oder Prednisolon), 2011., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/10/

945. ESMO, Cabazitaxel, https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards/scorecard-102-1

946. Heidenreich, A., Scholz, H.J., Rogenhofer, S., Arsov, C., Retz, M., Muller, S.C., et.al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme, Eur Urol, 2013. 63(6): p. 977-982., http://www.ncbi.nlm.nih.gov/pubmed/23116658

947. Eisenberger, M, Hardy-Bessard, AC, Kim, CS, Géczi, L, Ford, D, Mourey, L, et.al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m, J Clin Oncol, 2017. 35 (28)(28): p. 3198-3206., https://pubmed.ncbi.nlm.nih.gov/28809610/

948. Wit, R., Bono, J., Sternberg, C.N., Fizazi, K., Tombal, B., Wülfing, C., et.al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer, N Engl J Med, 2019. 381(26): p. 2506-2518., www.ncbi.nlm.nih.gov/pubmed/31566937

949. Hofman, Michael, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony, Goh, Jeffrey, et.al. TheraP: 177 Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603), Journal of Clinical Oncology, 2022. 40: p. 5000-5000.

950. Kuo, PH, Benson, T, Messmann, R, Groaning, M, Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial., J Nucl Med, 2022. 63 (6)(6): p. 816-818., https://pubmed.ncbi.nlm.nih.gov/35086895/

951. Kratochwil, C, Fendler, WP, Eiber, M, Hofman, MS, Emmett, L, Calais, J, et.al. Joint EANM/SNMMI procedure guideline for the use of , Eur J Nucl Med Mol Imaging, 2023. 50 (9)(9): p. 2830-2845., https://pubmed.ncbi.nlm.nih.gov/37246997/

952. Schäfer, H, Mayr, S, Büttner-Herold, M, Knorr, K, Steinhelfer, L, Böger, CA, et.al. Extensive , Eur Urol, 2023. 83 (5)(5): p. 385-390., https://pubmed.ncbi.nlm.nih.gov/35688660/

953. Leitlinienprogramm Onkologie (OL), Deutsche Krebsgesellschaft (DKG), Deutsche Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen. AWMF-Register-Nummer (032/054OL). Langversion 1.1, 2017., https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie

954. ESMO, Radium-223, https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards/scorecard-97-1

955. Gemeinsamer, Bundesausschuss, Nutzenbewertungsverfahren zum Wirkstoff Radium-​223-dichlorid (Erneute Nutzenbewertung § 13: Prostatakarzinom), 2020., https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/455/

956. Gillessen, Silke, Choudhury, Ananya, Rodriguez-Vida, Alejo, Nole, Franco, Gallardo Diaz, Enrique, Roumeguere, Thierry Andre, et.al. Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.Wolters Kluwer, Journal of Clinical Oncology, 2021. 39(15_suppl): p. 5002 - 5002., https://doi.org/10.1200/JCO.2021.39.15_suppl.5002

957. Yamada, Y, Beltran, H, Clinical and Biological Features of Neuroendocrine Prostate Cancer., Curr Oncol Rep, 2021. 23 (2)(2): p. 15., https://pubmed.ncbi.nlm.nih.gov/33433737/

958. Zhou, J, Ding, J, Qi, J, Comparison of Typical Prostate Adenocarcinoma and Rare Histological Variant Prostate Cancer Showed Different Characteristics and Prognosis: A Surveillance, Epidemiology, and End Results Database Analysis., Eur Urol, 2022. 82 (2)(2): p. 152-155., https://pubmed.ncbi.nlm.nih.gov/35221166/

959. Aggarwal, R, Huang, J, Alumkal, JJ, Zhang, L, Feng, FY, Thomas, GV, et.al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study., J Clin Oncol, 2018. 36 (24)(24): p. 2492-2503., https://pubmed.ncbi.nlm.nih.gov/29985747/

960. Schaeffer, EM, Srinivas, S, Adra, N, An, Y, Barocas, D, Bitting, R, et.al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology., J Natl Compr Canc Netw, 2023. 21 (10)(10): p. 1067-1096., https://pubmed.ncbi.nlm.nih.gov/37856213/

961. Zhu, J, Liang, X, Wu, D, Chen, S, Yang, B, Mao, W, et.al. Clinicopathological characteristics and survival outcomes in neuroendocrine prostate cancer: A population-based study., Medicine (Baltimore), 2021. 100 (15)(15): p. e25237., https://pubmed.ncbi.nlm.nih.gov/33847621/

962. Merkens, L, Sailer, V, Lessel, D, Janzen, E, Greimeier, S, Kirfel, J, et.al. Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation., J Exp Clin Cancer Res, 2022. 41 (1)(1): p. 46., https://pubmed.ncbi.nlm.nih.gov/35109899/

963. Conteduca, V, Oromendia, C, Eng, KW, Bareja, R, Sigouros, M, Molina, A, et.al. Clinical features of neuroendocrine prostate cancer., Eur J Cancer, 2019. 121 (): p. 7-18., https://pubmed.ncbi.nlm.nih.gov/31525487/

964. Aparicio, AM, Harzstark, AL, Corn, PG, Wen, S, Araujo, JC, Tu, SM, et.al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer., Clin Cancer Res, 2013. 19 (13)(13): p. 3621-30., https://pubmed.ncbi.nlm.nih.gov/23649003/

965. Kránitz, N, Szepesváry, Z, Kocsis, K, Kullmann, T, Neuroendocrine Cancer of the Prostate., Pathol Oncol Res, 2020. 26 (3)(3): p. 1447-1450., https://pubmed.ncbi.nlm.nih.gov/31414399/

966. Pouessel, D, Gallet, B, Bibeau, F, Avancès, C, Iborra, F, Sénesse, P, et.al. Liver metastases in prostate carcinoma: clinical characteristics and outcome., BJU Int, 2007. 99 (4)(4): p. 807-11., https://pubmed.ncbi.nlm.nih.gov/17155968/

967. Rummel, K, Benson, J, Roller, L, Prostate adenocarcinoma with osteolytic metastases: Case report and review of the literature., Radiol Case Rep, 2021. 16 (11)(11): p. 3565-3568., https://pubmed.ncbi.nlm.nih.gov/34567333/

968. Cheville, JC, Tindall, D, Boelter, C, Jenkins, R, Lohse, CM, Pankratz, VS, et.al. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival., Cancer, 2002. 95 (5)(5): p. 1028-36., https://pubmed.ncbi.nlm.nih.gov/12209687/

969. Okamura, S, Fujiwara, Y, Nagata, K, Multiple osteolytic bone and lung metastases from prostate cancer including small cell carcinoma with marked increases in CEA and Pro-GRP., Urol Case Rep, 2019. 24 (): p. 100883., https://pubmed.ncbi.nlm.nih.gov/31211092/

970. Sella, A, Konichezky, M, Flex, D, Sulkes, A, Baniel, J, Low PSA metastatic androgen- independent prostate cancer., Eur Urol, 2000. 38 (3)(3): p. 250-4., https://pubmed.ncbi.nlm.nih.gov/10940696/

971. Aggarwal, R, Romero, GR, Friedl, V, Weinstein, A, Foye, A, Huang, J, et.al. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer., Prostate Cancer Prostatic Dis, 2021. 24 (1)(1): p. 81-87., https://pubmed.ncbi.nlm.nih.gov/32286548/

972. Mahal, BA, Aizer, AA, Efstathiou, JA, Nguyen, PL, Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer., Cancer, 2016. 122 (1)(1): p. 78-83., https://pubmed.ncbi.nlm.nih.gov/26371600/

973. Bakht, MK, Yamada, Y, Ku, SY, Venkadakrishnan, VB, Korsen, JA, Kalidindi, TM, et.al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer., Nat Cancer, 2023. 4 (5)(5): p. 699-715., https://pubmed.ncbi.nlm.nih.gov/37038004/

974. Laguerre, F, Anouar, Y, Montero-Hadjadje, M, Chromogranin A in the early steps of the neurosecretory pathway., IUBMB Life, 2020. 72 (4)(4): p. 524-532., https://pubmed.ncbi.nlm.nih.gov/31891241/

975. Isgrò, MA, Bottoni, P, Scatena, R, Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects., Adv Exp Med Biol, 2015. 867 (): p. 125-43., https://pubmed.ncbi.nlm.nih.gov/26530364/

976. Hong, P, Guo, RQ, Song, G, Yang, KW, Zhang, L, Li, XS, et.al. Prognostic role of chromogranin A in castration-resistant prostate cancer: A meta-analysis., Asian J Androl, 2018. 20 (6)(6): p. 561-566., https://pubmed.ncbi.nlm.nih.gov/30084431/

977. Liu, Y, Zhao, S, Wang, J, Zhu, Z, Luo, L, Li, E, et.al. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis., Urol Int, 2019. 102 (4)(4): p. 373-384., https://pubmed.ncbi.nlm.nih.gov/30517936/

978. Burgio, SL, Conteduca, V, Menna, C, Carretta, E, Rossi, L, Bianchi, E, et.al. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone., Endocr Relat Cancer, 2014. 21 (3)(3): p. 487-93., https://pubmed.ncbi.nlm.nih.gov/24741024/

979. Fan, L, Wang, Y, Chi, C, Pan, J, Xun, S, Xin, Z, et.al. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer., BJU Int, 2017. 120 (2)(2): p. 226-232., https://pubmed.ncbi.nlm.nih.gov/28107595/

980. Szarvas, T, Csizmarik, A, Fazekas, T, Hüttl, A, Nyirády, P, Hadaschik, B, et.al. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer., BJU Int, 2021. 127 (1)(1): p. 44-55., https://pubmed.ncbi.nlm.nih.gov/32314509/

981. Ploussard, G, Rozet, F, Roubaud, G, Stanbury, T, Sargos, P, Roupret, M, Chromogranin A: a useful biomarker in castration-resistant prostate cancer., World J Urol, 2023. 41 (2)(2): p. 361-369., https://pubmed.ncbi.nlm.nih.gov/36527470/

982. Muoio, B, Pascale, M, Roggero, E, The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature., Int J Biol Markers, 2018. 33 (1)(1): p. 10-21., https://pubmed.ncbi.nlm.nih.gov/28885659/

983. Kamiya, N, Akakura, K, Suzuki, H, Isshiki, S, Komiya, A, Ueda, T, et.al. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy., Eur Urol, 2003. 44 (3)(3): p. 309-14; discussion 314., https://pubmed.ncbi.nlm.nih.gov/12932928/

984. Rosar, F, Ribbat, K, Ries, M, Linxweiler, J, Bartholomä, M, Maus, S, et.al. Neuron-specific enolase has potential value as a biomarker for [, EJNMMI Res, 2020. 10 (1)(1): p. 52., https://pubmed.ncbi.nlm.nih.gov/32449086/

985. Culine, S, El Demery, M, Lamy, PJ, Iborra, F, Avancès, C, Pinguet, F, Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers., J Urol, 2007. 178 (3 Pt 1)(3 Pt 1): p. 844-8; discussion 848., https://pubmed.ncbi.nlm.nih.gov/17631339/

986. Loriot, Y, Massard, C, Gross-Goupil, M, Di Palma, M, Escudier, B, Bossi, A, et.al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features., Ann Oncol, 2009. 20 (4)(4): p. 703-8., https://pubmed.ncbi.nlm.nih.gov/19179557/

987. Fléchon, A, Pouessel, D, Ferlay, C, Perol, D, Beuzeboc, P, Gravis, G, et.al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial., Ann Oncol, 2011. 22 (11)(11): p. 2476-2481., https://pubmed.ncbi.nlm.nih.gov/21436186/

988. Steineck, G, Reuter, V, Kelly, WK, Frank, R, Schwartz, L, Scher, HI, Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements., Acta Oncol, 2002. 41 (7-8)(7-8): p. 668-74., https://pubmed.ncbi.nlm.nih.gov/14651212/

989. Apostolidis, L, Nientiedt, C, Winkler, EC, Berger, AK, Kratochwil, C, Kaiser, A, et.al. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate., Oncotarget, 2019. 10 (1)(1): p. 17-29., https://pubmed.ncbi.nlm.nih.gov/30713600/

990. Corn, PG, Heath, EI, Zurita, A, Ramesh, N, Xiao, L, Sei, E, et.al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial., Lancet Oncol, 2019. 20 (10)(10): p. 1432-1443., https://pubmed.ncbi.nlm.nih.gov/31515154/

991. Brown, LC, Halabi, S, Somarelli, JA, Humeniuk, M, Wu, Y, Oyekunle, T, et.al. A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer., Prostate Cancer Prostatic Dis, 2022. 25 (4)(4): p. 762-769., https://pubmed.ncbi.nlm.nih.gov/35292724/

992. Beltran, Himisha, Dowlati, Afshin, Jain, Prantesh, Johnson, Melissa Lynne, Sanborn, Rachel E., Thompson, Jonathan Robert, et.al. Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN), Journal of Clinical Oncology, 2024. 42(4_suppl): p. 121-121., https://ascopubs.org/doi/abs/10.1200/JCO.2024.42.4_suppl.121

993. Papandreou, CN, Daliani, DD, Thall, PF, Tu, SM, Wang, X, Reyes, A, et.al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate., J Clin Oncol, 2002. 20 (14)(14): p. 3072-80., https://pubmed.ncbi.nlm.nih.gov/12118020/

994. Burdett, S., Boevé, L. M., Ingleby, F. C., Fisher, D. J., Rydzewska, L. H., Vale, C. L., et.al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer, Eur Urol, 2019. 76(1): p. 115-124., https://pubmed.ncbi.nlm.nih.gov/30826218/

995. Parker, C. C., James, N. D., Brawley, C. D., Clarke, N. W., Hoyle, A. P., Ali, A., et.al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE), Lancet, 2018. 392(10162): p. 2353-2366., https://pubmed.ncbi.nlm.nih.gov/30355464/

996. Buelens, S., Poelaert, F., Dhondt, B., Fonteyne, V., Visschere, P., Ost, P., et.al. Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer, Urologic oncology, 2018. 36(4): p. 158.e13-158.e20., https://pubmed.ncbi.nlm.nih.gov/29336978/

997. Boevé, L. M. S., Hulshof, M. C. C. M., Vis, A. N., Zwinderman, A. H., Twisk, J. W. R., Witjes, W. P. J., et.al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial, Eur Urol, 2019. 75(3): p. 410-418., https://pubmed.ncbi.nlm.nih.gov/30266309/

998. Roy, S, Fervaha, G, Spratt, DE, Sun, Y, Kishan, AU, Loblaw, A, et.al. Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis., Eur Urol, 2024. 86 (1)(1): p. 10-17., https://pubmed.ncbi.nlm.nih.gov/38570246/

999. Bossi, A, Foulon, S, Maldonado, X, Sargos, P, MacDermott, R, Kelly, P, et.al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design., Lancet, 2024. 404 (10467)(10467): p. 2065-2076., https://pubmed.ncbi.nlm.nih.gov/39580202/

1000. Slaoui, A., Albisinni, S., Aoun, F., Assenmacher, G., Al Hajj Obeid, W., Diamand, R., et.al. A systematic review of contemporary management of oligometastatic prostate cancer, World J Urol, 2019. 37(11): p. 2343-2353., https://pubmed.ncbi.nlm.nih.gov/30706122/

1001. Phillips, R., Shi, W. Y., Deek, M., Radwan, N., Lim, S. J., Antonarakis, E. S., et.al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer, JAMA Oncol, 2020. 6(5): p. 650-659., https://pubmed.ncbi.nlm.nih.gov/32215577/

1002. Connor, M. J., Smith, A., Miah, S., Shah, T. T., Winkler, M., Khoo, V., et.al. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer, Eur Urol Oncol, 2020. 3(5): p. 582-593., https://pubmed.ncbi.nlm.nih.gov/32891600/

1003. Parker, CC, James, ND, Brawley, CD, Clarke, NW, Ali, A, Amos, CL, et.al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial., PLoS Med, 2022. 19 (6)(6): p. e1003998., https://pubmed.ncbi.nlm.nih.gov/35671327/

1004. Ali, A, Hoyle, A, Haran, ÁM, Brawley, CD, Cook, A, Amos, C, et.al. Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial., JAMA Oncol, 2021. 7 (4)(4): p. 555-563., https://pubmed.ncbi.nlm.nih.gov/33599706/

1005. Jones, C., 1782P Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): Results from the STAMPEDE M1|RT comparison, 2023. Volume 34, Supplement 2S963October 2023:

1006. Solberg, A, Haugen, OA, Viset, T, Bergh, A, Tasdemir, I, Ahlgren, G, et.al. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial., Int J Radiat Oncol Biol Phys, 2011. 80 (1)(1): p. 55-61., https://pubmed.ncbi.nlm.nih.gov/20598453/

1007. Warde, P, Mason, M, Ding, K, Kirkbride, P, Brundage, M, Cowan, R, et.al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial., Lancet, 2011. 378 (9809)(9809): p. 2104-11., https://pubmed.ncbi.nlm.nih.gov/22056152/

1008. Ma, TM, Chu, FI, Sandler, H, Feng, FY, Efstathiou, JA, Jones, CU, et.al. Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)., Eur Urol, 2022. 82 (5)(5): p. 487-498., https://pubmed.ncbi.nlm.nih.gov/35934601/

1009. Xiao, M., Cong, R., Zhang, Q., Xiang, W., Xiao, H., Might definitive local therapy of the primary tumor improve the survival benefits of metastatic prostate cancer?-evidence from a meta-analysis, Ann Palliat Med, 2020. 9(3): p. 648-660., www.ncbi.nlm.nih.gov/pubmed/32312070

1010. Falkmer, U., Jarhult, J., Wersall, P., Cavallin-Stahl, E., A systematic overview of radiation therapy effects in skeletal metastases, Acta Oncol, 2003. 42(5-6): p. 620-633., http://www.ncbi.nlm.nih.gov/pubmed/14596519

1011. Bauman, G., Charette, M., Reid, R., Sathya, J., Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review, Radiother Oncol, 2005. 75(3): p. 258-270., http://www.ncbi.nlm.nih.gov/pubmed/16299924

1012. Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., et.al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 2011. 377(9768): p. 813-822., http://www.ncbi.nlm.nih.gov/pubmed/21353695

1013. Smith, M.R., Coleman, R.E., Klotz, L., Pittman, K., Milecki, P., Ng, S., et.al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events, Ann Oncol, 2015. 26(2): p. 368-374., http://www.ncbi.nlm.nih.gov/pubmed/25425475

1014. Yuen, K.K., Shelley, M., Sze, W.M., Wilt, T., Mason, M.D., Bisphosphonates for advanced prostate cancer, Cochrane Database Syst Rev, 2006. p. CD006250., http://www.ncbi.nlm.nih.gov/pubmed/17054286

1015. James, N.D., Pirrie, S.J., Pope, A.M., Barton, D., Andronis, L., Goranitis, I., et.al. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial, JAMA Oncol, 2016. 2(4): p. 493-499., http://www.ncbi.nlm.nih.gov/pubmed/26794729

1016. Kamba, T., Kamoto, T., Maruo, S., Kikuchi, T., Shimizu, Y., Namiki, S., et.al. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial, Int J Clin Oncol, 2016. p. 1-8., http://www.ncbi.nlm.nih.gov/pubmed/27614621

1017. Smith, M.R., Halabi, S., Ryan, C.J., Hussain, A., Vogelzang, N., Stadler, W., et.al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance), J Clin Oncol, 2014. 32(11): p. 1143-1150., http://www.ncbi.nlm.nih.gov/pubmed/24590644

1018. Saad, F., Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer, Clin Prostate Cancer, 2005. 4(1): p. 31-37., http://www.ncbi.nlm.nih.gov/pubmed/15992459

1019. Bubendorf, L., Schopfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., et.al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients, Hum Pathol, 2000. 31(5): p. 578-583., http://www.ncbi.nlm.nih.gov/pubmed/10836297

1020. Carlin, B.I., Andriole, G.L., The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma, Cancer, 2000. 88(12 Suppl): p. 2989-2994., http://www.ncbi.nlm.nih.gov/pubmed/10898342

1021. Eaton, C.L., Coleman, R.E., Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment, Cancer Treat Rev, 2003. 29(3): p. 189-198., http://www.ncbi.nlm.nih.gov/pubmed/12787713

1022. Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., et.al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, J. Natl. Cancer Inst, 2004. 96(11): p. 879-882., http://www.ncbi.nlm.nih.gov/pubmed/15173273

1023. Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ), Empfehlungen zur Therapie von TumorschmerzenAkdÄ, Arzneiverordnung in der Praxis; 34, 2007.

1024. Hartsell, W.F., Scott, C.B., Bruner, D.W., Scarantino, C.W., Ivker, R.A., Roach, M., III, et.al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases, J Natl Cancer Inst, 2005. 97(11): p. 798-804., http://www.ncbi.nlm.nih.gov/pubmed/15928300

1025. Roos, D.E., Turner, S.L., O'Brien, P.C., Smith, J.G., Spry, N.A., Burmeister, B.H., et.al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05), Radiother. Oncol, 2005. 75(1): p. 54-63., http://www.ncbi.nlm.nih.gov/pubmed/15878101

1026. Sze, W.M., Shelley, M., Held, I., Mason, M., Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials, Cochrane Database Syst Rev, 2011. p. CD004721.

1027. Chow, E., Harris, K., Fan, G., Tsao, M., Sze, W.M., Palliative radiotherapy trials for bone metastases: a systematic review, J. Clin. Oncol, 2007. 25(11): p. 1423-1436., http://www.ncbi.nlm.nih.gov/pubmed/17416863

1028. Koswig, S., Budach, V., Remineralisation und Schmerzlinderung von Knochenmetastasen nach unterschiedlich fraktionierter Strahlentherapie (10 mal 3 Gy vs. 1 mal 8 Gy). Eine prospektive Studie, Strahlenther Onkol, 1999. 175(10): p. 500-508., http://www.ncbi.nlm.nih.gov/pubmed/10554645

1029. Patchell, R.A., Tibbs, P.A., Regine, W.F., Payne, R., Saris, S., Kryscio, R.J., et.al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial, Lancet, 2005. 366(9486): p. 643-648., http://www.ncbi.nlm.nih.gov/pubmed/16112300

1030. George, R., Jeba, J., Ramkumar, G., Chacko, A.G., Leng, M., Tharyan, P., Interventions for the treatment of metastatic extradural spinal cord compression in adults, Cochrane. Database. Syst. Rev, 2008. p. CD006716., http://www.ncbi.nlm.nih.gov/pubmed/18843728

1031. Sartor, O., Reid, R.H., Hoskin, P.J., Quick, D.P., Ell, P.J., Coleman, R.E., et.al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer, Urology, 2004. 63(5): p. 940-945., http://www.ncbi.nlm.nih.gov/pubmed/15134985

1032. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Rote-Hand-Brief zu Aclasta® (Wirkstoff: Zoledronsäure): Berichte über Nierenfunktionsstörungen und Nierenversagen, 2010., http://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2010/rhb-aclasta.pdf

1033. Paul-Ehrlich-Institut (PEI), Rote-Hand-Brief: Prolia® (Denosumab), 2014., https://www.pei.de/DE/newsroom/veroffentlichungen-arzneimittel/sicherheitsinformationen-human/2014/ablage2014/2014-09-04-rhb-prolia-denosumab.html

1034. Paul-Ehrlich-Institut (PEI), Rote-Hand-Brief: Xgeva® (Denosumab), 2015., https://www.pei.de/DE/newsroom/veroffentlichungen-arzneimittel/sicherheitsinformationen-human/2015/ablage2015/2015-07-30-rhb-xgeva-denosumab.html

1035. Saad, F., Chen, Y.M., Gleason, D.M., Chin, J., Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases, Clin Genitourin Cancer, 2007. 5(6): p. 390-396., http://www.ncbi.nlm.nih.gov/pubmed/17956712

1036. Han, S, Woo, S, Kim, YI, Lee, JL, Wibmer, AG, Schoder, H, et.al. Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis., Diagnostics (Basel), 2021. 11 (4)(4):, https://pubmed.ncbi.nlm.nih.gov/33917006/

1037. Alongi, P, Laudicella, R, Lanzafame, H, Farolfi, A, Mapelli, P, Picchio, M, et.al. PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature., Cancers (Basel), 2022. 14 (7)(7):, https://pubmed.ncbi.nlm.nih.gov/35406542/

1038. Esen, B, Herrmann, K, Bavbek, S, Kordan, Y, Tilki, D, Esen, T, Prostate-specific Membrane Antigen Positron Emission Tomography as a Biomarker to Assess Treatment Response in Patients with Advanced Prostate Cancer., Eur Urol Focus, 2023. 9 (4)(4): p. 596-605., https://pubmed.ncbi.nlm.nih.gov/36842919/

1039. Halabi, S, Roy, A, Rydzewska, L, Guo, S, Godolphin, P, Hussain, M, et.al. Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer., J Clin Oncol, 2024. 42 (9)(9): p. 1044-1054., https://pubmed.ncbi.nlm.nih.gov/38181323/

1040. Fukuokaya, W, Yanagisawa, T, Mori, K, Urabe, F, Rajwa, P, Briganti, A, et.al. Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial., Eur Urol Oncol, 2024. ():, https://pubmed.ncbi.nlm.nih.gov/38688767/

1041. Gillessen, S, Attard, G, Beer, TM, Beltran, H, Bossi, A, Bristow, R, et.al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017., Eur Urol, 2018. 73 (2)(2): p. 178-211., https://pubmed.ncbi.nlm.nih.gov/28655541/

1042. Gillessen, S, Omlin, A, Attard, G, de Bono, JS, Efstathiou, E, Fizazi, K, et.al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015., Ann Oncol, 2015. 26 (8)(8): p. 1589-604., https://pubmed.ncbi.nlm.nih.gov/26041764/

1043. Brown, JC, Winters-Stone, K, Lee, A, Schmitz, KH, Cancer, physical activity, and exercise., Compr Physiol, 2012. 2 (4)(4): p. 2775-809., https://pubmed.ncbi.nlm.nih.gov/23720265/

1044. Brenner, DR, Yannitsos, DH, Farris, MS, Johansson, M, Friedenreich, CM, Leisure-time physical activity and lung cancer risk: A systematic review and meta-analysis., Lung Cancer, 2016. 95 (): p. 17-27., https://pubmed.ncbi.nlm.nih.gov/27040847/

1045. Friedenreich, CM, Neilson, HK, Lynch, BM, State of the epidemiological evidence on physical activity and cancer prevention., Eur J Cancer, 2010. 46 (14)(14): p. 2593-604., https://pubmed.ncbi.nlm.nih.gov/20843488/

1046. Schmid, D, Behrens, G, Keimling, M, Jochem, C, Ricci, C, Leitzmann, M, A systematic review and meta-analysis of physical activity and endometrial cancer risk., Eur J Epidemiol, 2015. 30 (5)(5): p. 397-412., https://pubmed.ncbi.nlm.nih.gov/25800123/

1047. Wolin, KY, Yan, Y, Colditz, GA, Lee, IM, Physical activity and colon cancer prevention: a meta-analysis., Br J Cancer, 2009. 100 (4)(4): p. 611-6., https://pubmed.ncbi.nlm.nih.gov/19209175/

1048. Wu, Y, Zhang, D, Kang, S, Physical activity and risk of breast cancer: a meta-analysis of prospective studies., Breast Cancer Res Treat, 2013. 137 (3)(3): p. 869-82., https://pubmed.ncbi.nlm.nih.gov/23274845/

1049. Moore, SC, Lee, IM, Weiderpass, E, Campbell, PT, Sampson, JN, Kitahara, CM, et.al. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults., JAMA Intern Med, 2016. 176 (6)(6): p. 816-25., https://pubmed.ncbi.nlm.nih.gov/27183032/

1050. Li, T, Wei, S, Shi, Y, Pang, S, Qin, Q, Yin, J, et.al. The dose-response effect of physical activity on cancer mortality: findings from 71 prospective cohort studies., Br J Sports Med, 2016. 50 (6)(6): p. 339-45., https://pubmed.ncbi.nlm.nih.gov/26385207/

1051. Sanchis-Gomar, F, Lucia, A, Yvert, T, Ruiz-Casado, A, Pareja-Galeano, H, Santos-Lozano, A, et.al. Physical inactivity and low fitness deserve more attention to alter cancer risk and prognosis., Cancer Prev Res (Phila), 2015. 8 (2)(2): p. 105-10., https://pubmed.ncbi.nlm.nih.gov/25416409/

1052. Vainshelboim, B, Müller, J, Lima, RM, Nead, KT, Chester, C, Chan, K, et.al. Cardiorespiratory fitness, physical activity and cancer mortality in men., Prev Med, 2017. 100 (): p. 89-94., https://pubmed.ncbi.nlm.nih.gov/28412186/

1053. Bourke, L, Smith, D, Steed, L, Hooper, R, Carter, A, Catto, J, et.al. Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis., Eur Urol, 2016. 69 (4)(4): p. 693-703., https://pubmed.ncbi.nlm.nih.gov/26632144/

1054. Schwingshackl, L, Schwedhelm, C, Galbete, C, Hoffmann, G, Adherence to Mediterranean Diet and Risk of Cancer: An Updated Systematic Review and Meta-Analysis., Nutrients, 2017. 9 (10)(10):, https://pubmed.ncbi.nlm.nih.gov/28954418/

1055. Chen, P, Zhang, W, Wang, X, Zhao, K, Negi, DS, Zhuo, L, et.al. Lycopene and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis., Medicine (Baltimore), 2015. 94 (33)(33): p. e1260., https://pubmed.ncbi.nlm.nih.gov/26287411/

1056. Markozannes, G, Tzoulaki, I, Karli, D, Evangelou, E, Ntzani, E, Gunter, MJ, et.al. Diet, body size, physical activity and risk of prostate cancer: An umbrella review of the evidence., Eur J Cancer, 2016. 69 (): p. 61-69., https://pubmed.ncbi.nlm.nih.gov/27816833/

1057. Richman, EL, Kenfield, SA, Chavarro, JE, Stampfer, MJ, Giovannucci, EL, Willett, WC, et.al. Fat intake after diagnosis and risk of lethal prostate cancer and all-cause mortality., JAMA Intern Med, 2013. 173 (14)(14): p. 1318-26., https://pubmed.ncbi.nlm.nih.gov/23752662/

1058. World Cancer Research Fund/American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Cancer: a Global Perspective. Continuous Update Project Expert Report 2018. Available at dietandcancerreport.org. ISBN 978-1-912259-47-2, 2018.

1059. Klein, EA, Thompson, IM, Tangen, CM, Crowley, JJ, Lucia, MS, Goodman, PJ, et.al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)., JAMA, 2011. 306 (14)(14): p. 1549-56., https://pubmed.ncbi.nlm.nih.gov/21990298/

1060. Brasky, TM, Darke, AK, Song, X, Tangen, CM, Goodman, PJ, Thompson, IM, et.al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial., J Natl Cancer Inst, 2013. 105 (15)(15): p. 1132-41., https://pubmed.ncbi.nlm.nih.gov/23843441/

1061. Wagner, D., Trudel, D., Van der Kwast, T., et al. (2013). Dietary intake of lycopene is associated with reduced risk of prostate cancer: Evidence from a meta-analysis. PLOS ONE, 8(6), e65976., 2013.

1062. van Gils, CH, Bostick, RM, Stern, MC, Taylor, JA, Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: an example of polymorphisms in the XRCC1 gene., Cancer Epidemiol Biomarkers Prev, 2002. 11 (11)(11): p. 1279-84., https://pubmed.ncbi.nlm.nih.gov/12433703/

1063. Horneber, M, Bueschel, G, Dennert, G, Less, D, Ritter, E, Zwahlen, M, How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis., Integr Cancer Ther, 2012. 11 (3)(3): p. 187-203., https://pubmed.ncbi.nlm.nih.gov/22019489/

1064. Johnson, SB, Park, HS, Gross, CP, Yu, JB, Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers., JAMA Oncol, 2018. 4 (10)(10): p. 1375-1381., https://pubmed.ncbi.nlm.nih.gov/30027204/

1065. Ntritsou, V, Mavrommatis, C, Kostoglou, C, Dimitriadis, G, Tziris, N, Zagka, P, et.al. Effect of perioperative electroacupuncture as an adjunctive therapy on postoperative analgesia with tramadol and ketamine in prostatectomy: a randomised sham-controlled single-blind trial., Acupunct Med, 2014. 32 (3)(3): p. 215-22., https://pubmed.ncbi.nlm.nih.gov/24480836/

1066. Beard, C, Stason, WB, Wang, Q, Manola, J, Dean-Clower, E, Dusek, JA, et.al. Effects of complementary therapies on clinical outcomes in patients being treated with radiation therapy for prostate cancer., Cancer, 2011. 117 (1)(1): p. 96-102., https://pubmed.ncbi.nlm.nih.gov/20803609/

1067. Elliott, SP, Meng, MV, Elkin, EP, McAninch, JW, Duchane, J, Carroll, PR, Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE., J Urol, 2007. 178 (2)(2): p. 529-34; discussion 534., https://pubmed.ncbi.nlm.nih.gov/17570425/

1068. Albers et al. (2005) Qualitätssicherung der radikalen Prostatektomie. Dtsch Arztebl 2005; 102:A 3582-6, 2005.

1069. Dindo, D., Demartines, N., Clavien, P.A., Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, 2004. 240(2): p. 205-213., https://pubmed.ncbi.nlm.nih.gov/15273542/

1070. Beyer, J., Wessela, S., Hakenberg, O.W., Kuhlisch, E., Halbritter, K., Froehner, M., et.al. Incidence, risk profile and morphological pattern of venous thromboembolism after prostate cancer surgery, J Thromb Haemost, 2009. 7(4): p. 597-604., http://www.ncbi.nlm.nih.gov/pubmed/19143928

1071. Musch, M., Klevecka, V., Roggenbuck, U., Kroepfl, D., Complications of pelvic lymphadenectomy in 1,380 patients undergoing radical retropubic prostatectomy between 1993 and 2006, J. Urol, 2008. 179(3): p. 923-928., http://www.ncbi.nlm.nih.gov/pubmed/18207170

1072. Briganti, A., Chun, F.K., Salonia, A., Suardi, N., Gallina, A., Da Pozzo, L.F., et.al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer, Eur Urol, 2006. 50(5): p. 1006-1013., http://www.ncbi.nlm.nih.gov/pubmed/16959399

1073. Bolderston, A, Lloyd, NS, Wong, RK, Holden, L, Robb-Blenderman, L, The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline., Support Care Cancer, 2006. 14 (8)(8): p. 802-17., https://pubmed.ncbi.nlm.nih.gov/16758176/

1074. Hegarty, S. E., Dunne, M. T., Clarke-Moloney, M., et al. (2019). Topical agents and dressings for the management of radiation-induced skin reactions: A systematic review. Journal of Medical Radiation Sciences, 66(2), 139–146, 2019.

1075. Chan, RJ, Webster, J, Chung, B, Marquart, L, Ahmed, M, Garantziotis, S, Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials., BMC Cancer, 2014. 14 (): p. 53., https://pubmed.ncbi.nlm.nih.gov/24484999/

1076. Skóra, M., Bulik, M., Adamczyk, A., et al. (2020). Honey-based products in radiotherapy-induced skin toxicity management: A review. Wound Repair and Regeneration, 28(5), 617–626, 2020.

1077. Vernia, P., Fracasso, P.L., Casale, V., Villotti, G., Marcheggiano, A., Stigliano, V., et.al. Topical butyrate for acute radiation proctitis: randomised, crossover trial, Lancet, 2000. 356(9237): p. 1232-1235., http://www.ncbi.nlm.nih.gov/pubmed/11072942

1078. Sanguineti, G., Franzone, P., Marcenaro, M., Foppiano, F., Vitale, V., Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study, Strahlenther. Onkol, 2003. 179(7): p. 464-470., http://www.ncbi.nlm.nih.gov/pubmed/12835883

1079. Sherman, D.M., Mangini, L., Poirier, P., Kadish, S.P., Double-blind comparison of loperamide and placebo in the treatment of radiation-induced diarrhea, Adv Ther, 1989. 6: p. 103-111.

1080. Yavuz, M.N., Yavuz, A.A., Aydin, F., Can, G., Kavgaci, H., The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study, Int. J Radiat. Oncol. Biol. Phys, 2002. 54(1): p. 195-202., http://www.ncbi.nlm.nih.gov/pubmed/12182992

1081. Fuccio, L, Guido, A, Laterza, L, Eusebi, LH, Busutti, L, Bunkheila, F, et.al. Randomised clinical trial: preventive treatment with topical rectal beclomethasone dipropionate reduces post-radiation risk of bleeding in patients irradiated for prostate cancer., Aliment Pharmacol Ther, 2011. 34 (6)(6): p. 628-37., https://pubmed.ncbi.nlm.nih.gov/21790680/

1082. O'Brien, PC, Franklin, CI, Poulsen, MG, Joseph, DJ, Spry, NS, Denham, JW, Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial--Trans-Tasman Radiation Oncology Group., Int J Radiat Oncol Biol Phys, 2002. 54 (2)(2): p. 442-9., https://pubmed.ncbi.nlm.nih.gov/12243820/

1083. Marras F, et al. "Radiation-induced proctitis in prostate cancer patients: Incidence and management." J Radiat Oncol. 2020;9(3):215-223., 2020.

1084. Pan H, et al. "Incidence and risk factors of chronic radiation proctitis after radiotherapy for prostate cancer." Radiat Oncol. 2015;10:30. DOI: 10.1186/s13014-015-0331-8., 2015.

1085. McGough, C., Baldwin, C., Frost, G., Andreyev, H.J., Role of nutritional intervention in patients treated with radiotherapy for pelvic malignancy, Br. J. Cancer, 2004. 90(12): p. 2278-2287., http://www.ncbi.nlm.nih.gov/pubmed/15162154

1086. Lilleby, W, Fosså, SD, Waehre, HR, Olsen, DR, Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy., Int J Radiat Oncol Biol Phys, 1999. 43 (4)(4): p. 735-43., https://pubmed.ncbi.nlm.nih.gov/10098428/

1087. Xiao, J, Zhang, M, Wu, D, Side effects of prostate cancer therapies and potential management., J Biol Methods, 2024. 11 (3)(3): p. e99010018., https://pubmed.ncbi.nlm.nih.gov/39544189/

1088. Spampinato, S, Rancati, T, Waskiewicz, JM, Avuzzi, B, Garibaldi, E, Faiella, A, et.al. Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivors., Acta Oncol, 2023. 62 (11)(11): p. 1440-1450., https://pubmed.ncbi.nlm.nih.gov/37801288/

1089. Knight, K, Wade, S, Balducci, L, Prevalence and outcomes of anemia in cancer: a systematic review of the literature., Am J Med, 2004. 116 Suppl 7A (): p. 11S-26S., https://pubmed.ncbi.nlm.nih.gov/15050883/

1090. Marks, LB, Yorke, ED, Jackson, A, Ten Haken, RK, Constine, LS, Eisbruch, A, et.al. Use of normal tissue complication probability models in the clinic., Int J Radiat Oncol Biol Phys, 2010. 76 (3 Suppl)(3 Suppl): p. S10-9., https://pubmed.ncbi.nlm.nih.gov/20171502/

1091. Denton, A., Forbes, A., Andreyev, J., Maher, E.J., Non surgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis, Cochrane Database Syst Rev, 2002. p. CD003455., http://www.ncbi.nlm.nih.gov/pubmed/11869662

1092. Heumann, P, Aguado-Barrera, ME, Avuzzi, B, Azria, D, Briers, E, Bultijnck, R, et.al. Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study., Radiother Oncol, 2023. 178 (): p. 109426., https://pubmed.ncbi.nlm.nih.gov/36442608/

1093. Andreyev, HJ, Muls, AC, Norton, C, Ralph, C, Watson, L, Shaw, C, et.al. Guidance: The practical management of the gastrointestinal symptoms of pelvic radiation disease., Frontline Gastroenterol, 2015. 6 (1)(1): p. 53-72., https://pubmed.ncbi.nlm.nih.gov/25580207/

1094. Spetz, A.C., Zetterlund, E.L., Varenhorst, E., Hammar, M., Incidence and management of hot flashes in prostate cancer, J. Support. Oncol, 2003. 1(4): p. 263-70, 272., http://www.ncbi.nlm.nih.gov/pubmed/15334868

1095. Cervenakov, I., Kopecny, M., Jancar, M., Chovan, D., Mal'a, M., 'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate, Int Urol Nephrol, 2000. 32(1): p. 77-79., http://www.ncbi.nlm.nih.gov/pubmed/11057778

1096. Morote, J., Orsola, A., Planas, J., Trilla, E., Raventos, C.X., Cecchini, L., et.al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy, J. Urol, 2007. 178(4 Pt 1): p. 1290-1295., http://www.ncbi.nlm.nih.gov/pubmed/17698136

1097. Abrahamsen, B., Nielsen, M.F., Eskildsen, P., Andersen, J.T., Walter, S., Brixen, K., Fracture risk in Danish men with prostate cancer: a nationwide register study, BJU Int, 2007. 100(4): p. 749-754., http://www.ncbi.nlm.nih.gov/pubmed/17822455

1098. Malcolm, J.B., Derweesh, I.H., Kincade, M.C., Diblasio, C.J., Lamar, K.D., Wake, R.W., et.al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer, Can. J. Urol, 2007. 14(3): p. 3551-3559., http://www.ncbi.nlm.nih.gov/pubmed/17594745

1099. Qaseem, A., Snow, V., Shekelle, P., Casey, D.E., Jr., Cross, J.T., Jr., Owens, D.K., et.al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians, Ann. Intern. Med, 2008. 148(2): p. 141-146., http://www.ncbi.nlm.nih.gov/pubmed/18195338

1100. Weissbach, L., Diagnostik von Knochenmetastasen urologischer Tumoren und deren Behandlung mit Bisphosphonaten. Interdisziplinäre Konsensuskonferenz Frankfurt 2006, Urologe A, 2006. 45(12): p. 1527-1531., http://www.ncbi.nlm.nih.gov/pubmed/17091278

1101. Hakimian, P., Blute, M., Jr., Kashanian, J., Chan, S., Silver, D., Shabsigh, R., Metabolic and cardiovascular effects of androgen deprivation therapy, BJU Int, 2008. 102(11): p. 1509-1514., http://www.ncbi.nlm.nih.gov/pubmed/18727614

1102. Saylor, P.J., Smith, M.R., Metabolic complications of androgen deprivation therapy for prostate cancer, J. Urol, 2009. 181(5): p. 1998-2006., http://www.ncbi.nlm.nih.gov/pubmed/19286225

1103. Efstathiou, J.A., Bae, K., Shipley, W.U., Hanks, G.E., Pilepich, M.V., Sandler, H.M., et.al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02, Eur Urol, 2008. 54(4): p. 816-823., http://www.ncbi.nlm.nih.gov/pubmed/18243498

1104. Efstathiou, J.A., Bae, K., Shipley, W.U., Hanks, G.E., Pilepich, M.V., Sandler, H.M., et.al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31, J Clin Oncol, 2009. 27(1): p. 92-99., http://www.ncbi.nlm.nih.gov/pubmed/19047297

1105. Beer, T.M., Myrthue, A., Calcitriol in the treatment of prostate cancer, Anticancer Res, 2006. 26(4A): p. 2647-2651., http://www.ncbi.nlm.nih.gov/pubmed/16886675

1106. Johansson, J.E., Wersall, P., Brandberg, Y., Andersson, S.O., Nordstrom, L., Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study, Scand J Urol Nephrol, 2001. 35(4): p. 288-294., http://www.ncbi.nlm.nih.gov/pubmed/11676354

1107. Bogdanos, J., Karamanolakis, D., Milathianakis, K., Repousis, P., Chloraki-Bobota, A., Majed, H., et.al. Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases, Anticancer Res, 2004. 24(3b): p. 1957-1961., http://www.ncbi.nlm.nih.gov/pubmed/15274384

1108. Winquist, E., Julian, J.A., Moore, M.J., Nabid, A., Sathya, J., Wood, L., et.al. Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia, J Clin Oncol, 2009. 27(4): p. 644-646., http://www.ncbi.nlm.nih.gov/pubmed/19103725

1109. Iversen, P., Tammela, T.L., Vaage, S., Lukkarinen, O., Lodding, P., Bull-Njaa, T., et.al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6, Eur Urol, 2002. 42(3): p. 204-211., http://www.ncbi.nlm.nih.gov/pubmed/12234503

1110. Widmark, A., New principles in the treatment of prostate cancer--the oncologist's view, Scand. J Urol. Nephrol. Suppl, 2003. p. 23-27., http://www.ncbi.nlm.nih.gov/pubmed/12841324

1111. Tyrrell, C., Immediate Treatment with Bicalutamide, 150 mg/d, Following Radiotherapy in Localized or Locally Advanced Prostate Cancer, Rev. Urol, 2004. 6 Suppl 2: p. S29-S36., http://www.ncbi.nlm.nih.gov/pubmed/16985858

1112. Perdona, S., Autorino, R., De, Placido S., D'Armiento, M., Gallo, A., Damiano, R., et.al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial, Lancet Oncol, 2005. 6(5): p. 295-300., http://www.ncbi.nlm.nih.gov/pubmed/15863377

1113. Sternberg, CN, Freedland, SJ, George, DJ, Morgans, AK, Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale., Clin Genitourin Cancer, 2024. 22 (6)(6): p. 102171., https://pubmed.ncbi.nlm.nih.gov/39241313/

1114. Chi, KN, Protheroe, A, Rodríguez-Antolín, A, Facchini, G, Suttman, H, Matsubara, N, et.al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial., Lancet Oncol, 2018. 19 (2)(2): p. 194-206., https://pubmed.ncbi.nlm.nih.gov/29326030/

1115. N Agarwal, S Chowdhury, A Bjartell, et al. Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT). J Clin Oncol, 39 (2021), p. 5068, 2021.

1116. Sachdeva et al. Bone Resorptive Agents and Their Appropriate Use and Timing. 2024 ASCO Annual Meeting., 2024.

1117. Conde-Estévez, D, Henríquez, I, Muñoz-Rodríguez, J, Rodriguez-Vida, A, Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions., Expert Opin Drug Metab Toxicol, 2022. 18 (9)(9): p. 601-613., https://pubmed.ncbi.nlm.nih.gov/36111393/

1118. Hussain, A, Jiang, S, Varghese, D, Appukkuttan, S, Kebede, N, Gnanasakthy, K, et.al. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States., BMC Cancer, 2022. 22 (1)(1): p. 304., https://pubmed.ncbi.nlm.nih.gov/35317768/

1119. Pan, A, Reingold, RE, Zhao, JL, Moy, A, Kraehenbuehl, L, Dranitsaris, G, et.al. Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide., J Urol, 2022. 207 (5)(5): p. 1010-1019., https://pubmed.ncbi.nlm.nih.gov/35020444/

1120. Birtle, AJ, Formisano, L, Descamps, V, Weisenseel, P, Vilaseca, A, Early Identification and Management of Patients with Rash on Apalutamide., Oncol Ther, 2024. 12 (3)(3): p. 609-620., https://pubmed.ncbi.nlm.nih.gov/39088147/

1121. Podgoršek, E, Mehra, N, van Oort, IM, Somford, DM, Boerrigter, E, van Erp, NP, Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor-Darolutamide., Clin Pharmacokinet, 2023. 62 (8)(8): p. 1049-1061., https://pubmed.ncbi.nlm.nih.gov/37458966/

1122. Oishi, T, Hatakeyama, S, Tabata, R, Fujimori, D, Kawashima, Y, Tanaka, R, et.al. Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: A multicenter retrospective study., Prostate, 2023. 83 (2)(2): p. 198-203., https://pubmed.ncbi.nlm.nih.gov/36314250/

1123. Gilbar, P., Hain, A., Peereboom, V.M., Nail toxicity induced by cancer chemotherapy, J Oncol Pharm Pract, 2009. 15(3): p. 143-155., http://www.ncbi.nlm.nih.gov/pubmed/19171552

1124. Scotte, F., Tourani, J.M., Banu, E., Peyromaure, M., Levy, E., Marsan, S., et.al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand, J. Clin. Oncol, 2005. 23(19): p. 4424-4429., http://www.ncbi.nlm.nih.gov/pubmed/15994152

1125. Scotte, F., Banu, E., Medioni, J., Levy, E., Ebenezer, C., Marsan, S., et.al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot, Cancer, 2008. 112(7): p. 1625-1631., http://www.ncbi.nlm.nih.gov/pubmed/18286527

1126. Kimura, S, Shigeta, K, Tamura, S, Uchino, K, Kimura, T, Ozaki, Y, et.al. Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022., Int J Clin Oncol, 2024. 29 (5)(5): p. 559-563., https://pubmed.ncbi.nlm.nih.gov/38538963/

1127. Watanabe, K, Kosaka, T, Hongo, H, Oya, M, Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer., Sci Rep, 2021. 11 (1)(1): p. 8367., https://pubmed.ncbi.nlm.nih.gov/33863964/

1128. Levy, M.H., Back, A., Benedetti, C., Billings, J.A., Block, S., Boston, B., et.al. NCCN clinical practice guidelines in oncology: palliative care, J Natl Compr. Canc. Netw, 2009. 7(4): p. 436-473., https://pubmed.ncbi.nlm.nih.gov/19406043/

1129. Roila, F., Hesketh, P.J., Herrstedt, J., Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference, Ann. Oncol, 2006. 17(1): p. 20-28., http://www.ncbi.nlm.nih.gov/pubmed/16314401

1130. Kris, M.G., Hesketh, P.J., Somerfield, M.R., Feyer, P., Clark-Snow, R., Koeller, J.M., et.al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006, J Clin Oncol, 2006. 24(18): p. 2932-2947., http://www.ncbi.nlm.nih.gov/pubmed/16717289

1131. Jordan, K., Sippel, C., Schmoll, H.J., Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations, Oncologist, 2007. 12(9): p. 1143-1150., http://www.ncbi.nlm.nih.gov/pubmed/17914084

1132. Scotté F, Schwartzberg L, Iihara H, Aapro M, Gralla R, Hesketh PJ, Jordan K, Chow R, Herrstedt J. 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Support Care Cancer. 2023 Dec 20;32(1):45., 2023.

1133. Loprinzi, CL, Lacchetti, C, Bleeker, J, Cavaletti, G, Chauhan, C, Hertz, DL, et.al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update., J Clin Oncol, 2020. 38 (28)(28): p. 3325-3348., https://pubmed.ncbi.nlm.nih.gov/32663120/

1134. Hershman, DL, Lacchetti, C, Dworkin, RH, Lavoie Smith, EM, Bleeker, J, Cavaletti, G, et.al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline., J Clin Oncol, 2014. 32 (18)(18): p. 1941-67., https://pubmed.ncbi.nlm.nih.gov/24733808/

1135. Grisold, W, Cavaletti, G, Windebank, AJ, Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention., Neuro Oncol, 2012. 14 Suppl 4 (Suppl 4)(Suppl 4): p. iv45-54., https://pubmed.ncbi.nlm.nih.gov/23095830/

1136. Peterson, D.E., Bensadoun, R.J., Roila, F., Management of oral and gastrointestinal mucositis: ESMO clinical recommendations, Ann. Oncol, 2008. 19 Suppl 2: p. ii122-ii125., http://www.ncbi.nlm.nih.gov/pubmed/18456749

1137. Hutton, N, Palliative care, time, and core values., Patient Educ Couns, 2005. 56 (3)(3): p. 255-6., https://pubmed.ncbi.nlm.nih.gov/15721966/

1138. Vanbutsele, G, Pardon, K, Van Belle, S, Surmont, V, De Laat, M, Colman, R, et.al. Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trial., Lancet Oncol, 2018. 19 (3)(3): p. 394-404., https://pubmed.ncbi.nlm.nih.gov/29402701/

1139. Ghabashi, EH, Sharaf, BM, Kalaktawi, WA, Calacattawi, R, Calacattawi, AW, The Magnitude and Effects of Early Integration of Palliative Care Into Oncology Service Among Adult Advanced Cancer Patients at a Tertiary Care Hospital., Cureus, 2021. 13 (5)(5): p. e15313., https://pubmed.ncbi.nlm.nih.gov/34211813/

1140. Haun, MW, Estel, S, Rücker, G, Friederich, HC, Villalobos, M, Thomas, M, et.al. Early palliative care for adults with advanced cancer., Cochrane Database Syst Rev, 2017. 6 (6)(6): p. CD011129., https://pubmed.ncbi.nlm.nih.gov/28603881/

1141. Aaronson, NK, Ahmedzai, S, Bergman, B, Bullinger, M, Cull, A, Duez, NJ, et.al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology., J Natl Cancer Inst, 1993. 85 (5)(5): p. 365-76., https://pubmed.ncbi.nlm.nih.gov/8433390/

1142. Mendoza, TR, Wang, XS, Cleeland, CS, Morrissey, M, Johnson, BA, Wendt, JK, et.al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory., Cancer, 1999. 85 (5)(5): p. 1186-96., https://pubmed.ncbi.nlm.nih.gov/10091805/

1143. Janjua S, Brown M, Parker R, Prue G, Closier P, Cramp F. Physical activity for the management of cancer‐related fatigue in adults. Cochrane Database Syst Rev. 2022 Dec 1;2022(12):CD015348., 2022.

1144. American College of Physicians. (2021). Guidelines for chronic fatigue syndrome and fatigue-related disorders. Available at: acponline.org., 2021.

1145. Yellen, SB, Cella, DF, Webster, K, Blendowski, C, Kaplan, E, Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system., J Pain Symptom Manage, 1997. 13 (2)(2): p. 63-74., https://pubmed.ncbi.nlm.nih.gov/9095563/

1146. Piper, BF, Dibble, SL, Dodd, MJ, Weiss, MC, Slaughter, RE, Paul, SM, The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer., Oncol Nurs Forum, 1998. 25 (4)(4): p. 677-84., https://pubmed.ncbi.nlm.nih.gov/9599351/

1147. Smets, EM, Garssen, B, Bonke, B, De Haes, JC, The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue., J Psychosom Res, 1995. 39 (3)(3): p. 315-25., https://pubmed.ncbi.nlm.nih.gov/7636775/

1148. Cleeland, CS, Ryan, KM, Pain assessment: global use of the Brief Pain Inventory., Ann Acad Med Singap, 1994. 23 (2)(2): p. 129-38., https://pubmed.ncbi.nlm.nih.gov/8080219/

1149. Breivik, H, Borchgrevink, PC, Allen, SM, Rosseland, LA, Romundstad, L, Hals, EK, et.al. Assessment of pain., Br J Anaesth, 2008. 101 (1)(1): p. 17-24., https://pubmed.ncbi.nlm.nih.gov/18487245/

1150. Melzack, R, The McGill Pain Questionnaire: major properties and scoring methods., Pain, 1975. 1 (3)(3): p. 277-299., https://pubmed.ncbi.nlm.nih.gov/1235985/

1151. Tait, RC, Chibnall, JT, Krause, S, The Pain Disability Index: psychometric properties., Pain, 1990. 40 (2)(2): p. 171-182., https://pubmed.ncbi.nlm.nih.gov/2308763/

1152. Freynhagen, R, Baron, R, Gockel, U, Tölle, TR, painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain., Curr Med Res Opin, 2006. 22 (10)(10): p. 1911-20., https://pubmed.ncbi.nlm.nih.gov/17022849/

1153. Smith, MR, Lee, H, Nathan, DM, Insulin sensitivity during combined androgen blockade for prostate cancer., J Clin Endocrinol Metab, 2006. 91 (4)(4): p. 1305-8., https://pubmed.ncbi.nlm.nih.gov/16434464/

1154. Baracos, VE, Martin, L, Korc, M, Guttridge, DC, Fearon, KCH, Cancer-associated cachexia., Nat Rev Dis Primers, 2018. 4 (): p. 17105., https://pubmed.ncbi.nlm.nih.gov/29345251/

1155. Fearon, K, Strasser, F, Anker, SD, Bosaeus, I, Bruera, E, Fainsinger, RL, et.al. Definition and classification of cancer cachexia: an international consensus., Lancet Oncol, 2011. 12 (5)(5): p. 489-95., https://pubmed.ncbi.nlm.nih.gov/21296615/

1156. Ottery, FD, Definition of standardized nutritional assessment and interventional pathways in oncology., Nutrition, 1996. 12 (1 Suppl)(1 Suppl): p. S15-9., https://pubmed.ncbi.nlm.nih.gov/8850213/

1157. Prado, CM, Lieffers, JR, McCargar, LJ, Reiman, T, Sawyer, MB, Martin, L, et.al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study., Lancet Oncol, 2008. 9 (7)(7): p. 629-35., https://pubmed.ncbi.nlm.nih.gov/18539529/

1158. Madeddu, C, Dessì, M, Panzone, F, Serpe, R, Antoni, G, Cau, MC, et.al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome., Clin Nutr, 2012. 31 (2)(2): p. 176-82., https://pubmed.ncbi.nlm.nih.gov/22047681/

1159. Stene, GB, Helbostad, JL, Balstad, TR, Riphagen, II, Kaasa, S, Oldervoll, LM, Effect of physical exercise on muscle mass and strength in cancer patients during treatment--a systematic review., Crit Rev Oncol Hematol, 2013. 88 (3)(3): p. 573-93., https://pubmed.ncbi.nlm.nih.gov/23932804/

1160. McClement, SE, Harlos, M, When advanced cancer patients won't eat: family responses., Int J Palliat Nurs, 2008. 14 (4)(4): p. 182-8., https://pubmed.ncbi.nlm.nih.gov/18681346/

1161. Taylor, B, Experiences of sexuality and intimacy in terminal illness: a phenomenological study., Palliat Med, 2014. 28 (5)(5): p. 438-47., https://pubmed.ncbi.nlm.nih.gov/24449801/

1162. Wang, K, Ariello, K, Choi, M, Turner, A, Wan, BA, Yee, C, et.al. Sexual healthcare for cancer patients receiving palliative care: a narrative review., Ann Palliat Med, 2018. 7 (2)(2): p. 256-264., https://pubmed.ncbi.nlm.nih.gov/29156921/

1163. Williams, M, Addis, G, Addressing patient sexuality issues in cancer and palliative care., Br J Nurs, 2021. 30 (10)(10): p. S24-S28., https://pubmed.ncbi.nlm.nih.gov/34037445/

1164. Hordern, AJ, Street, AF, Communicating about patient sexuality and intimacy after cancer: mismatched expectations and unmet needs., Med J Aust, 2007. 186 (5)(5): p. 224-7., https://pubmed.ncbi.nlm.nih.gov/17391082/

1165. Gilbert, E, Perz, J, Ussher, JM, Talking about sex with health professionals: the experience of people with cancer and their partners., Eur J Cancer Care (Engl), 2016. 25 (2)(2): p. 280-93., https://pubmed.ncbi.nlm.nih.gov/25040442/

1166. Schmalz, C, Oberguggenberger, AS, Nagele, E, Bliem, B, Lanceley, A, Nordin, A, et.al. Sexual health-a topic for cancer patients receiving oncological treatment with palliative intent., BMC Palliat Care, 2024. 23 (1)(1): p. 189., https://pubmed.ncbi.nlm.nih.gov/39075384/

1167. Chambers, S. K., Ng, S. K., Baade, P., et al. (2012). Psychological distress and quality of life in men with prostate cancer. Journal of Clinical Oncology, 30(23), 2713-2719., 2012.

1168. Dinh, KT, Reznor, G, Muralidhar, V, Mahal, BA, Nezolosky, MD, Choueiri, TK, et.al. Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer., J Clin Oncol, 2016. 34 (16)(16): p. 1905-12., https://pubmed.ncbi.nlm.nih.gov/27069075/

1169. Watts, S, Leydon, G, Birch, B, Prescott, P, Lai, L, Eardley, S, et.al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates., BMJ Open, 2014. 4 (3)(3): p. e003901., https://pubmed.ncbi.nlm.nih.gov/24625637/

1170. Sharpley, CF, Bitsika, V, Christie, DR, Understanding the causes of depression among prostate cancer patients: development of the Effects of Prostate Cancer on Lifestyle Questionnaire., Psychooncology, 2009. 18 (2)(2): p. 162-8., https://pubmed.ncbi.nlm.nih.gov/18613289/

1171. Couper, JW, Love, AW, Duchesne, GM, Bloch, S, Macvean, M, Dunai, JV, et.al. Predictors of psychosocial distress 12 months after diagnosis with early and advanced prostate cancer., Med J Aust, 2010. 193 (S5)(S5): p. S58-61., https://pubmed.ncbi.nlm.nih.gov/21542448/

1172. Sharp, L., & O’Leary, E. (2019). Cancer-related anxiety in men with prostate cancer: prevalence and correlates. Psycho-Oncology, 28(5), 1085-1091., 2019.

1173. Chambers, S. K., et al. (2015). A randomised controlled trial of mindfulness interventions for men with advanced prostate cancer. Journal of Clinical Oncology, 33(5), 565-571., 2015.

1174. Pitman, A, Suleman, S, Hyde, N, Hodgkiss, A, Depression and anxiety in patients with cancer., BMJ, 2018. 361 (): p. k1415., https://pubmed.ncbi.nlm.nih.gov/29695476/

1175. Oefelein, M.G., Prognostic significance of obstructive uropathy in advanced prostate cancer, Urology, 2004. 63(6): p. 1117-1121., http://www.ncbi.nlm.nih.gov/pubmed/15183963

1176. Ku, J.H., Lee, S.W., Jeon, H.G., Kim, H.H., Oh, S.J., Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences?, Urology, 2004. 64(5): p. 895-899., http://www.ncbi.nlm.nih.gov/pubmed/15533473

1177. Chung, S.Y., Stein, R.J., Landsittel, D., Davies, B.J., Cuellar, D.C., Hrebinko, R.L., et.al. 15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents, J Urol, 2004. 172(2): p. 592-595., http://www.ncbi.nlm.nih.gov/pubmed/15247739

1178. Docimo, S.G., Dewolf, W.C., High failure rate of indwelling ureteral stents in patients with extrinsic obstruction: experience at 2 institutions, J Urol, 1989. 142(2 Pt 1): p. 277-279., http://www.ncbi.nlm.nih.gov/pubmed/2746744

1179. Yossepowitch, O., Lifshitz, D.A., Dekel, Y., Gross, M., Keidar, D.M., Neuman, M., et.al. Predicting the success of retrograde stenting for managing ureteral obstruction, J Urol, 2001. 166(5): p. 1746-1749., http://www.ncbi.nlm.nih.gov/pubmed/11586215

1180. Feng, M.I., Bellman, G.C., Shapiro, C.E., Management of ureteral obstruction secondary to pelvic malignancies, J Endourol, 1999. 13(7): p. 521-524., http://www.ncbi.nlm.nih.gov/pubmed/10569528

1181. Anast, J.W., Andriole, G.L., Grubb, R.L., Managing the local complications of locally advanced prostate cancer, Curr Urol Rep, 2007. 8(3): p. 211-216., http://www.ncbi.nlm.nih.gov/pubmed/17459270

1182. Ganatra, A.M., Loughlin, K.R., The management of malignant ureteral obstruction treated with ureteral stents, J Urol, 2005. 174(6): p. 2125-2128., http://www.ncbi.nlm.nih.gov/pubmed/16280741

1183. Dowling, R.A., Carrasco, C.H., Babaian, R.J., Percutaneous urinary diversion in patients with hormone-refractory prostate cancer, Urology, 1991. 37(2): p. 89-91., http://www.ncbi.nlm.nih.gov/pubmed/1992595

1184. Wright, AA, Zhang, B, Ray, A, Mack, JW, Trice, E, Balboni, T, et.al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment., JAMA, 2008. 300 (14)(14): p. 1665-73., https://pubmed.ncbi.nlm.nih.gov/18840840/

1185. Sudore, RL, Fried, TR, Redefining the "planning" in advance care planning: preparing for end-of-life decision making., Ann Intern Med, 2010. 153 (4)(4): p. 256-61., https://pubmed.ncbi.nlm.nih.gov/20713793/

1186. Merino, S., & Wilmott, M. (2020). Withdrawing anticancer treatment: A systematic review of factors influencing physicians' decision-making. Palliative Medicine, 34(5), 625-639., 2018.

1187. Laryionava, K., et al. (2018). Cancer patients' preferences for palliative care and their perception of symptoms and burden: A cross-sectional study. Journal of Pain and Symptom Management, 56(5), 731-738., 2020.

1188. Weber, B. A, Roberts, B. L., Mills, T. L., Physical and emotional predictors of coping and adjustment in men treated for prostate cancer, Journal of Clinical Psychology in Medical Settings, 2004. 11(1): p. 1-9.

1189. Ferrell, BR, Temel, JS, Temin, S, Smith, TJ, Integration of Palliative Care Into Standard Oncology Care: ASCO Clinical Practice Guideline Update Summary., J Oncol Pract, 2017. 13 (2)(2): p. 119-121., https://pubmed.ncbi.nlm.nih.gov/28972832/

1190. Skolarus, TA, Wolf, AM, Erb, NL, Brooks, DD, Rivers, BM, Underwood, W, et.al. American Cancer Society prostate cancer survivorship care guidelines., CA Cancer J Clin, 2014. 64 (4)(4): p. 225-49., https://pubmed.ncbi.nlm.nih.gov/24916760/

1191. Mehnert, A, Hartung, TJ, Friedrich, M, Vehling, S, Brähler, E, Härter, M, et.al. One in two cancer patients is significantly distressed: Prevalence and indicators of distress., Psychooncology, 2018. 27 (1)(1): p. 75-82., https://pubmed.ncbi.nlm.nih.gov/28568377/

1192. Radbruch, L., & Payne, S. (2009). Standards und Richtlinien für die Palliativversorgung in Europa: Eine Empfehlung des Europäischen Palliativpflegeverbands (EAPC). European Journal of Palliative Care, 16(6), 278-289., 2009.

1193. MacDonald, R., Fink, H.A., Huckabay, C., Monga, M., Wilt, T.J., Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: a systematic review of effectiveness, BJU. Int, 2007. 100(1): p. 76-81., http://www.ncbi.nlm.nih.gov/pubmed/17433028

1194. Manassero, F., Traversi, C., Ales, V., Pistolesi, D., Panicucci, E., Valent, F., et.al. Contribution of early intensive prolonged pelvic floor exercises on urinary continence recovery after bladder neck-sparing radical prostatectomy: results of a prospective controlled randomized trial, Neurourol. Urodyn, 2007. 26(7): p. 985-989., http://www.ncbi.nlm.nih.gov/pubmed/17487874

1195. Anderson, C.A., Omar, M.I., Campbell, S.E., Hunter, K.F., Cody, J.D., Glazener, C.M., Conservative management for postprostatectomy urinary incontinence, Cochrane Database Syst Rev, 2015. 1: p. CD001843., http://www.ncbi.nlm.nih.gov/pubmed/25602133

1196. Wang, W., Huang, Q.M., Liu, F.P., Mao, Q.Q., Effectiveness of preoperative pelvic floor muscle training for urinary incontinence after radical prostatectomy: a meta-analysis, BMC Urol, 2014. 14: p. 99., http://www.ncbi.nlm.nih.gov/pubmed/25515968

1197. Zhu, Y.P., Yao, X.D., Zhang, S.L., Dai, B., Ye, D.W., Pelvic floor electrical stimulation for postprostatectomy urinary incontinence: a meta-analysis, Urology, 2012. 79(3): p. 552-555., http://www.ncbi.nlm.nih.gov/pubmed/22386394

1198. Geraerts, I., Van, Poppel H., Devoogdt, N., De, Groef A., Fieuws, S., Van, Kampen M., Pelvic floor muscle training for erectile dysfunction and climacturia 1 year after nerve sparing radical prostatectomy: a randomized controlled trial, Int J Impot. Res, 2016. 28(1): p. 9-13., http://www.ncbi.nlm.nih.gov/pubmed/26538105

1199. Prota, C., Gomes, C.M., Ribeiro, L.H., de, Bessa J., Jr., Nakano, E., Dall'oglio, M., et.al. Early postoperative pelvic-floor biofeedback improves erectile function in men undergoing radical prostatectomy: a prospective, randomized, controlled trial, Int J Impot. Res, 2012. 24(5): p. 174-178., http://www.ncbi.nlm.nih.gov/pubmed/22573231

1200. Zippe, C.D., Pahlajani, G., Penile rehabilitation following radical prostatectomy: role of early intervention and chronic therapy, Urol Clin. North Am, 2007. 34(4): p. 601-18, viii., https://www.ncbi.nlm.nih.gov/pubmed/17983900

1201. Otto, U., Dombo, O., Studie zur Identifikation von Prädiktoren für die individuelle Rehabilitationsdauer und den langfristigen Rehabilitationserfolg. Patienten mit Prostatacarcinom, in Stationäre Rehabilitation bei Mamma-, Magen- und Prostatacarcinom, Arbeitsgemeinschaft für Krebsbekämpfung der Träger der gesetzlichen Kranken- und Rentenversicherung im Lande Nordrhein-Westfalen , Editor. 2002, Roderer: Regensburg. p. 85-138.

1202. Vahlensieck, W., Gack, M., Gleissner, J., Hoffmann, W., Liedke, S., Otto, U., et.al. Struktur- und Prozessqualität der stationären urologischen Rehabilitation, Urologe A, 2005. 44(1): p. 51-56., http://www.ncbi.nlm.nih.gov/pubmed/15602650

1203. Dombo, O., Otto, U., Rehabilitation. Allgemeine Grundlagen, in Uroonkologie, Rübben, H. , Editor. 2007, Springer: Berlin. p. 203-218.

1204. Dombo, O., Otto, U., Stress-Inkontinenz beim Mann: Anatomische und funktionelle Besonderheiten, J Urol Gynaecol, 2004. p. 7-12.

1205. Dorschner, W., Stolzenburg, J.U., Neuhaus, J., Anatomische Grundlagen der Harninkontinenz, Urologe A, 2001. 40(3): p. 223-233., http://www.ncbi.nlm.nih.gov/pubmed/11405132

1206. Otto, U., Grosemans, P., Hoffmann, W., Dombo, O., Rehabilitation in der urologischen Onkologie, Urologe B, 1998. 38(Suppl 1): p. 35-40.

1207. Dombo, O., Rehabilitation der postoperativen Stressinkontinenz beim Mann nach radikaler Prostatovesikulektomie und Zystoprostatektomie. DissertationUniv. Hamburg, 1998.

1208. Hoffmann, W., Liedtke, S., Otto, U., Das videoendoskopische Biofeedback-Sphinktertraining zur Therapie der postoperativen Harninkontinenz nach radikalchirurgischen Operationen, Extracta Urol, 2002. 3: p. 32-33.

1209. Hoffmann, W., Liedke, S., Dombo, O., Otto, U., Die Elektrostimulation in der Therapie der postoperativen Harninkontinenz. Therapeutischer Nutzen unter Berücksichtigung der Lebensqualität, Urologe A, 2005. 44(1): p. 33-40., http://www.ncbi.nlm.nih.gov/pubmed/15580472

1210. Davison, B.J., So, A.I., Goldenberg, S.L., Quality of life, sexual function and decisional regret at 1 year after surgical treatment for localized prostate cancer, BJU. Int, 2007. 100(4): p. 780-785., http://www.ncbi.nlm.nih.gov/pubmed/17578466

1211. Herkommer, K., Niespodziany, S., Zorn, C., Gschwend, J.E., Volkmer, B.G., Versorgung der erektilen Dysfunktion nach radikaler Prostatektomie in Deutschland. Einschätzung durch den Urologen vs. Patientenbefragung, Urologe A, 2006. 45(3): p. 336, 338-336, 342., http://www.ncbi.nlm.nih.gov/pubmed/16341512

1212. Noldus, J., Die Nerverhaltende radikale retropubische Prostatektomie, Forum DKI, 2002. Sonderheft 1: p. 49.

1213. Walsh, P.C., Partin, A.W., Epstein, J.I., Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years, J Urol, 1994. 152(5 Pt 2): p. 1831-1836., http://www.ncbi.nlm.nih.gov/pubmed/7523730

1214. Walsh, P.C., Marschke, P., Ricker, D., Burnett, A.L., Patient-reported urinary continence and sexual function after anatomic radical prostatectomy, Urology, 2000. 55(1): p. 58-61., http://www.ncbi.nlm.nih.gov/pubmed/10654895

1215. Walsh, P.C., Preservation of sexual function in the surgical treatment of prostatic cancer--an anatomic surgical approach, Important Adv. Oncol, 1988. p. 161-170., http://www.ncbi.nlm.nih.gov/pubmed/3042603

1216. Catalona, W.J., Ramos, C.G., Carvalhal, G.F., Contemporary results of anatomic radical prostatectomy, CA Cancer J Clin, 1999. 49(5): p. 282-296., http://www.ncbi.nlm.nih.gov/pubmed/11198955

1217. Michel, M.S., Trojan, L., Knoll, T., Bross, S., Alken, P., Bewährte und neue urologische Therapien des Prostatakarzinoms, Radiologe, 2003. 43(6): p. 441-447., http://www.ncbi.nlm.nih.gov/pubmed/12827258

1218. Bannowsky, A., Schulze, H., van der, Horst C., Seif, C., Braun, P.M., Junemann, K.P., Nocturnal tumescence: a parameter for postoperative erectile integrity after nerve sparing radical prostatectomy, J Urol, 2006. 175(6): p. 2214-2217., http://www.ncbi.nlm.nih.gov/pubmed/16697842

1219. Sommer, F., Klotz, T., Schmitz-Drager, B.J., Lifestyle issues and genitourinary tumours, World J. Urol, 2004. 21(6): p. 402-413., http://www.ncbi.nlm.nih.gov/pubmed/14673616

1220. Montorsi, F., Brock, G., Lee, J., Shapiro, J., Van Poppel, H., Graefen, M., et.al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy, Eur. Urol, 2008. 54(4): p. 924-931., http://www.ncbi.nlm.nih.gov/pubmed/18640769

1221. Bannowsky, A., Schulze, H., van der, Horst C., Stubinger, J.H., Portillo, F.J., Junemann, K.P., Erektionsstatus nach nervenerhaltender radikaler Prostatektomie. Nächtliche Früherektion als Parameter der postoperativen organisch-erektilen Integrität, Urologe A, 2005. 44(5): p. 521-526., http://www.ncbi.nlm.nih.gov/pubmed/15726311

1222. Zellner, M., Riedel, R., Rehabilitation der Erektionsfunktion nach radikaler Prostatektomie, Uro news, 2008. p. 28-34.

1223. Schwarz, R., Psychosoziale Onkologie: Position, Prinzipien und Perspektiven, Forum DKG, 2000. 15: p. 22-24.

1224. Weis, J., Leitlinien und Qualitätssicherung in der Psychoonkologie, in Diagnostik und Behandlungsziele in der Psychoonkologie, Schumacher, A. and Broeckamann, S., Editors. 2004, Pabst: Lengerich. p. 84-92.

1225. Cella, D., Quality of life, in Psycho-Oncology, Holland, J.C. , Editor. 1998, Oxford University Pr.: Oxford. p. 1135-1146.

1226. Faller, H., Krebs, in Psychologische Gesundheitsförderung, Diagnostik und Prävention, Jerusalem, M. and Weber, H., Editors. 2003, Hogrefe: Göttingen. p. 655-675.

1227. Koch, U., Weis, J., Krankheitsbewältigung bei Krebs und Möglichkeiten der UnterstützungSchattauer, 1998.

1228. Mehnert, A., Lehmanns, C., Koch, U., Prävalenz und Diagnostik psychischer Störungen in der Onkologie, Onkologe, 2006. 12(1): p. 18-26.

1229. Leitlinienprogramm Onkologie (OL), Deutsche Krebsgesellschaft (DKG), Deutsche Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), S3-Leitlinie Psychoonkologische Diagnostik, Beratung und Behandlung von erwachsenen Krebspatienten. AWMF-Register-Nummer (032/051OL). Langversion 1.1, 2014., https://www.leitlinienprogramm-onkologie.de/leitlinien/psychoonkologie

1230. Zettl, S., Psychoonkologische Betreuung von Patienten mit Prostatakarzinom: Was kann der Urologe leisten?, J Urol Urogyn, 2003. 10: p. 12-15.

1231. Herschbach, P., Das "Zufriedenheitsparadox" in der Lebensqualitätsforschung - wovon hängt unser Wohlbefinden ab?, Psychother. Psychosom Med Psychol, 2002. 52(3-4): p. 141-150., http://www.ncbi.nlm.nih.gov/pubmed/11941521

1232. Colleoni, M., Mandala, M., Peruzzotti, G., Robertson, C., Bredart, A., Goldhirsch, A., Depression and degree of acceptance of adjuvant cytotoxic drugs, Lancet, 2000. 356(9238): p. 1326-1327., http://www.ncbi.nlm.nih.gov/pubmed/11073026

1233. Herschbach, P., Heussner, P., Sellschopp, A., eds., Psycho-Onkologie. Perspektiven heuteDustri, 2006.

1234. Stetinga, S.K., Dunn, J., Gardiner, R., Heathcote, P., Yaxley, J., The supportive care needs of men with prostate cancer, Psychooncology, 2001. 10: p. 66-75.

1235. Zettl, S., Hartlapp, J., Sexualstörungen durch Krankheit und TherapieSpringer, 1997.

1236. Kuchler, T., Bestmann, B., Rappat, S., Henne-Bruns, D., Wood-Dauphinee, S., Impact of psychotherapeutic support for patients with gastrointestinal cancer undergoing surgery: 10-year survival results of a randomized trial, J Clin Oncol, 2007. 25(19): p. 2702-2708., http://www.ncbi.nlm.nih.gov/pubmed/17602075

1237. Watzke, B., Psychotherapeutische Versorgung in der Onkologie, PsychotherapeutenJ, 2008. 4: p. 328-336.

1238. Bo, Y., Jiansheng, W., Effects of Exercise on Cancer-related Fatigue and Quality of Life in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Meta-analysis of Randomized Clinical Trials, Chin Med Sci J, 2017. 32(1): p. 13-21., http://www.ncbi.nlm.nih.gov/pubmed/28399980

1239. Teleni, L., Chan, R.J., Chan, A., Isenring, E.A., Vela, I., Inder, W.J., et.al. Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials, Endocr. Relat Cancer, 2016. 23(2): p. 101-112., http://www.ncbi.nlm.nih.gov/pubmed/26584972

1240. Hasenoehrl, T., Keilani, M., Sedghi Komanadj, T., Mickel, M., Margreiter, M., Marhold, M., et.al. The effects of resistance exercise on physical performance and health-related quality of life in prostate cancer patients: a systematic review, Support Care Cancer, 2015. 23(8): p. 2479-2497., http://www.ncbi.nlm.nih.gov/pubmed/26003426

1241. Warren, K.S., McFarlane, J.P., Is routine digital rectal examination required for the followup of prostate cancer?, J Urol, 2007. 178(1): p. 115-119., http://www.ncbi.nlm.nih.gov/pubmed/17499293

1242. Wang, L., Hricak, H., Kattan, M.W., Chen, H.N., Kuroiwa, K., Eisenberg, H.F., et.al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram, Radiology, 2007. 242(1): p. 182-188., http://www.ncbi.nlm.nih.gov/pubmed/17090712

1243. Haider, M.A., Chung, P., Sweet, J., Toi, A., Jhaveri, K., Menard, C., et.al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy, Int J Radiat Oncol Biol Phys, 2008. 70(2): p. 425-430., http://www.ncbi.nlm.nih.gov/pubmed/17881141

1244. Sarosdy, M.F., Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy, Cancer, 2007. 109(3): p. 536-541., http://www.ncbi.nlm.nih.gov/pubmed/17183557

1245. Agarwal, P.K., Oefelein, M.G., Testosterone replacement therapy after primary treatment for prostate cancer, J Urol, 2005. 173(2): p. 533-536., https://www.ncbi.nlm.nih.gov/pubmed/15643240

1246. Kaufman, J.M., Graydon, R.J., Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men, J Urol, 2004. 172(3): p. 920-922., https://www.ncbi.nlm.nih.gov/pubmed/15310998

1247. Lopez, A.M., Pena, M.A., Hernandez, R., Val, F., Martin, B., Riancho, J.A., Fracture risk in patients with prostate cancer on androgen deprivation therapy, Osteoporos. Int, 2005. 16(6): p. 707-711., http://www.ncbi.nlm.nih.gov/pubmed/15714259

1248. Keating, N.L., O'Malley, A.J., Smith, M.R., Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer, J Clin Oncol, 2006. 24(27): p. 4448-4456., http://www.ncbi.nlm.nih.gov/pubmed/16983113

1249. D'Amico, A.V., Denham, J.W., Crook, J., Chen, M.H., Goldhaber, S.Z., Lamb, D.S., et.al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions, J Clin Oncol, 2007. 25(17): p. 2420-2425., http://www.ncbi.nlm.nih.gov/pubmed/17557956

1250. Pinthus, J.H., Trachtenberg, J., Klotz, L., Cardiovascular effects of androgen depletion and replacement therapy, Urology, 2006. 67(6): p. 1126-1132., http://www.ncbi.nlm.nih.gov/pubmed/16765164

1251. Bojesen, A., Juul, S., Birkebaek, N., Gravholt, C.H., Increased mortality in Klinefelter syndrome, J Clin Endocrinol. Metab, 2004. 89(8): p. 3830-3834., http://www.ncbi.nlm.nih.gov/pubmed/15292313

1252. Bojesen, A., Juul, S., Birkebaek, N.H., Gravholt, C.H., Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses, J Clin Endocrinol. Metab, 2006. 91(4): p. 1254-1260., http://www.ncbi.nlm.nih.gov/pubmed/16394093

1253. Edelman, M.J., Meyers, F.J., Siegel, D., The utility of follow-up testing after curative cancer therapy. A critical review and economic analysis, J Gen Intern Med, 1997. 12(5): p. 318-331., http://www.ncbi.nlm.nih.gov/pubmed/9159703

1254. Echlin, K.N., Rees, C.E., Information needs and information-seeking behaviors of men with prostate cancer and their partners: a review of the literature, Cancer Nurs, 2002. 25(1): p. 35-41., http://www.ncbi.nlm.nih.gov/pubmed/11838718

1255. Kornblith, A.B., Herr, H.W., Ofman, U.S., Scher, H.I., Holland, J.C., Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care, Cancer, 1994. 73(11): p. 2791-2802., http://www.ncbi.nlm.nih.gov/pubmed/8194021

1256. Carlson, L.E., Ottenbreit, N., St, Pierre M., Bultz, B.D., Partner understanding of the breast and prostate cancer experience, Cancer Nurs, 2001. 24(3): p. 231-239., http://www.ncbi.nlm.nih.gov/pubmed/11409068

1257. Lavery, J.F., Clarke, V.A., Prostate cancer: Patients' and spouses' coping and marital adjustment, Health Med, 1999. 4: p. 289-302.

1258. Feldman-Stewart, D., Brundage, M.D., Hayter, C., Groome, P., Nickel, J.C., Downes, H., et.al. What questions do patients with curable prostate cancer want answered?, Med Decis Making, 2000. 20(1): p. 7-19., http://www.ncbi.nlm.nih.gov/pubmed/10638532

1259. Crawford, E.D., Bennett, C.L., Stone, N.N., Knight, S.J., DeAntoni, E., Sharp, L., et.al. Comparison of perspectives on prostate cancer: analyses of survey data, Urology, 1997. 50(3): p. 366-372., http://www.ncbi.nlm.nih.gov/pubmed/9301699

1260. da Silva, F.C., Fossa, S.D., Aaronson, N.K., Serbouti, S., Denis, L., Casselman, J., et.al. The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853, Eur J Cancer, 1996. 32A(1): p. 72-77., http://www.ncbi.nlm.nih.gov/pubmed/8695246

1261. Davison, B.J., Goldenberg, S.L., Gleave, M.E., Degner, L.F., Provision of individualized information to men and their partners to facilitate treatment decision making in prostate cancer, Oncol Nurs Forum, 2003. 30(1): p. 107-114., http://www.ncbi.nlm.nih.gov/pubmed/12515988

1262. Fischer, M., Visser, A., Voerman, B., Garssen, B., van Andel, G., Bensing, J., Treatment decision making in prostate cancer: patients' participation in complex decisions, Patient Educ Couns, 2006. 63(3): p. 308-313., http://www.ncbi.nlm.nih.gov/pubmed/16965887

1263. Voerman, B., Visser, A., Fischer, M., Garssen, B., van Andel, G., Bensing, J., Determinants of participation in social support groups for prostate cancer patients, Psychooncology, 2007. 16(12): p. 1092-1099., http://www.ncbi.nlm.nih.gov/pubmed/17278186

1264. Roesch, S.C., Adams, L., Hines, A., Palmores, A., Vyas, P., Tran, C., et.al. Coping with prostate cancer: a meta-analytic review, J. Behav. Med, 2005. 28(3): p. 281-293., http://www.ncbi.nlm.nih.gov/pubmed/16015462

1265. Gray, R.E., Fitch, M., Phillips, C., Labrecque, M., Fergus, K., To tell or not to tell: patterns of disclosure among men with prostate cancer, Psychooncology, 2000. 9(4): p. 273-282., http://www.ncbi.nlm.nih.gov/pubmed/10960925

1266. Gray, R.E., Fitch, M., Davis, C., Phillips, C., Interviews with men with prostate cancer about their self-help group experience, J Palliat Care, 1997. 13(1): p. 15-21., http://www.ncbi.nlm.nih.gov/pubmed/9105153

1267. Fayers, P.M., Machin, P., Quality of Life: The assessment, analysis and interpretation of patient-reported outcomesWiley, 2013.

1268. Cella, D.F., Tulsky, D.S., Quality of life in cancer: definition, purpose, and method of measurement, Cancer Invest, 1993. 11(3): p. 327-336., http://www.ncbi.nlm.nih.gov/pubmed/8485655

1269. Koller, M., Lorenz, W., Quality of life: a deconstruction for clinicians, J. R. Soc. Med, 2002. 95(10): p. 481-488., http://www.ncbi.nlm.nih.gov/pubmed/12356967

1270. Koller, M., Neugebauer, E.A., Augustin, M., Bussing, A., Farin, E., Klinkhammer-Schalke, M., et.al. Die Erfassung von Lebensqualität in der Versorgungsforschung - konzeptionelle, methodische und strukturelle Voraussetzungen (Memorandum III: Methoden der Versorgungsforschung), Gesundheitswesen, 2009. 71(12): p. 864-872., http://www.ncbi.nlm.nih.gov/pubmed/19806535

1271. Efficace, F., Bottomley, A., Osoba, D., Gotay, C., Flechtner, H., D'haese, S., et.al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials--does HRQOL evaluation in prostate cancer research inform clinical decision making?, J Clin Oncol, 2003. 21(18): p. 3502-3511., http://www.ncbi.nlm.nih.gov/pubmed/12972527

1272. Martin, N.E., Massey, L., Stowell, C., Bangma, C., Briganti, A., Bill-Axelson, A., et.al. Defining a standard set of patient-centered outcomes for men with localized prostate cancer, Eur Urol, 2015. 67(3): p. 460-467., http://www.ncbi.nlm.nih.gov/pubmed/25234359

1273. Szymanski, K.M., Wei, J.T., Dunn, R.L., Sanda, M.G., Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors, Urology, 2010. 76(5): p. 1245-1250., http://www.ncbi.nlm.nih.gov/pubmed/20350762

1274. Beyer, B., Huland, H., Feick, G., Graefen, M., "Expanded prostate cancer index composite"(EPIC-26): Funktionelles Behandlungsergebnis bei Patienten mit lokalisiertem Prostatakarzinom, Urologe A, 2015. 54(11): p. 1591-1595., http://www.ncbi.nlm.nih.gov/pubmed/26347350

1275. Aaronson, N.K., Methodologic issues in assessing the quality of life of cancer patients, Cancer, 1991. 67(3 Suppl): p. 844-850., http://www.ncbi.nlm.nih.gov/pubmed/1986856

1276. van Andel, G., Bottomley, A., Fossa, S.D., Efficace, F., Coens, C., Guerif, S., et.al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer, Eur. J Cancer, 2008. 44(16): p. 2418-2424., http://www.ncbi.nlm.nih.gov/pubmed/18774706

1277. Koller, M., Aaronson, N.K., Blazeby, J., Bottomley, A., Dewolf, L., Fayers, P., et.al. Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach, Eur J Cancer, 2007. 43(12): p. 1810-1820., http://www.ncbi.nlm.nih.gov/pubmed/17689070

1278. Dewolf, L., Koller, M., Velikova, G., Johnson, C., Scott, N., Bottomley, A., EORTC Quality of Life Group translation procedureEORTC, 2009.

1279. Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), in Manual Qualitätsindikatoren. Manual für Autoren, 2009.

1280. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft (DKG) e.V., Stiftung Deutsche Krebshilfe (DKH), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e.V.). Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 4.0, 2025., https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Methodik/QIEP_OL_2025__Version_4.0.pdf

1281. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom, Leitlinienreport 8.1, [2025], AWMF Registernummer: 043-022OL, Zugriff am 14.08.2025, 2025., https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom

1282. National Institutes of Health (NIH), National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03, 2010., https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf